







Acinetobacter baumannii is increasingly being isolated in the nosocomial environment
where it is a cause of pneumonia, bacteremia, meningitis and urinary tract infections,
particularly in immunocompromised patients, although there are reports of it being the
causative agent in community-acquired pneumonias. Prior use of antimicrobials is a risk
factor for infection and the use of the fluoroquinolone ciprofloxacin has been associated with
the selection of fluoroquinolone-resistant strains in the clinical environment.
Ciprofloxacin has been in clinical use since the 1980s and has good activity against Gram
negative organisms but it is being superseded by a new generation of fluoroquinolones which
retain good potency against Gram negative organisms but also exhibit enhanced activity
against Gram positive organisms. The fluoroquinolones are bactericidal drugs that act on the
essential cellular enzymes DNA Gyrase and Topoisomerase IV, subunits GyrA and ParC
respectively. Resistance to this class of drug is mediated through mutations in the target
enzymes. Studies with clinical isolates ofA. baumannii have shown that a mutation in
GyrA, specifically serine 83, is found in strains resistant to ciprofloxacin and in high-level
resistant strains with a concurrent serine 80 mutation in ParC.
In this thesis, the anti-Acinetobacter activity of the newer fluoroquinolones are investigated
by MIC and kill-curve and it is shown that they are 2-16-fold more potent than ciprofloxacin.
The target enzymes GyrA and ParC are investigated by polymerase chain reaction,
restriction fragment length polymorphism and sequencing. It was found that a serine 83
mutation in GyrA conferred resistance to ciprofloxacin and also to the newer
fluoroquinolones except trovafloxacin. Strains exhibiting high-level resistance were found
to carry a ParC mutation in serine 80 in addition to the GyrA mutation.
The selection of fluoroquinolone resistance in vitro was investigated by step-wise selection
in order to investigate the mutational frequency and the development of resistance. It was
found that ciprofloxacin selects for a GyrA mutation in one-step at a high frequency. The
newer fluoroquinolones however required multiple steps of low frequency selection to
acquire this mutation. ParC mutations were found not to be required for high-level
resistance suggesting an alternative resistance mechanism.
Mutants were subcultured on antibiotic-free media and their fluoroquinolone MICs were re-
tested to look for spontaneous revertants. A revertant was investigated by sequencing of
gyrA and parC but no changes were found. Narrow-range MICs with non-fluoroquinolones
showed small differences in MIC between parent, mutant and revertant suggesting changes
in permeability. The outer membrane profile was investigated and a porin of 45.5kDa was
found to have increased expression in the mutant and this level was lower in the revertant.
The porin was extracted and N-terminally sequenced. It was found to have homology to
porin D in Pseudomonas aeruginosa, a porin associated with imipenem resistance. The
narrow-range MICs of imipenem followed this pattern.
These data suggest that the new fluoroquinolones are not only more potent than
ciprofloxacin but that the development of resistance will be reduced once they are in clinical
use. These data also demonstrate that GyrA is the primary target of the fluoroquinolones and
that ParC mutations are not necessary to achieve high-level resistance.
ii
Declaration




Firstly I would like to thank my supervisor Prof. SGB Amyes for his help and
support throughoutmy PhD. I would also like to thank Dr. Ken Coleman and
GlaxoSmithKline for funding this PhD.
There are many people I would like to thank, firstly my parents for encouragement
and support, Richard Cooper (Sunday tea), Alan White (Guinness) and Dr Jan Braun
(Saturday dinners), Ian Jack (music), Sonja Giersen, the Molecular Chemotherapy
Group for tolerating me, as well as the Department ofMedical Microbiology,
University of Edinburgh, where there are many people I have turned to for advice.
Special thanks go to Robert Brown and Richard Gibbs from MPRL for their help and
Tanittha Chatsuwan, Dr Tammie Schneiders and Dr Leila Vali from Molecular
Chemotherapy.
I would also like to thank Dr Richard Paul and Dr David Wallace, my biology
teachers from my school days for their inspirational classes and opening my eyes to
the world of living things.
Dedication
I would like to dedicate this thesis to the late Gabriele Cortopassi (1964-1998)
iv
Publications and Presentations
1. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 1999. Anti-Acinetobacter activity of
gemifloxacin (SB-265805) compared with 11 compounds by MIC. 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA.
2. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 1999. Bactericidal activity of
gemifloxacin (SB-265805) and six comparator fluoroquinolones against Acinetobacter
baumannii. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.
San Francisco, USA.
3. Higgins, P. G., Coleman, K., and Amyes, S. G. B. 2000. High level fluoroquinolone
resistance in Acinetobacter baumannii requires a mutation in both gyrA and parC. In
Programme and Abstracts of the 3rd European Congress of Chemotherapy, Madrid,
Spain , Poster M114.
4. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 2000. High-level fluoroquinolone
resistance in Acinetobacter baumannii is associated with increased expression of a
45.5kDa porin. 5th International Symposium on the Biology of Acinetobacter.
Noordwijkerhout, The Netherlands.
5. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 2000. Bactericidal and bacteriostatic
activity of gemifloxacin against Acinetobacter spp. in vitro. Journal of Antimicrobial
Chemotherapy. 45:71-77.
6. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 2001. High-level fluoroquinolone
resistance in Acinetobacter baumannii requires a mutation in GyrA but does not require
a mutation in ParC with laboratory-bred mutants. 22nd International Congress of
Chemotherapy. Amsterdam, The Netherlands.
7. Higgins, P. G., K. Coleman, and S. G. B. Amyes. 2001. Mutation rates of Acinetobacter
baumannii against gemifloxacin, moxifloxacin and ciprofloxacin. 41st Interscience
Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA.
v
Abbreviations
Acb Acinetobacter calcoaceticus-Acinetobacter baumannii
complex
AFLP amplified fragment length polymorphism
bp base pair
CCCP carbonyl cyanide m-chloropheny 1 -hydrazone
DNA deoxyribonucleic acid
DNTP deoxynucleoside triphosphate
ds DNA double stranded DNA
1ST isosensitest
kDa kilo Daltons
MIC minimum inhibitory concentration
MQ MilliQ pyrogen-free water
MW molecular weight
OBC... optimum bactericidal concentration
PCR polymerase chain reaction
OMP outer membrane protein
VI
PAGE polyacrylamide gel electrophoresis
PFGE pulsed-field gel electrophoresis
QRDR quinolone resistance determining region
RFLP restriction fragment length polymorphism
RNA ribonucleic acid








List of Publications vii
Contents viii
Chapter 1: Introduction 1
1.1 The Early Years of Drug Discovery 1
1.2 Classes of Antibiotic 2
1.3 The Fluoroquinolones . 4
1.3.1 Position 1 5
1.3.2 Position 5 8
1.3.3 Position 6 9
1.3.4 Position 7 10
1.3.5 Position 8 11
1.4 Bacterial Topoisomerases 12
1.4.1 DNA Gyrase 13
1.4.2 Topoisomerase IV 16
viii
1.5 Fluoroquinolone Action on DNA Gyrase and Topoisomerase IV 16
1.6 Antibiotic Resistance ...19
1.6.1 Fluoroquinolone Resistance 20
1.6.2 DNA Gyrase QRDR 21
1.6.3 Mutations in GyrB 24
1.6.4 Mutations in Topoisomerase IV 25
1.6.5 Mutations in ParE 26
1.6.6 Efflux-Mediated Fluoroquinolone Resistance 27
1.6.7 Outer Membrane Permeability 30
1.6.8 Fluoroquinolone Resistance in Acinetobacter baumannii 31
1.7 The Genus Acinetobacter 32
1.7.1 Speciation of the Acinetobacters 34
1.7.2 Acinetobacter in the Clinical Setting 36
1.7.3 Risk Factors Associated with Infection 37
1.7.4 Typing of Acinetobacter 39
1.7.5 Treatment of Acinetobacter baumannii Infections 42
1.8 Conclusions 43
1.9 Aims of this Thesis 44
ix
Chapter 2: Materials and Methods 45
2.1 Bacterial Strains 45
2.2 Media, Buffers and Reagents 45
2.3 Antimicrobial Agents 46
2.4 MIC Determination and Breakpoints 47
2.5 Optimum Bactericidal Concentration 47
2.6 Time-Kill Kinetics 47
2.7 PCR Reagents 48
2.7.1 PCR Primers 49
2.7.2 Preparation of DNA for PCR 50
2.7.3 Phenol:Chloroform:lsoamyl alcohol DNA extraction 50
2.7.4 Visualisation of PCR Products by Agarose Gel Electrophoresis 51
2.7.5 Speciation of Acinetobacter spp. Using tDNA fingerprinting 51
2.7.6 PCR of the gyrA QRDR 52
2.7.7 PCR of the parC QRDR 52
2.7.8 PCR of 45.5kDa Porin Using Degenerate Primers 52
2.7.9 Inverse PCR 53
2.7.10 Cloning of the Porin 53
x
2.7.11 Sequencing of PCR Products 54
2.7.12 HintI RFLP of gyrA and parC 54
2.8 Fluoroquinolone Selection of Mutants 55
2.9 Isolation and Analysis of the Outer Membrane Proteins 55
2.9.1 SDS-PAGE of Outer Membrane Proteins 56
2.9.2 Visualisation of Protein Bands: Coomassie Stain 57
2.9.3 Visualisation of Protein Bands: Silver Stain 57
2.9.4 Ion-Exchange, Electroelution and Amino Acid
Sequencing of a 45.5kDa Porin 58
2.10 Pulsed-Field Gel Electrophoresis 59




Chapter 4: Killing Kinetics of Seven Fluoroquinolones against
A. baumannii ATCC 19606 72
4.1 Introduction 72
4.2 Results 72








Chapter 6: Mutations leading to Fluoroquinolone Resistance in
Clinical Isolates of A. baumannii 91
6.1 Introduction 91
6.2 Results 91
6.2.1 Antibiotic Susceptibility 91
6.2.2 Restriction of gyrA and parC ' 92
6.2.3 Sequencing of gyrA 95
6.2.4 Sequencing of parC 97
6.3 Outer Membrane Profiles 98
6.4 Pulsed-Field Gel Electrophoresis 100
6.5 Discussion 102
xii
Chapter 7: In-vitro Fluoroquinolone Selection 105
7.1 Introduction 105
7.2 Results 105
7.2.1 Ciprofloxacin-selection of A. baumannii ATCC 19606 105
7.2.2 Gemifloxacin-selection of ATCC 19606 107
7.2.3 Analysis of gyrA and parC QRDR 108
7.2.4 Moxifloxacin-Selection of ATCC 19606 111
7.3.1 Ciprofloxacin-Selection of SB13 112
7.3.2 Gemifloxacin-Selection of SB13 113
7.3.3 Moxifloxacin-Selection of SB13 116
7.4 Sensitivity to Non-Fluoroquinolones 117
7.5 Discussion 120
Chapter 8: Stability of Gemifloxacin-Selected Mutants and
Identification of a Porin 125
8.1 Introduction 125
8.2 Passage of ATCC 19606 Mutants 125
8.3.1 Passage of SB 13 Mutants 127
8.3.2 Narrow-Range MICs 127
8.4 Growth Rates of Gemifloxacin-Selected SB 13 Mutants 128
xiii
8.5 Analysis of BE 1 rev gyrA and parC QRDR 130
8.6.1 SDS-PAGE of Outer Membrane Proteins 131
8.6.2 Purification ofthe45.5kDa Porin 133
8.7.1 N-Terminal Sequencing of the Porin 133
8.7.2 Determination of the Nucleotide Sequence of 28 Amino Acids of the Porin 133
8.7.3 Inverse PCR 134
8.7.4 Cloning of the PCR Fragment 135
8.8 Re-selection of BE1 rev on Gemifloxacin 136
8.9 Discussion 137
Chapter 9: Conclusions 143
Appendices 148
Appendix I: Degenerate Primer Design 145
Appendix II: Schematic Diagram of Inverse PCR 146
Appendix III: tRNA Fingerprinting Profiles from Figure 3.1 147
Appendix IV: Acinetobacter spp. Identification by tRNA 150
Appendix V: Dose Response Curves to A. baumannii ATCC 19606 152
Appendix VI: MICs of all Acinetobacter Isolates 156





"We must learn to shoot microbes with magic bullets" - Paul Ehrlich
1.1 The Early Years of Drug Discovery
In 1902, Paul Ehrlich was shown how to stain the tubercule microbe by Robert Koch
and so began an interest in the use of dyes to visualise cells and the career of a man
who would revolutionise the way that chemotherapeutic agents would be discovered.
After observing how methylene blue stained only the nerve endings in a live rabbit,
he hit upon the idea that there must be one dye that will stain and kill microbes but
not tissue from an animal. By chemically altering existing dyes, Ehrlich synthesised
and tested hundreds ofmodified dyes, eventually one worked, preparation 606,
Dioxy-diamino-arsenobenzol-dihydro-chloride, a compound which had anti-
trypanosome activity and was also active against Treponemapallidum, the spirochete
that is the causative agent of syphilis (de Kruif, 1926).
Ehrlich's idea, the structural modification of antimicrobials to increase activity,
continues to this day. From the modification of the side-chains surrounding a p~
lactam ring with cephalosporins and carbapenems, to the addition of a fluorine atom




1.2 Classes of antibiotic
Antibiotics should posses certain properties to be of use to mankind: most notably
that they should kill, or at the very least prevent microbes from replicating, without
harming the host. Most do this by targeting bacterial metabolic pathways that do not
exist in man; for example, cell-wall synthesis (Figure 1.1). Others have a higher
affinity for the bacterial target such as the quinolones, with an affinity for bacterial
topoisomerase that is more than 1000-fold greater than human topoisomerase (Koga
et al, 1980) and trimethoprim, which inhibits mammalian dihydrofolate reductase
100,000-fold less efficiently than the bacterial enzyme. Bacterial but not mammalian
RNA polymerase is targeted by rifampicin, preventing RNA synthesis. In the case of
protein synthesis inhibitors, the aminoglycosides and macrolides target the 30S and
50S ribosome subunits of bacteria but not the eukaryotic 40S and 80S ribosomal
subunits.
The penicillins, probably the most widely recognised class of antibiotics, are
derivatives of the first chemotherapeutically effective drug, penicillin G. Discovered
accidentally by Fleming in 1929, it was not until 10 years later that Chain and Florey
embarked on purifying the active compound. In doing so, it was discovered that
different media would produce variations of the drug ofvarying potency. Further
developments came wdth the removal of the side-chain and replacing it with a variety
of substituents to yield a semi-synthetic compound that was not acid-labile and thus
could be administered orally. It was also resistant to some of the early (3-lactamases
(Stanier et al, 1987). This modification of the structure has continued and today we
have {3-lactam drugs with greater distribution through the body, increased half-life,
greater resistance to p-lactamases and a broader spectrum of activity.
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The fluoroquinolones are a synthetic class of antimicrobial whose roots lie in the
antimalarial drugs mepacrine and chloroquine (Wise, 2000). The first quinolone,
nalidixic acid, was synthesised after it was noted that the by-product distillates in the
manufacture of the anti-malarial chloroquine had antimicrobial properties (Lesher et
al, 1962; Smith, 1984). Figure 1.2 shows the structure of nalidixic acid. It is a
naphthyridine derivative that was used primarily for urinary tract infections owing to
its poor serum and tissue concentration and narrow-spectrum of activity, which was
confined to the Enterobacteriacae (Stamey et al, 1967).





Further quinolone development yielded drugs with minor modifications to the
nalidixic acid structure but these did not result in any major advance in antimicrobial
spectrum or pharmacokintetic activity. It was not until Koga et al, (1980) improved
absorption and activity with the addition of a fluorine at position 6 of the quinolone
pharmacore (Figure 1.3) that the development of the class of drugs known as the
fluoroquinolones took off. It should be noted that strictly speaking, C-6 fluorine
substituted quinolone drugs with a nitrogen at position 8 are naphthyridones, while
those with a carbon at this position are the "true" fluoroquinolones. However, for
this thesis, all drugs with a fluorine at position 6 will be termed fluoroquinolones.
4
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Figure 1.3. Fluoroquinolone pharmacore
It has been estimated that as many as 10,000 analogues of nalidixic acid have now
been investigated and much of this has focused on the fluoroquinolone pharmacore.
The addition of various subgroups to this basic design will now be outlined. Some of
the subgroups have not been possible to change without loss of basic activity. These
are positions 2, 3, 4 and 6. Position 2 must be hydrogen as any larger molecule may
create steric hindrance at positions 3 and 4. Position 3 and 4 must be a carboxyl and
an oxygen as these are essential for hydrogen bonding to DNA bases (Shen et al,
1989a, 1989b) or chelation to DNA phosphates via a Mg2+ bridge (Palumbo et al,
1993). The fluorine at position 6 is essential for potency as it is 5-100x more active
than any other group (Domagala, 1994)'.
1.3.1 Position 1
A cyclopropyl group at this position has been shown to control potency and have
some effect on pharmacokinetics. It has been reported that this confers Gram
negative activity and many fluoroquinolones having this substituent are active
against Gram negative organisms, for example ciprofloxacin (Figure 1.4).
5
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Other substituents include a 2,4-difluorophenyl moiety found in trovafloxacin and
tosufloxacin (Figures 1.5 & 1.6) which are equal, or in some cases more potent than
ciprofloxacin against Gram negative organisms. Clearly drug potency is not the
result of a single parameter. Another structure at this position is found in
levofloxacin which has a fused ring between positions 1 and 8 (Figure 1.7).
6
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The rank order of potency is cited as cyclopropyl > 2,4-difluorophenyl > fused ring.




Substitutions at this position are thought to contribute to potency against Gram
positive organisms (Domagala, 1994) for example sparfloxacin and grepafloxacin
exhibiting increased activity (Figures 1.8 & 1.9). However there have been side-






It was the addition of fluorine at this position giving greater absorption in the body
and increased activity that has led to the development of this class of drug. The
fluorine atom is responsible for the potency seen against DNA gyrase. However,
there has been a recent interest in quinolones without a fluorine at this position
(Lawrence et al, 2001). Compound BMS-340280 shows greater potency than the
newer fluoroquinolone moxifloxacin against both sensitive and resistant Gram
positive organisms thus casting doubt on the validity of the necessity of the C6
fluorine. BMS-340280 (Figure 1.10) does however have a di-fluoromethoxy
substituent at position 8, although an analogue of this without the C-8 moiety is still






The C-7 substituent is the most adaptable site for chemical change. It determines
potency and target preference in Streptococcus pneumoniae (Alovero et al, 2000)
and is an area where much intensive research is focused. This area also controls the
pharmacokinetic properties of the drugs, with a basic nitrogen required for oral
efficacy. A five- or six-membered ring is the most commonly found substitution at
position C-7, for example, gemifloxacin (Figure 1.11) and trovafloxacin (Figure 1.5),
have an aminopyrrolidine substituent at C-7 compared to a methyl group in nalidixic
acid (Figure 1.2). A piperazine substituent as seen with ciprofloxacin (Figure 1.4)
confers Gram negative activity. A bulky C-7 substitution is associated with a




C-8 substitutions control pharmacokinetics and enhance anaerobe activity. A CF
substitution is the most potent, with a methoxy substitution as seen with
moxifloxacin and gatifloxacin conferring less activity (Figures 1.12 & 1.13). The






Taken together, there are many claims as to what constitutes a potent
fluoroquinolone, even the idea that the C-6 fluorine is necessary. Since much of the
work done on these drugs is sponsored by pharmaceutical companies trying to
market their product as the best, it is easy to see how the data becomes somewhat
muddled. However, what is certain, is that positions 2, 3 and 4 will not be altered
from the basic pharmacore (Figure 1.3) and position 5 substitutions are associated
with toxicity. The remaining positions will continue to be developed within this
class of drug. In so doing, the potency, pharmakokinetic and broad-spectrum activity
of the fluoroquinolones will improve.
1.4 Bacterial Topoisomerases
A typical bacterium, if one such exists, is in the order of 2 x 1 pm in dimension, with
a chromosome of double stranded DNA which is 1300pm in length (Smith, 1986).
In order for the DNA to fit inside the bacterium, it is negatively supercoiled around
an RNA core. During transcription or DNA synthesis, the double stranded DNA is
unzipped to allow either a messenger RNA template to be made or a new DNA
strand to be synthesised. This unzipping of the DNA causes topological stress
upstream of the RNA polymerase or replication fork and induces the formation of
positive supercoils which need to be removed. To relieve this stress and remove the
positive supercoils, a topoisomerase known as DNA Gyrase, makes double-stranded
breaks in the DNA and introduces negative supercoils. After DNA synthesis, the
daughter chromosomes are unlinked by another Topoisomerase, Topoisomerase IV,
in a process called decatenation. Both these enzymes are essential to bacteria and are




DNA Gyrase is a heterotetramer composed of two A subunits and two B subunits,
encoded by the gyrA and gyrB genes. In E. coli, GyrA is 97kDa in size and GyrB
90kDa (Reece and Maxwell, 1991). Figure 1.14 shows two 59kDa fragments of
GyrA with the active-site tyrosine 122 highlighted in green. The GyrA subunits bind
to DNA, the GyrB subunits are ATPases that catalyse the re-setting of the enzyme
after the introduction of a negative supercoil. Figures 1.15 and 1.16 show the GyrB
subunits and a section through the dimer showing the ATP-binding site. The figures
were generated from the proteins' x,y,z coordinates using RasMol. For the purposes
of x-ray crystallography, a non-hydrolysable analogue ofATP, ADPMP, was used
and is visible in Figure 1.16. The hydrolysis ofATP is not required to introduce the
negative supercoiling, instead, upon binding to Gyrase, it induces a conformational
shift. (Berger et al, 1996). The DNA binds to the C-terminal DNA-binding domain
ofGyrA and a segment of approximately 130bp wraps around the tetramer
(Kampranis and Maxwell, 1996). DNA is cleaved in each DNA strand leaving a 4bp
staggered cut (Critchlow and Maxwell, 1996). A covalent DNA-protein intermediate
complex is formed between a DNA phosphate and a tyrosine residue (Tyr 122 in E.
coli) ofGyrA. Bond energy is conserved and no energy co-factor is required for
breakage or re-joining ofDNA. The severed DNA ends come apart and a gate opens
to allow the passage of double stranded DNA. Resealing of the DNA reduces the




Figure 1.14. E. coli59kDadimer of GyrA showing the position of the active-site
tyrosine 122 (green), the alpha helices (magenta), beta sheets (yellow) and other
residues (white). Figure generated from GenBank accession number 1AJ6.
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Figure 1.15. The GyrB dimer showing both subunits and the N- and C- domains.
The function of the "hole" is unknown and may result from the crystallisation of the










Like DNA Gyrase, topoisomerase IV is composed of 4 subunits, two each ofParC
and ParE. Topoisomerase IV has strong decatenating activity and its mechanism of
DNA breakage and reunion is similar to that ofDNA Gyrase. The ParC and ParE
subunits are homologous to GyrA and GyrB respectively. 36% of the ParC amino
acids are identical to those found in GyrA and 40% ofParE amino acids are identical
to those found in GyrB (Hooper, 1998). One of the principal differences between
DNA Gyrase and Topoisomerase IV is that whilst Gyrase wraps DNA around itself,
Topoismerase IV does not. Indeed, removal of the GyrA C-terminal converts Gyrase
into an eirzyme with strong decatenating activity suggesting that wrapping favours
intramolecular strand passage (Kampranis and Maxwell, 1996).
1.5 Fluoroquinolone Action on DNA Gyrase and
Topoisomerase IV
Fluoroquinolones act on DNA Gyrase and topoisomerase IV by preventing strand
passage of double stranded DNA on what is termed cleavable complexes. The




Figure 1.17. Strand passage. DNA is in two-planes, circle and dash coming out of
the page, bold horizontal line across the page. DNA Gyrase cleaves one strand of




The original model of quinolone action was proposed by Shen et al, (1989a,b). It
proposed that the drug binds to single-stranded DNA trapping the enzyme. This was
based on observations that quinolones bind preferentially to single-stranded DNA but
not to duplex DNA. The model suggests that four quinolone molecules bind
cooperatively, their C-4 and C-5 substituents hydrogen-bonded to the DNA bases
(Figure 1.18). The quinolones were thought to be in two pairs, interacting with each
other via it-n stacking and tail-tail hydrophobic interaction between theirN-l and C-
8 substituents. However this model relies on the DNA being cut by Gyrase, leaving
the 4bp single-stranded DNA, and it has been shown that Tyrl22 mutants which
cannot cleave DNA can still bind quinolone, a finding also demonstrated with
topoisomerase IV (Marians and Hiasa, 1997; Maxwell, 1997).
17
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Another model on quinolone action has been proposed, the Mg2+ bridge model
(Palumbo et al, 1993). This model proposes that the C7 and N-l substituents are not
involved in binding to nucleic acid as is thought to happen in the Shen model. The
C-4 and C-5 substituents chelate to DNA phosphates (Figure 1.19). The planar ring
structures of the quinolones are proposed to stack with DNA bases. This has also
been shown with human topoisomerase.il where one drug molecule intercalates into
DNA while a second molecule is externally bound to the first drug molecule and
DNA by two Mg2+ bridges (Kwok, Zeng and Hurley, 1999). Support for this model
comes from Fan et al, however their data suggest that it is gyrase-mediated
unwinding of duplex DNA and not single-stranded DNA that is the target (Fan et al
1995). In fact, it has been shown that fluoroquinolone binding is followed by a
conformational change of the Gyrase-DNA complex and that is responsible for the
inhibition of the enzyme and that cleavage ofDNA is not necessary for the drug to
bind to its target (Kampranis and Maxwell, 1998a; Kampranis and Maxwell, 1998b).
18
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Bacteria have been on this world for over 3 billion years. In this time they have had
to constantly evolve and adapt themselves to their ever-shifting environment. From
the pre-Eukaryotic era when they would have competed amongst their fellow
Prokaryotes for nutrients, to the present day where they have still to compete with
other Prokaryotes, but also have to compete with the Eukaryotes. Whether they are
soil-dwelling, marine, fresh-water, commensal or pathogenic, bacteria are under
stress to survive. In order to compete, many microbes produce a variety of
antimicrobial compounds such as antibiotics and bacteriocins whose aim is to inhibit
non-related species, although some target related species. In this background, it is
not surprising that they have the propensity to develop mechanisms of resistance to
antimicrobials. However, not only do they have the ability to mutate and acquire
resistance to modern antimicrobials, some bacteria have a natural resistance to
antibiotics. Resistance is not just a phenomenon of the antibiotic-era. In a study by
Dancer on coliforms from glacial ice in the Canadian High Arctic, it was found that
some of the organisms they collected were resistant to ampicillin, nalidixic acid,
trimethoprim and tetracycline (Dancer, Shears and Piatt, 1997). This finding is made
19
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all the more remarkable when they estimate that some of the organisms were over
2000 years old, well before the modern age of antibiotic pressure.
Antimicrobial resistance can occur in a number ofways, but can be summarised in
three: destruction of the drug before it reaches the target site, prevention of the drug
reaching its target or altering the target so that the drug has reduced affinity. With
the natural or semi-synthetic drugs, mechanisms exist for all three strategies. The
synthetic drugs on the other hand are believed to be "indestructible" to enzymatic
attack because an organism will never have encountered the drug "in the wild". The
fluoroquinolones come under the latter category and it is through mutational events
in the target site that lead to decreased affinity of the target to the drug combined
with changes in the cell envelope, that lead to resistance.
1.6.1 Fluoroquinolone Resistance
Resistance to the fluoroquinolones is mediated chiefly through mutations in the drug
targets: DNA Gyrase and TopoisomeraSe IV. The mutations are found in specific
regions of the genes called the quinolone resistance determining region (QRDR)
(Figures 1.20 & 1.21). In E. coli these are found between amino acids 67 and 106 in
GyrA and 426-447 in GyrB (Yoshida et al, 1990; Yoshida et al, 1991). A new
mutation in GyrA has recently been described in E. coli, Ala51Val, extending the
QRDR (Friedman, Lu and Drlica, 2001). Other mechanisms that contribute to
decreased sensitivity to these drugs are active efflux and reduced permeability. DNA
Gyrase and Topoisomerase IV are studied by restriction fragment length
polymorphism, sequencing of the genes and transformation assays. A mutation in
the gene that confers resistance is not dominant and is the basis for transformation
assays. If a sensitive gene is introduced into a resistant microbe and then
subsequently challenged with a fluoroquinolone, the organism is sensitive. Using
these methods, a picture ofwhat causes resistance and how it develops has been built
and will be outlined in the next sections.
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Figure 1.20. QRDR of 59kDa GyrA of E. coli. The QRDR of amino acids 67-106 is
coloured orange, serine 83 red and the protein backbone in blue. Note the dose
proximity of the active-site tyrosine (green). Figure generated from GenBank
accession number 1AJ6.
1.6.2 DNA Gyrase QRDR
The DNA Gyrase QRDR ofboth Gram negative and Gram positive organisms have
been extensively studied in both clinical isolates and laboratory generated mutants.
These data show that GyrA is normally the primary target of the fluoroquinolones in
Gram negative bacteria. In the case ofGram positive organisms, the primary target
is ParC, with GyrA the secondary target, although not all drugs exhibit this target
preference (Alovero et al,2000; Gonzalez 1998; Tavio 1999).
21
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Figure 1.21. Enlargement of Figure 1.20 showing the QRDR of GyrA. Amino acid
residues that are involved in resistance are highlighted in colour. The active site Tyr
122 is shown in cyan. Figure generated from GenBank accession number 1AJ6.
In E. coli, Yoshida and coworkers, using laboratory-generated mutants selected on
nalidixic acid or pipemidic acid, established GyrA mutations were present by
transformation with a wild type gyrAgene (Yoshida 1990). Sequencing
showed mutations that conferred the highest MICs were associated with a serine83-
leucine/tryptophan substitution. Using computer analysis on the effect of this
mutation, they hypothesised that the mutation causes a conformational change
combined with an altered hydrophobic profile ofthis region. This amino acid
substitution at position 83 is the most common mutation found in both Gram
negative and Gram positive organisms (Dessus-Babus et 1998; Mouneimne et al,
1999; Pan and Fisher, 1998; Piddock, 1999; Wise et al, 1997). The serine mutation
in E. coli has been found to reduce binding to radio labelled norfloxacin (Willmott
and Maxwell, 1993). Vertical transfer of this mutation has been found to be stable in
S. aureus after 500 generations in an antibiotic-free environment (Jones et al, 2000).
Other mutations contribute less to resistance and include in decreasing order for MIC
Asp87Asn, Gly81Cys, Ala84Pro, Ala67Ser and Glnl06His (Table 1.1).
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Not all organisms have a serine residue at position 83 ofGyrA. In Citrobacter
freundii and P. aeruginosa, a Thr83Ile mutation in GyrA is found in resistant isolates
(Nakano et al, 1997; Tavio et al, 2000).
Table 1.1. Mutations found in laboratory mutants of E. coli, the selecting agent and
Ciprofloxacin MIC's


























P. aeruginosa is innately more resistant to the fluoroquinolones than E. coli and a
single mutation in GyrA raises the MIC to above breakpoint values for ciprofloxacin
(Nakano et al, 1997). Wild type clinical isolates are susceptible to ciprofloxacin with
MIC's ranging from 0.05-1.56 mg/L. Nakano and coworkers (1997) found that a
Thr83Ile mutation in GyrA gave MICs of 12.5 - 25mg/L and Asp87Gly 6.25mg/L.
A GyrA Thr83Ile combined with a ParC Ser80Leu gave MICs of 12.5-50 mg/L. A
double GyrA mutation combined with the ParC Ser83Leu gave anMIC of 100 mg/L.
Thus the effect ofequivalent target-site mutations are not equal and other factors
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must be involved. A clue to this is that the most hydrophobic drug of those tested by
Nakano, sparfloxacin, showed the greatest increase in MIC. This finding suggests
that efflux and/or permeability may have a role to play in sensitivity to these drugs.
In S. pneumoniae, the fluoroquinolone C-7 substituent has been found to determine
potency and target preference (Alovero et al, 2000). Using analogues of
ciprofloxacin with a benzenesulfonylamido group added to the C-7 piperazinyl ring,
Serine 81 mutations were found in GyrA. This contrasts with ciprofloxacin selecting
for a ParC mutation (Alovero et al, 2000). In a separate study, Pestova and
coworkers (2000) attribute this altered target preference to C-8 substitutions, with C-
7 involved in efflux. They found that both moxifloxacin and sparfloxacin target
GyrA whereas ciprofloxacin targets ParC . It is difficult to interpret data by using
structurally dissimilar fluoroquinolones, as moxifloxacin, ciprofloxacin and
sparfloxacin differ not only in C-7 and C-8 but also at position C-5. The use of
structural analogues, as in the former study, gives a clearer picture of the
development of resistance and the use ofdissimilar drugs only muddies the water.
1.6.3 Mutations in GyrB
Mutations in GyrB occur less frequently and are responsible for a modest increase in
resistance. Yoshida investigated mutations in GyrB ofE. coli (Yoshida et al, 1991).
Using laboratory selected E. coli isolated from nalidixic acid or enoxacin plates, it
was found that mutants could be divided into two groups. Group 1 were resistant to
all the quinolones tested and had an Asp426-Asn mutation in GyrB. Group 2
mutants carried a Lys447-Glu mutation in GyrB and were resistant to acidic
quinolones but hypersusceptible to amphoteric quinolones. The wild type parent had
a ciprofloxacin MIC of 0.0125 mg/L and nalidixic acid MIC of 3.13 mg/L. Group 1
mutants had MICs of 0.05 and 50mg/L respectively while group 2 had MICs of
0.031 and 50mg/L respectively. These mutations are near hydrophilic regions of the
GyrB enzyme as predicted by a hydrophobicity plot of the amino acid sequence.
24
Chapter 1: Introduction
This area is thought to constitute the surface of the molecule and that the mutations
will shift the local conformation of the molecule, reducing its binding affinity.
In C. freundii, a His417-Leu substitution in GyrB has been found but its role is
unknown, however it did not on its own confer resistance (Tavio et al, 2000). A
Ser464-Phe mutation in GyrB has been described in P. aeruginosa (Mouneimne et
al, 1999). Complementation with E. coli wild-type GyrB showed a 66-fold reduction
in ciprofloxacin MIC. However, this mutation is quite rare. In their study it was
found in only 2/28 isolates, with a GyrA mutation being found in all isolates tested.
In S. pneumoniae, GyrB mutations were found to be of no significance (Jones et al,
2000). These data suggest that GyrB mutations are quite rare and it is GyrA
mutations that are ofmore importance in the development of fluoroquinolone
resistance.
1.6.4 Mutations in Topoisomerase IV
ParC mutations are found in Gram negative organisms most often when there is a
concurrent mutation in GyrA. In Gram positive microbes, as we have seen, ParC can
be both a primary and secondary target. As a GyrA mutation often confers clinical
resistance, a ParC mutation merely raises the MIC higher and in effect are
superfluous. However this is not the case with all microbes. In E. coli, high-level
resistance is mediated through a double GyrA mutation in conjunction with a Ser80
mutation in ParC (Heisig, 1996). With sequential laboratory generated mutants, it
has been found that resistance follows a pattern of a Ser83-Leu substitution in GyrA,
a Ser80 in ParC and then an Asp87-Asn in GyrA (Bagel et al, 1999). The first two
mutations have not been found to compromise supercoiling or decatenation in DNA
Gyrase or Topoisomerase IV respectively although the Asp87Asn does reduce
Gyrase-mediated supercoiling in vitro. In P. aeruginosa, mutations in ParC have
been mapped to regions that are analogous to those found in GyrA, namely Ser80-
Leu, although Glu84Lys has been reported (Mouneimne et al, 1999). As strains with
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a ParC mutation also have a GyrA mutation, it is possible to complement an isolate
with sensitive GyrA and it has been shown that the ParC mutation on its own
contributes nothing to resistance.
In Enterococcus faecalis ParC is the primary target (Kanematsu et al, 1998). The S.
aureus ParC enzyme is called GrlA and the most commonly found mutation is
Ser80-Phe which confers ciprofloxacin resistance (Jones et al, 2000).
1.6.5 Mutations in ParE
Like GyrB, mutations in ParE are rare and their contribution is minor. In Gram
negative organisms, very few studies have looked at mutations in ParE. Everett et al
(1996) found no amino acid changes in either E. coli ParE or GyrB. Just how minor
ParE mutations are is illustrated in a study of S. aureus GrlB (Tanaka et al, 1998).
Looking at the inhibitory activity of levofloxacin on purified topoisomerase IV, the
IC50 for the wild type was 2.3pg/ml, an Asp432-Asn mutation in GrlB was 14pg/ml
and 3.4pg/ml with an Asn470-Asp mutant. The authors concluded that position 432
may be responsible for quinolone resistance. However, the IC50 of a Phe80 and
Lys84 GrlA protein was 180 and 130|ig/ml respectively and if combined as a double
mutation, an IC50 of 1160pg/ml was recorded. Clearly the effect of a GrlB mutation
on its own is not sufficient to confer resistance. At best, it will increase the MIC of a
strain with a GrlA mutation 2-4 fold.
Janoir reports a new mutation in S. pneumoniae ParE with an in vitro mutant selected
on moxifloxacin (Janoir et al, 2001). The mutant had a Ser81-Phe mutation in GyrA
and a Hisl03-Tyr mutation outside the QRDR of ParE. This double mutation
increased the moxifloxacin MIC 4-fold, ciprofloxacin 2-fold and a 2-fold decrease to
novobiocin. A mutant with only the GyrA mutation had a 2-fold moxifloxacin
increase and no difference in ciprofloxacin or novobiocin MIC.
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1.6.6 Efflux-mediated fluoroquinolone resistance
It is not only topoisomerase mutations that confer fluoroquinolone resistance, active
efflux of the drug via efflux pumps has been shown to contribute to resistance in both
clinical and laboratory mutants. These pumps have been found in both Gram
negative and Gram positive organisms and have the ability to pump out a wide range
of substrates giving rise to multi-drug resistance (MDR) phenotypes. In Gram
negatives, the MDR phenotype has been described in Stenotrophomonas maltophilia,
P. aeruginosa E. coli and A. baumannii (Li, Livermore andNikaido, 1994; Mazzariol
et al, 2001; Zhang, Li and Poole, 2000; Magnet et al, 2001).
There are two types of efflux pump that differ in their construction among Gram
negative bacteria. One, the EmrE pump ofE. coli is a member of the Smr family
(Staphylococcal multidrug resistance) in which drugs are pumped into the
periplasmic space (Nikaido, 1998). It is composed of a single cytoplasmic
membrane-spanning H+ antiport protein. This type ofpump is not known to
contribute significantly to clinical resistance. The second type ofpump, known as
the RND type (resistance-nodulation-division) contains at least three components, a
transporter protein in the cytoplasmic membrane, an outer membrane pore and a
linker protein that is found within the periplasm (Paulsen, Brown and Skurray, 1996)
(Figure 1.22). Examples ofRND pumps are the AcrAB system ofE. coli, AdeABC
ofA. baumannii and MexAB-OprM ofP. aeruginosa. These pumps can efflux drugs
directly out of the cell and into the medium and if coupled with a permeability
barrier, can lead to significant resistance levels. In a laboratory E. coli mutant that
had GyrA mutations, knocking out the AcrAB efflux pump converted it from
resistant to ciprofloxacin and ofloxacin to hypersusceptibility (Oethinger et al, 2000).
One criticism of laboratory mutants is that their phenotypes may not be found in
vivo. However, overexpression ofAcrAB has been reported in 9/10 high-level
fluoroquinolone resistant E. coli clinical isolates (Mazzariol et al, 2001).
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Fluoroquinolone resistance attributed to a transferable plasmid has been reported
(Martinez-Martinez, Pascual and Jacoby, 1998). Upon transformation with the
plasmid from K pneumoniae, the MIC of fluoroquinolones and non-
fluoroquinolones were raised, suggesting that the plasmid encoded a multiresistance
efflux pump. The fluoroquinolone MICs of susceptible organisms rose 4-30 fold, but
not to a concentration conferring resistance. Therefore the authors failed to
demonstrate fluoroquinolone resistance. However, if this were to happen in the
clinical setting, the results could prove to be disastrous. Possession of this efflux
system could allow an organism the opportunity to accumulate a Gyrase mutation
and thus become resistant. By also carrying the plasmid, the organism would be at a
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selective advantage in areas with high drug usage and thus may be extremely
difficult to eradicate.
In Gram positive organisms, efflux pumps are investigated using the pump inhibitor
reserpine to block its action and show increased drug accumulation and sensitivity
(Beyer et al, 2000). Reserpine has no established effect on Gram negative pumps
although Miyamae et al (1998) and Vila et al (2002) have recently claimed limited
success with reserpine on Bacteroidesfragilis and A. baumannii. A more effective
method to illustrate active efflux is with CCCP. CCCP is an uncoupler that is used to
break the proton motive force and thus inhibit the pump. These methods have shown
that resistant organisms efflux more drug than sensitive strains (Denis and Moreau,
1993; Li, Livermore and Nikaido, 1994). Drug potency has been shown not to
correlate with accumulation i.e. the most potent drugs do not necessarily accumulate
the most (Bazile et al, 1992).
Other studies have shown there is a correlation between hydrophobicity and
accumulation in S. aureus and an inverse correlation in E. coli and P. aeruginosa
(Piddock, Jin and Griggs, 2001). Table 1.2 shows drug accumulation and
corresponding MIC in P. aeruginosa. Ciprofloxacin is more potent and hydrophilic
than sparfloxacin yet accumulates less drug. In the same study, DNA Gyrase
inhibition assays found a correlation between potency and MIC. Thus it is the
inhibitory activity of the drugs that are important and not how much they
accumulate. However, if less drug reaches the target, their inhibitory effect will be
less. P. aeruginosa intrinsically accumulates less fluoroquinolone than E. coli and
this is attributed to a low number of porins that lowers its permeability. High-
molecular weight drugs appear to also limit their accumulation in P. aeruginosa.
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Table 1.2. Drug accumulation and MIC of P. aeruginosa
Accumulation
Drug MIC (mg/L) (ng drug/ mg dry cell)
Ciprofloxacin 0.5 36
Sparfloxacin 1 48
1.6.7 Outer Membrane Permeability
One other factor found to contribute to fluoroquinolone resistance in Gram negatives
are changes in the outer membrane leading to a decrease in permeability. This
mechanism has also been linked to resistance with other classes ofantibiotic; for
example imipenem resistance in A. baumannii associated with reduced expression of
a 33-36kDa OMP (Clark, 1996). In P. aeruginosa a reduction in protein D2 has been
linked to a decrease in both sparfloxacin and imipenem sensitivity
(Micheahamzehpour, Furet and Pechere, 1991). Outer membrane protein expression
is not the sole parameter in permeability as lipopolysaccharide has been linked to
reduced fluoroquinolone diffusion into P. aeruginosa and S. typhimurium
(Micheahamzehpour, Furet and Pechere, 1991; Hirai, Aoyama et al, 1986a).
However not all OMP mutants exhibit reduced fluoroquinolone sensitivity so their
contribution alone is not clear-cut. In a study on Klebsiella pneumoniae, Hernandez
found an association with an altered OMP profile and resistance to p-lactams but not
with fluoroquinolones, suggesting porin specificity (Hernandez-Alles et al, 2000).
However, in an efflux strain, an altered OMP profile does show fluoroquinolone
resistance (Chevalier et al, 2000). Given that diffusion ofdrug reaches its maximum
concentration within 3 minutes of challenge, it seems unlikely that a reduction in
permeability will contribute to resistance unless it is coupled with efflux (Li,
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Livermore and Nikaido, 1994). Therefore the role ofOMPs is secondary to active
drug efflux.
1.6.8 Fluoroquinolone Resistance in A. baumannii
The gyrA QRDR ofA. baumannii was first investigated by Vila using primers
designed from conserved amino acid motifs from diverse GyrA proteins (Vila et al,
1995). Analysis of the gyrA QRDR showed 71% identity to E. coli, and 69% with P.
aeruginosa at the nucleotide level. The protein sequence has 82% identity with E.
coli, 74% with S. aureus, 75% with Campylobacter jejuni and 83% with P.
aeruginosa.
It was found that the same GyrA amino acids were mutated in resistant strains ofA.
baumannii as are found in other Gram negative organisms, namely a Ser83-Leu
substitution. The major difference was that whereas in E. coli the serine 83 mutation
still leaves the organism susceptible to ciprofloxacin, in A. baumannii it conferred
resistance. In E. coli this mutation raises the wild type ciprofloxacin MIC from
0.0125mg/L to 0.39mg/L (Yoshida et al, 1990). In A. baumannii the wild type
ciprofloxacin MIC's are < lmg/L and the serine mutation confers an MIC of 4-
16mg/L. Thus it seems that the effect of equivalent mutations are not equal. One
explanation of this could be that A. baumannii Gyrase is innately less sensitive than
that ofE. coli. Results ofDNA gyrase supercoiling inhibition assays demonstrated
that sensitive A. baumannii Gyrase had a minimal effective dose that was 5-10 times
less sensitive to ciprofloxacin than wild type E. coli Gyrase (Moreau et al, 1996).
Another explanation is that A. baumannii exhibits low outer membrane permeability
coupled with efflux (Hancock, 1998). Other mutations in A. baumannii GyrA were
found but these appear to have little effect on MIC sensitivity. These mutations have
also been found by Seward and Towner (1998).
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Moreau measured drug accumulation in A. baumannii and found no significant
difference in accumulation with regard to MIC, although the more hydrophobic drug
pefloxacin accumulated less than ciprofloxacin (Moreau et al, 1996).
The ParC gene was investigated by Vila (Vila et al, 1997). At the nucleotide level,
A. baumannii parC has 72% identity with E. coli, 71% with that ofSalmonella
typhimurium and 72% with Haemophilus influenzae and at the protein level, 89%
identity with E. coli, 88% with S. typhimurium and 84% with H. influenzae. The
QRDR showed a Ser80-Leu mutation in those strains already carrying a GyrA Ser83-
Leu mutation. These mutations recorded ciprofloxacin MICs of 32-128mg/L. One
strain had a Glu84-Lys mutation in conjunction with a GyrA Ser83Leu mutation,
recording an MIC of 64mg/L. Seward also investigated the ParC gene and found that
the double Ser83/Ser80 mutation gave ciprofloxacin MICs of 64 mg/L. One strain
had a second mutation in ParC, Tyr74-Cys, but this appears to have no net effect as it
recorded an MIC that is equal to the single mutation (Seward and Towner, 1998).
Thus in A. baumannii ciprofloxacin resistance is mediated through a single mutation
in GyrA, at serine 83. High-level resistance is found in strains with a GyrA mutation
and a concurrent serine 80 mutation in ParC.
1.7 The Genus Acinetobacter
The genus Acinetobacter are Gram negative cocco-bacilli that are strict aerobes and
do not ferment glucose. They are non-motile, oxidase negative and catalase positive
(Vila, 1998). The organisms are widely distributed in the environment and are
sometimes part of the human skin flora. Although not strictly pathogenic, they are
becoming increasingly important nosocomial pathogens in intensive care units
(ICU), although they have been associated with community acquired pneumonia
(CAP) in the tropics (Anstey, Currie and Withnall, 1992).
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The acinetobacters are often cited as being commensal organisms and a study by
Seifert et al on the distribution ofAcinetobacter spp on human skin confirms this
(Seifert et al, 1997). While it was found that members of the genus were recovered
from humans, A. baumannii was only found in 1% of samples compared with 47%
for the less clinically relevant A. Iwoffii. In a contrasting study by Adams, 21% of
health care workers were found to be carrying A. calcoaceticus (Adams and Marrie,
1982a).
One question that has been puzzling researchers is where does A. baumannii come
from? The organism has been isolated from many surfaces in hospitals and is hard to
eradicate once it has established itself. Experiments have shown that the organism
can survive on dry menstra for up to 30 days (Jawad et al, 1996). It has been
recovered from computer keyboards (Neely, Maley and Warden, 1999) where it was
found that gloved medical staff would go from patient to computer keyboard without
removing gloves and that other staffnot touching patients would enter and retrieve
data from the same computer. Thus a reservoir for the organism was established
leading to a rise in the number of colonisations in their burns unit. It has been
recovered from bed rails in an ICU outbreak where patients were moved between
different sectors of the ICU (Catalano et al, 1999). Feather pillows have been found
to harbour A. baumannii (Weernink et al, 1995) and even vegetables (Berlau et al,
1999) where genospecies 1, 2, 3 & 13TU were significantly more resistant to
ciprofloxacin and gentamicin than the other genospecies isolated. It is not only A.
baumannii that has been isolated from inanimate objects. Kappstein et al describes
tap aerators as being the reservoir for an A. junii outbreak in a childrens oncology
ward. Disturbingly, the organism was found only in the tap aerators of the staff room
(Kappstein et al, 2000).
Given that the organism survives well in the hospital environment, one can conclude
that effective control measures to prevent spread of the organism need to be
implemented and strictly adhered to. In Holland, guidelines are in force to prevent
the spread ofMRSA from patients transferred from abroad. They are placed in strict
isolation upon admission to a Dutch hospital. In a retrospective study by Bernards, 3
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patients were colonised with MRSA and multi-resistant Acinetobacter and placed in
3 separate hospitals. The MRSA did not spread but two of the Acinetobacters did.
The "clean" hospital used airborne precautions while the other two didn't (A. T.
Bernards, PhD thesis).
The distribution of the organism on skin may be transient. It has been found that the
colonisation rates of patients increased with their length of stay (Seifert et al, 1997).
Patients carried more Acinetobacter than healthy controls although 7/40 of the
controls were laboratory workers and may well have picked up the organisms in their
laboratories. A quantitative count of the organisms showed that they were present at
2 log2 less than Gram positive skin organisms. Previous work looking at skin
colonisation was done with old taxonomy and thus may be unreliable. Of the body
sites tested, the throat and perineum was the least colonised and that the rest of the
body was equally distributed with the organisms.
1.7.1 Speciation of the Acinetobacters
Speciation of acinetobacter has been a problematic area for some considerable time.
Traditionally, biochemical tests have been employed to speciate bacteria and clinical
laboratories routinely use biochemical test strips such as the API-20NE system.
However this has a success rate reported to be as low as 45% and cannot differentiate
between genospecies 1, 2, 3, & 13TU (Bernards et al, 1996). Because of the
difficulty in differentiating between these genospecies by phenotypic methods,
Tjernberg and coworkers suggested naming them the A. calcoaceticus-baumannii
complex (Acb) (I. Tjernberg PhD thesis). Recently, more automated systems like
Vitek have been used as they are less labour intensive and species identification is
done by machine. However with the acinetobacters, the use of such techniques does
not guarantee successful identification. In a study by O'Hara and co-workers to
evaluate Vitek GNI+ and Crystal E/NF identification systems, it was found that the
overall accuracy for correctly identifying Gram negative bacilli was less than 90%
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(OHara, Westbrook and Miller, 1997). The accuracy for non-Enterobacteriacae was
60%, with the Vitek identifying 1/5 ofA Iwoffii correctly.
A Vitek system has also given false positive results for imipenem sensitivity with 32
out of 35 isolates testing sensitive using more traditional sensitivity tests (Tsakris et
al, 2000). It was not until the advent of molecular methods to speciate the organism
did a true picture of the genus became known. Bouvet and Grimont (1986) used
DNA-DNA hybridisation to identify 12 Acinetobacter genospecies. They named
A. baumannii, A. haemolyticus, A. johnsonii, A. junii, and emended A. calcoaceticus
and A. Iwoffiii. Prior to this only A. calcoaceticus and A. Iwoffii were approved
names and A. calcoaceticus was the only one in Bergeys Manual. Tjernberg used
DNA-DNA hybridisation to further identify 3 other genospecies, 13TU, 14TU and
15TU (I. Tjernberg PhD thesis). This technique has been further used in conjunction
with AFLP and 16S rRNA to speciate the clinically isolated phenoms I and II and
name them A. ursingii and A. schindleri (Nemec et al, 2001). An environmental
isolate, A. venetianus, has also been described (di Cello et al, 1997). Since then, 6
more genospecies have been identified but are as yet unnamed with the exception of
species 12, A. radioresistens.
Other methods used to speciate have included cell envelope profiles (Dijkshoorn,
Michel and Degener, 1987), ribotyping (Koeleman et al, 1997; Seifert et al, 1997;
Vaneechoutte et al, 1999), carbon source utilisation (Bouvet and Grimont, 1987) and
gyrB sequences (Yamamoto, Bouvet and Harayama, 1999). These methods have
good discrimination although have the disadvantage of being tedious and require
many hours ofwork. A rapid method exists which is PCR based and relies on
species specific conserved regions of the spacer regions of tRNA (Ehrenstein et al,
1996). It has been proven to be quick and reliable for identification ofmost
Acinetobacter spp although it cannot differentiate between A baumannii & 13TU
and A. calcoaceticus & group 3 (Ehrenstein et al, 1996). For routine use it is
probably the best option however DNA-DNA hybridisation remains the only method
that will differentiate with certainty.
35
Chapter 1: Introduction
1.7.2 Acinetobacter in the clinical setting
Acinetobacter spp cause a range of nosocomial illnesses including pneumonia,
bacteraemia, secondary meningitis, urinary tract infections and surgical wound
infections. Speciation has revealed that 73-90% ofAcinetobacter infections are
associated withH. baumannii or genospecies 13TU (Seifert et al, 1997) although a
10-year study by Traub and Bauer (2000) found that genospecies 3 was the most
prevalent species isolated, accounting for almost 50% of 2359 isolates. A. baumannii
accounted for 15%. Traub only employed phenotypic tests and these are not
adequate to differentiate between genospecies 1, 2, 3 and 13TU, therefore the true
total for A. baumannii may be higher.
Acinetobacter is a significant coloniser of materials such as ventillator tubings,
endotracheal tube, intravascular access devices, surgical drains and urinary catheters.
Outbreaks and infections associated with contaminated suction bottles and catheters
in neonatal units, arterial lines, central venous catheters and ventilators are well
documented (Minnaganti and Cunha, 2000; Pillay et al, 1999; Richards et al, 1999;
Lesseva, 1998; Seifert et al, 1995).
The incidence of bacteraemias caused by Acinetobacter spp. increased year on year
in England and Wales over the 1990s. Data from the Public Health Laboratory
Service are shown graphically in Figure 1.23. These data show that the numbers of
bacteraemias has more than tripled in the nine-year period. To put this into
perspective, during this same period, Salmonella typhi bacteraemias decreased from
182-181 cases, E. coli rose from 7780-11329 cases and P. aeruginosa from 1084-
1367. Although acinetobacter is not the most prevalent Gram negative pathogen
causing bacteraemia, it has shown the greatest rise in this period. Gram positive
bacteraemias caused by S. aureus doubled from 4890 in 1990 to 10235 in 1999 while
S. pneumoniae went from 3507-4001. These data do not include other infections.
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Figure 1.23. Incidence of Acinetobacter spp. bacteraemia
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1.7.3 Risk Factors Associated with Infection
The biggest risk factor for infection (as opposed to colonisation) is an
immunocompromised status. Even the reports ofCAP linked with an Acinetobacter
infection was associated with a compromised host: smoking, alcoholism, an
underlying chronic obstructive airway disease and a history ofpneumonia are cited
by Anstey, Currie and Withnall (1992). There are other factors like survival on
innate objects previously discussed and transmission through inadequate infection
controls. However, prior-use ofbroad-spectrum antibiotics has a large role to play in
the dissemination of this organism. The use of ceftazidime to treat Pseudomonas
infections and inadvertently selecting for Acinetobacter has been well-documented
(Koeleman et al, 1997; Yoo et al, 1999) as has the use of a fluoroquinolone
(Cendrero et al, 1999; Husni et al, 1999). Villers et al (1998) found a relationship
between intravenous ciprofloxacin and Acinetobacter infection and hypothesised that
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oral ciprofloxacin exerts less selective pressure in the gut. Length of stay has also
been linked to infections (Koeleman et al, 1997).
The selective pressure of ciprofloxacin also results in an increase in fluoroquinolone
resistance. Muder et al (1991) looked at the association between prior
fluoroquinolone use and ciprofloxacin resistance among Gram negative bacteria.
They found a significant relationship between prior drug use and resistant bacteria,
with a stronger association seen with those in long-term care as opposed to acute
care. This finding is not seen in all hospitals. Pieroni looked at the incidence of
ciprofloxacin resistance in blood-culture isolates before and after the introduction of
ciprofloxacin in 1989. He found that there was no significant increase in resistance
to this drug in either Acinetobacter spp or Pseudomonas. Resistance rates to other
drugs in this hospital remained low over the 16-year study period suggesting a
prudent antibiotic policy (Pieroni et al, 1997).
A study by Fagon et al (1996) looked at the mortality relationship between
colonisation ofAcinetobacter or Pseudomonas spp in patients undergoing
mechanical ventilation and those with pneumonia due to these pathogens (<10
cfu/ml, >103 cfu/ml respectively). As patients undergoing this procedure are usually
the most severely ill and have the most severe nosocomial infections, it is sometimes
hard to establish ifmortality is due to the infection or if the patient would have died
as a result of their underlying illness. They found that there was a relationship, with
29% mortality of those colonised (28% for non-colonised patients) and 73% of those
infected.
There has been speculation as to seasonal variation in Acinetobacter infections, with
one report from Germany stating no difference was found between seasons (Seifert et
al, 1997) and another from the USA contrary to this which found a higher incidence
between July and October (McDonald, Banerjee and Jarvis, 1999). However given
the fact that most infections occur in ICU wards and that in the USA these will be
air-conditioned and thus climatically-stable, it seems unlikely that warm summer
days will lead to a higher incidence of infection. An alternative explanation for
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McDonald and co-workers could be that during summer holidays, experienced staff
are temporarily replaced with part-time staff and this combined with an influx of
freshly-graduated junior doctors, leads to an increase in patient-to-patient
transmission mediated through a breakdown in infection control measures. Hand
carriage ofGram negative organisms on hospital workers is well-documented, with
colonisation rates of 31% and 21% of healthcare workers carrying A. calcoaceticus
on their hands. This is unsurprising given that Husni reports that only 10% of
healthcare workers wash their hands between patients (Adams and Marrie, 1982a;
Adams and Marrie, 1982b; Husni et al, 1999).
1.7.4 Typing of Acinetobacter
As with speciation, many methods have been employed in the study of the spread of
this organism through the nosocomial environment. It is ofparamount importance
during an outbreak to determine if the organism responsible is either a clone and thus
spreading between patients, or unrelated strains that are endogenous to the patient.
Another reason why this is important is'to discover the source of an outbreak, so that
adequate measures to eradicate the organism can commence. Early attempts to type
Acinetobacter relied upon phenotypic characteristics such as biotypes and
antibiotypes. For example, carbon utilisation at different temperatures (Bouvet and
Grimont, 1987). However, as we will see, these methods are unreliable. Once again,
it was the development ofmolecular techniques such as pulsed-field gel
electrophoresis (PFGE) that have led to a better understanding of the epidemiology
of the organism and also its reservoirs.
In a comparative study, perhaps the easiest to interpret, Seifert and coworkers
compared 4 different methods for epidemiologic typing ofA. baumannii: plasmid
profile, antimicrobial susceptibility, PFGE with the restriction enzyme Apal, and
biotyping (Seifert et al, 1994). Plasmid profiles were found to be good and may be
used as a cost-effective first-step in epidemiologic typing. However, one of their
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outbreak strains lacked a plasmid and so was untypable with this method. Antibiotic
testing put some strains in the same group but with PFGE they were not identical.
Biotyping has poor discrimination and classified as the same biotype isolates that had
different PFGE patterns. In conclusion to this, it was found that PFGE is
reproducible and easily readable, a finding that has also been reported by Gouby
(Gouby et al, 1992).
Another more recent study looked at an outbreak ofA. baumannii and typed them by
antibiotyping and ribotyping (Biendo et al, 1999). These methods appeared to
correlate but they had to combine results as they had 4 antibiotypes and 7 ribotypes.
Biotyping did not discriminate well as it grouped different DNA groups together.
Seifert compared ribotyping and PFGE and found that PFGE was more
discriminatory as it identified 49 distinct patterns and 7 variants while ribotyping
only identified 8 patterns with Clal and 31 patterns with EcoRl (Seifert and
GernerSmidt, 1995). However they conclude that while PFGE is a more
discriminatory method for typing, ribotyping may be used to speciate within the Acb
complex as it generates bands that are unique to each DNA group.
Another method used for typing is infrequent restriction site PCR (IRS-PCR). This
has been reported to be as discriminatory as PFGE but is less laborious and time-
consuming (Riffard et al, 1998). Yoo et al (1999) used IRS-PCR to investigate an
outbreak and found that the outbreak strain was isolated from the Y-piece of a
mechanical ventilator and also from the hands of two health care workers. However
no comparative studies of this technique has been done to date on Acinetobacter spp.
Comparisons have been conducted between PFGE and IRS-PCR on other Gram
negatives with Garaizar et al (2000) stating that interassay and intercentre IRS-PCR
has low reproducibility and discrimination compared to PFGE, a finding that is
contradicted by others (Riffard et al, 1998; Su et al, 2000).
Epidemiological studies suggest that Northern Europe is experiencing the spread of
epidemic Acinetobacter clones (Dijkshoorn et al, 1996). A survey of 31 A.
baumannii isolates comprising 14 strains from 14 outbreaks and 17 sporadic strains
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from north-western European cities were typed using numerous methods, both
phenotypic and genotypic. It was shown that 12 strains from unrelated outbreaks
were linked into two clusters. The sporadic strains were more heterogeneous. This
suggests that the outbreak strains have a common clonal origin. Interestingly, at both
the genomic and outer membrane protein profile typing level, the strains were
homogeneous, but their biotype and antibiograms showed more variability,
illustrating how undiscriminating some of these methods can be. Not all outbreak
strains could be grouped in this way therefore outbreaks are not exclusively caused
by the two clones. In a follow-up to this, the development of ciprofloxacin resistance
was investigated during a 20 month period (Horrevorts et al, 1997). It was found
that two strains had the same OMP profile but had different carbon source growth
requirements. There was a shift in these requirements with the conversion of strains
to being ciprofloxacin resistant. The switch coincided with the introduction of
ciprofloxacin in the ICU. The protein profiles were found to resemble clones from
group 1 (described above). The data suggest ciprofloxacin exerted selection
pressure.
Given these facts, one can ask the question if the same Acinetobacter clones are
found throughout the world. Seward looked at the epidemiology of fluoroquinolone
resistant strains and found that the strains were genotypically distinct and conclude
that resistance is occurring independently worldwide (Seward and Towner, 1998).
Taking all this together, molecular methods and in particular PFGE, are the most
discriminating and reproducible technique for epidemiological studies; however they
are time consuming and often need sophisticated software to read the banding
patterns. There is a need for simple tests that can be used in routine clinical
laboratories for surveillance purposes.
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1.7.5 Treatment of Acinetobacter baumannii infections
With the organism being innately resistant to many antimicrobials, what treatments
are available? The fluoroquinolones are still prescribed and with prudent use and a
knowledge of the indigenous strains in a hospital, they are very effective as seen in
the survey undertaken by Pieroni et al (1997). If fluoroquinolone use is not an
option, then a carbapenem such as imipenem can be effective. Resistance to this
drug is on the increase. A world-wide survey undertaken by the SENTRY
Antimicrobial Surveillance Programme found nearly 11 % of isolates were resistant
to imipenem (Gales et al, 2001). Another option is ampicillin/sulbactam (Cisneros et
al, 1996). However, perhaps one of the best treatments for Acinetobacter infections





• A. baumannii is a serious nosocomial pathogen
• Incidence ofbacteraemia is increasing
• Acinetobacter is multiresistant
• Clonal spread of resistant strains threatens hospital patients
• Fluoroquinolone resistance is on the increase
• Infection is associated with this class of drug as is selection of resistant
phenotypes
• There is a reliance on carbapenems but this class of antibiotic for therapy is under
threat
• There is a need for newer, more active drugs
• Little is known about how the new fluoroquinolones compare to the older
members of this drug class against A. baumannii
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1.9 Aims of This Thesis
• Speciate a cohort ofAcinetobacter spp. using a molecular method
• Compare the potency of the old and newer fluoroquinolones against
Acinetobacter spp. by kill-curve and agar dilution MIC
• Determine the mechanism of resistance to the newer fluoroquinolones with A.
baumannii
• Investigate the in vitro development of fluoroquinolone resistance in A.
baumannii and compare the mutation rates of ciprofloxacin to gemifloxacin and
moxifloxacin
• Examine other factors that may contribute to fluoroquinolone resistance
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2.1 Bacterial strains
The standard laboratory strains Escherichia coli NCTC 10418, Pseudomonas
aeruginosa NCTC 10662, Staphylococcus aureus NCTC 6571 and Acinetobacter
baumannii ATCC 19606 were used as controls for the determination ofMICs. One
hundred and one isolates ofAcinetobacter spp. (47 A. baumannii, 18 A. anitratus, 18
A. Iwoffii, 13 A. calcoaceticus and 4 unspeciated Acinetobacter spp.) were
bloodstream isolates obtained from the University of Iowa College ofMedicine,
Iowa City, USA. They had been previously speciated in a Vitek machine.
The standard Acinetobacter DNA groups listed in Table 2.1 were used for molecular
speciation and were a gift from Dr K. Towner except Species 2, which was gift from
Scott Cameron. Strains were stored at -70°C in Nutrient Broth (Oxoid, Basingstoke,
UK) containing 10% glycerol and subcultured overnight on MacConkey agar
(Oxoid) at 37°C except for Acinetobacter spp. 6, 5 & 12 which were subcultured on
Nutrient Agar (Oxoid) at 30°C.
2.2 Media, Buffers and Reagents
All buffers were made with chemicals purchased from Sigma (Poole, UK) unless
otherwise stated. Acetic acid and Hydrochloric acid were purchased from BDH
(Poole, UK). Saline was made with 0.8% NaCl and sterilised before use. Media was
purchased in powder form from Oxoid (Basingstoke, UK) and made with distilled
water before sterilisation.
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Table 2.1. Standard Acinetobacter strains
Genospecies No.* Species Name Strain No.
Species 1. A. calcoaceticus ATCC 23055
Species 2. A. baumannii ATCC 19606
Species 3. unnamed ATCC 19004
Species 4. A. haemolyticus ATCC 17906
Species 5. A. junii ATCC 17908
Species 6. unnamed ATCC 17979
Species 7. A. johnsonii ATCC 17909
Species 8. A. Iwoffii ATCC 5866
Species 12. A. radioresistens
* (Bouvet and Grimont, 1986; Bouvet and Jeanjean, 1989)
2.3 Antimicrobial Agents
The following antibacterial agents were used: Gemifloxacin (GlaxoSmithKline,
Collegeville, PA, USA), Ciprofloxacin (Bayer A. G., Leverkusen, Germany),
Trovafloxacin (Pfizer, Sandwich, UK), Grepafloxacin (GlaxoSmithKline, Stevenage,
UK), Azithromycin (Mast Diagnostics, Merseyside, UK), Imipenem (Merck Sharpe
Dohme, Rahway, NJ, USA), Sparfloxacin (Dainippon, Japan), Cefuroxime (Sigma,
Poole, UK), Moxifloxacin (Bayer A. G., Leverkusen, Germany), Levofloxacin
(Hoechst Marion Roussel, Romainville, France), Ofloxacin (Sigma), Gatifloxacin
(Grunethal, Aachen, Germany), Sulbactam (Pfizer, Sandwich, UK), Tetracycline &
Chloramphenicol (Sigma).
46
Chapter 2: Materials and Methods
2.4 MIC determination and Breakpoints
The agar dilution method was used to determine MICs on 1ST agar using the British
Society for Antimicrobial Chemotherapy guidelines for susceptibility testing (British
Society for Antimicrobial Chemotherapy, 1991). Briefly, an overnight culture in 1ST
broth was diluted in sterile 0.8% saline and approximately 104 organisms inoculated
onto the antibiotic-containing media. Breakpoint values were taken from the BSAC
guidelines unless otherwise indicated and are as follows: gemifloxacin, 0.5mg/L
(Wise and Andrews, 1999), moxifloxacin, lmg/L (Andrews et al, 1999),
sparfloxacin 2mg/L (Phillips et al, 1994), cefuroxime 2mg/L, ciprofloxacin lmg/L,
imipenem 4mg/L, ofloxacin 4mg/L, azithromycin 0.5mg/L, levofloxacin 4mg/L/ml,
gatifloxacin 2mg/L, trovafloxacin 2mg/L (Heinemann et al, 2000).
2.5 Optimum Bactericidal Concentration
To determine the optimum bactericidal concentration (OBC) of gemifloxacin,
ciprofloxacin, moxifloxacin, levofloxacin, grepafloxacin, trovafloxacin and
sparfloxacin, nutrient broth was inoculated withA baumannii ATCC 19606 and
incubated overnight at 37°C. Doubling dilutions of the test agent (0.03-256 mg/L) in
nutrient broth were inoculated with 0.2 ml overnight culture (final volume 10 ml)
and incubated for a further 3 h at 37°C. The viable count of the resulting cultures was
determined by serial dilution and plating onto nutrient agar (Lewin et al, 1989). The
results were plotted on a graph to determine the OBC, the OBC being the lowest
point on the graph.
2.6 Time-Kill Kinetics
The killing kinetics were performed at the OBC and at four times the MIC (MIC
values were previously determined for strain ATCC 19606 as: gemifloxacin 0.12
fig/ml: trovafloxacin 0.06 pg/ml: moxifloxacin 0.25 pg/ml: levofloxacin 0.5 pg/ml:
ciprofloxacin 0.5 pg/ml: grepafloxacin 0.12 ug/ml & sparfloxacin 0.12 pg/ml).
Briefly, 5 ml sterile double-strength nutrient broth was dispensed into 20 ml
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universal tubes and sterile distilled water was added to give a final volume of 9.8 ml.
A starting inoculum of 107 organisms (0.2ml overnight culture) was added to the
tubes and incubated for 2 hours until in log-phase. The antibiotic was added and an
initial count was determined by serial dilution and plating onto nutrient agar.
Samples were taken every 30 minutes for 3 hours and these were serially diluted and
plated onto nutrient agar. A final count was taken after 24 hours. All plates were
incubated overnight in air at 37°C (Lewin et al, 1989).
2.7 PCR Reagents
All PCR reactions were performed with Promega reagents (Promega, Southampton,
UK). Taq polymerase (5u/pl) in buffer A (10 x buffer: 500mM KC1, lOOmM Tris-
HC1 pH 8.0, 1% TritonX-100), MgCU (25mM) and deoxynucleoside triphosphates
(lOOmM). Ultra pure pyrogen-ffee water (MilliQPF, Millipore) was used as the
diluent.
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2.7.1 PCR Primers
Table 2.2 shows the sequences for the primers for the QRDR ofGyrA (gyrA), ParC
(parC), genotypic speciation (T3A/T5B), a 45.5kDa porin (ABOMP1& 2), inverse
PCR of the porin (ABINV1 & 2) andMl 3.
Table 2.2. PCR primers
Gene PCR Primer Sequence Reference












ABOMP1b 5'ga a/gGCI*aa Vg ggitt c/t gtiga a/g g3' Degenerate










I: inosine,a Oswel DNA Service (Southampton, UK), bMWG-Biotech,
clnvitrogen (Groningen, The Netherlands)
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2.7.2 Preparation of DNA for PCR
A 1 jj.1 loopful of overnight culture on solid media was suspended in 50pi sterile
pyrogen-free water and boiled for 10 minutes. The suspension was centrifuged
briefly at 13,000g and the supernatant used as template.
2.7.3 Phenol:chloroform:isoamyl alcohol DNA extraction
Phenol:chloroform:isoamyl alcohol (25:24:1) (PCI) was used to cleanup DNA for
inverse PCR. Sample containing DNA was mixed with an equal quantity ofPCI and
vortexed for 3 minutes. After centrifugation at 13,000g for 5 minutes at room
temperature, the supernatant was removed to a new tube and another equal quantity
ofPCI was added, vortexed and centrifuged as previously described. The
supernatant was removed and an equal quantity of chloroform added, vortexed and
centrifuged as before. The supernatant was transferred to a new eppendorf and 10%
its volume of 3M NaOAc and 2 x volume of 100% EtOH added (EtOH
precipitation). The mixture was placed at -20°C for 30 minutes and then centrifuged
at 13,000g for 20 minutes at 4°C. The supernatant was discarded and the pellet
washed with 500pl 70% EtOH. The pellet was dried in a heating block and
resuspended in distilled water (Laboratory ofMolecular Biology protocol).
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2.7.4 Visualisation of PGR products by Agarose Gel
Electrophoresis
PCR products were visualised on a 1.5% electrophoresis grade agarose gel (Gibco
BRL, Paisley, UK) dissolved in 40mM Tris-acetic acid 20mM disodium EDTA
(TAE buffer) pH8. Ten pi ofPCR product was added to lpl PCR loading buffer
(Promega, Southampton, UK) and run in TAE buffer at 100 volts. A lOObp DNA
Ladder or PCR Marker (Promega) was used as molecular weight markers. The
lOObp marker has bands from lOObp up to 1.5kb, lOObp apart. The PCR marker has
bands at 50, 150, 300, 500, 150 and lOOOkb. The gel was stained with 0.5pg/ml
Ethidium bromide and visualised on a UV transilluminator or in a Bio-Rad GelDoc
2000 (Bio-Rad, Hemel Hemstead, UK).
2.7.5 Speciation of Ac/nefobacferspp using tDNA
fingerprinting
The 101 Acinetobacter isolates were speciated by a genotypic fingerprinting method
using universal primers T3A and T5B that anneal to the spacer regions of tRNA as
described by Ehrenstein et al (1996) (Table 2.2). The standard Acinetobacter strains
listed in Table 2.1 were subjected to the same PCR and their banding pattern was
used to define each species and the clinical isolates were compared to this. Template
DNA was prepared as described earlier and 2pl of the lysate was used in each
reaction containing 0.2mM each DNTP, 1 pM each primer, 1 x PCR buffer, 1,5mM
MgCl2, 2 units Taq polymerase, MQ water to final volume 50pl. Cycling parameters
were as follows: 2 minutes at 94°C initial denaturation followed by 45 cycles of 40
seconds at 94°C, 40 seconds at 50°C and 2 minutes at 72°C. A final extension of
72°C for 3 minutes. PCR products were visualised as previously described.
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2.7.6 PCR of the gyrA QRDR
The primers used for amplifying gyrA are shown in Table 2.2. Isolation of template
DNA has been previously described. A PCR reaction (50pl) of 1,25mM MgCfy
O.lmM DNTPs, 1 x reaction buffer, 0.05mM each primer, 2.5pl template and 0.2
units of Taq in pyrogen-free water were cycled at the following parameters: 2
minutes at 94°C followed by 30 cycles of 94°C for 1 minute, 57.5°C for 1 minute and
72°C for 1 minute with a final extension of 72°C for 5 minutes producing a product
of 342bp.
2.7.7 PCR of the pa/C QRDR
The parC primers were derived from the sequence published by Vila et al (1997)
using Primer 3 software (http: and waldo.wi.mit.edu/cgi-
bin/primer/primer3.cgi/primer3_www.cgi, 2001) by Dr Ahmed Hamouda (Table
2.2). A PCR reaction (50pl) of 1.25mM MgCfy O.lmM DNTPs, 1 x reaction buffer,
0.05mM each primer, 2.5pl template and 0.2 units of Taq in pyrogen-free water were
cycled at the following parameters: 2 minutes at 94°C followed by 30 cycles of 94°C
for 1 minute, 58°C for 1 minute and 72°C for 1 minute with a final extension of 72°C
for 5 minutes, producing a product of 197bp.
2.7.8 PCR of 45.5kDa Porin using Degenerate Primers
A 40 amino acid fragment of the 45.5kDa porin from mutant strain BE1, a resistant
mutant dervied from SB 13, was used to design degenerate primers that gave an 87bp
PCR product (Table 2.2). Design of the primers is shown in Appendix I. Template
DNA was extracted as previously described from mutant BE1. A PCR reaction
(50pi) of 8mM MgCL, O.lmM DNTPs, 1 x reaction buffer, 0.05mM each primer,
2.5pi template and 0.2 units of Taq in pyrogen-free water were cycled at the
52
Chapter 2: Materials and Methods
following parameters: 2 minutes at 94°C followed by 30 cycles of 94°C for 1 minute,
55°C for 1 minute and 72°C for 1 minute with a final extension of 72°C for 5
minutes. The PCR product was directly sequenced and analysed as previously
described.
2.7,9 Inverse PCR
Inverse PCR was used to try to determine the sequence of the 45.5kDa OMP both
upstream and downstream of the partial amino acid sequence. The region of interest
containing a known sequence is circularised and primers derived from the known
sequence are used to amplify DNA in opposite directions (Appendix II). Whole
genomic DNA (2.5pg) was digested with the restriction en2ymes HaeIII, Alul, Rsal,
or double digested with Haelll & Alul, Haelll & Rsal and Alul & Rsal for two hours
at 37°C. The DNA was re-extracted using PCI. Assuming that 2.5pg ofDNA
remained, the sample was diluted to 40ng/pl. Five pi was added to ligation solution
(Promega) at a final concentration of l-10ng/pl DNA and the ligation was performed
at 16°C overnight. A control ligation of A, ladder cut with Hindlll was performed to
determine if a ligation reaction was successful. The mixture was then EtOH
precipitated as previously described. The PCR reaction was then carried out using
lpl of ligated DNA solution, lOpM of each primer, 0.25mM DNTPs, 2.5mM MgCl2.
The PCR cycles were as follows: 1 cycle of 96°C for 4 minutes followed by 30
cycles of 94°C 1 minute, 55°C 1 minute, 72°C 1 minute and a final extension of 72°C
5 minutes (Laboratory ofMolecular Biology protocol).
2.7.10 Cloning of the Porin
The 87 base pair PCR product was cloned into a pCR®4-TOPO® vector (Invitrogen)
by Mr Richard Gibbs and the plasmid was extracted. The vector carries Ml3
priming sites 73bp upstream and 60bp downstream of the insertion point. Using
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these primers, the OMP sequence was amplified by PCR using Promega reagents
previously described. The 255bp product was run on a gel, excised and purified with
a Gel Extraction Kit (Qiagen) and sequenced using the M13 primers.
2.7.11 Sequencing of PCR products
The PCR products ofgyrA andparC were purified using a PCR cleanup kit (Qiagen)
and run on an automatic sequencer. DNA sequences were analysed using Chromas
software and the gyrA and parC sequences compared to the published sequences of
A. baumannii ATCC 19606, GenBank accession numbers AF100557 and AF108132
respectively, using the online search facility BLAST
(http://www.ncbi.nlm.nih.gov/BLAST). The amino acid sequences were translated
using the EXPASY translate website (http://www.expasy.ch/tools/dna.html). Multi-
alignment ofDNA or amino acid sequences was performed with the online website
multalin (http://www.toulouse.inra.fr/multalin.html). The PCR products of the
45.5kDa porin was sequenced directly and also after cloning.
2.7.12 HintI Restriction Fragment Length Polymorphism of
gyrA and parC
The loss of the Hinjl restriction site in the gyrA and parC PCR products ofA.
baumannii is associated with a serine mutation at position 83 and 80 in GyrA and
ParC respectively (Vila et al, 1997; 1995). A lOpl aliquot of PCR product was
added to 2pl restriction enzyme buffer (lOmM Tris-HCl pH 7.3, 50mM NaCl,
O.lmM EDTA, ImM DTT, 50% glycerol), 0.2pi bovine serum albumin (0.5 mg/ml)
and 5u Hinjl (Promega), final volume 20pl, and incubated for 2 hours at 37°C. The
resulting products were run on a 1.5% agarose gel and visualised as previously
described. If the restriction site is cut by the enzyme, gyrA gives two products of
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291 and 52bp and parC 144 and 53bp. ATCC 19606 was used as a wild-type control
(both genes cut), SB 13 as a gyrA control (not cut) and SB21 as aparC control
(uncut).
2.8 Fluoroquinolone selection of mutants
Mutants were selected from A. baumannii ATCC 19606 and the clinical isolate
SB 13, which carries a GyrA Serine 83 mutation, at 2 x MIC on gemifloxacin,
ciprofloxacin ormoxifloxacin-containing 1ST agar (Oxoid, Basingstoke, UK). An
overnight culture ofATCC 19606 in 1ST broth was used to inoculate the selection
O
t
plates. This was sufficient for mutation rates >10 . For mutation rates lower than
this, 10ml of overnight culture was centrifuged at 15,000g and concentrated 10-fold
before plating onto selection plates. All selection was done on triplicate plates. A
viable count was performed to determine the inoculum to calculate the mutation-
frequency. Selection plates were incubated at 37°C in air for 48 hours before mutant
colonies were subcultured and tested for increased fluoroquinolone MICs.
Gemifloxacin-selected mutants were subcultured onto MacConkey agar (Oxoid) for
10 x passage to determine mutant stability. Further selection of 2nd, 3rd and 4th
generation mutants was performed at 2 x MIC.
2.9 Isolation and Analysis of the Outer Membrane Proteins
(OMPs)
The OMPs were extracted from exponentially growing cells using previously
described methods (Masuda, Sakagawa and Ohya, 1995). A 10ml aliquot of an
overnight culture was used to inoculate 2L of pre-warmed LB broth (20g Tryptone
(Difco), lOg Yeast Extract (Difco), lOg NaCl). The broth was incubated at 35°C
with vigorous shaking in an orbital incubator until log-phase (3-4 hours). The cells
were harvested by centrifugation at 8000g for 15 minutes. The supernatant was
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discarded and the cells resuspended in 40ml 30mM Tris-Cl pH 7. The cell
suspension was sonicated on ice at an intensity of 7 microns for 30 seconds on and
30 seconds off for 5 minutes and the unbroken cells pelleted at 8,000g for 10
minutes. The supernatant was removed and centrifuged at 100,000g for 1 hour to
pellet the membranes. The supernatant was removed and the pellet resuspended in
2ml 1.5% sarkosyl to solubilise the inner membrane and incubated at room
temperature for 30 minutes. A final centrifiigation at 100,000g pelleted the sarkosyl-
insoluble outer membranes, which were resuspended in 0.5ml Tris-Cl pH 7 or
pyrogen-ffee water and frozen at -70°C until needed. To increase the yield ofOMPs,
a modification to the method was as follows: after sonication, sarkosyl was added
and incubated as described previously. The cell suspension was centrifuged at
8,000g for 10 minutes to remove unbroken cells and then ultracentrifuged as
described. This did not alter OMP profiles.
2.9.1 SDS-PAGE of Outer Membrane Proteins
The outer membrane proteins were separated by SDS-PAGE (Laemmli, 1970).
OMPs were standardised to 0.6mg protein/ml in sample buffer (62.5mM Tris-HCl
pH 6.8, 0.2% SDS, 10% glycerol, 1% 2-mercaptoethanol, 0.001% bromophenol
blue) and boiled for 3 minutes before loading onto a 4% stacking gel and 10%
separating gel (acrylamide/bisacrylamide 37:1) in electrode buffer (25mM Tris-HCl
pH 8.8, 0.2% SDS). A constant current of 16mA was applied for the loading phase
and the current was increased to 24mA for separating. Molecular weights were
determined from standard bands using Precision Protein Standards (Bio-Rad) and
were detected with Coomassie brilliant blue. All gel analysis was carried out using
Quantity One software (Bio-Rad).
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2.9.2 Visualisation of Protein Bands: Coomassie Stain
Gels were stained with Coomassie brilliant blue in a 1-step stain, 4-step destain
method (Table 2.3) or silver stained.




Propan-2-ol Methanol Acetic acid Distilled
H20
1 (overnight) ig 500ml - 200ml 1300ml
2 (1 hour) 100mg 200ml - 200ml 1600ml
3 (1 hour) 48mg - - 200ml 1800ml
4 (1 hour) - - 800ml 200ml 1000ml
5 (leave) - - - 200ml 1800ml
2.9.3 Visualisation of Protein Bands: Silver Stain
The samples were treated and run on SDS-PAGE as previously described. After
running the gel, it was placed in prefix A for 30 minutes (50% methanol, 10% acetic
acid), prefix B for 30 minutes (5% methanol, 7% acetic acid), fixed in 10%
glutaraldehyde (BDH) before being washed twice in distilled water and left in
distilled water overnight. The water was discarded and the gel was treated with
100ml 5mg/L dithiothreitol for 30 minutes. An ammoniacal silver nitrate solution
was added to the gel (0.6% AgNo3, 0.076% NaOH, 1.4ml ammonia solution (BDH
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analar, SG 0.88) for 15 minutes and then washed in 4 x 200ml distilled water. 200ml
developer was added (0.005% citric acid, 0.019% formaldehyde solution (BDH
analar, 38-40%) and left until protein bands were visible (Microbial Pathogenicity
Research Laboratories protocol).
2.9.4 Ion-Exchange, Electroelution and Amino Acid
Sequencing of a 45.5kDa Porin
In order to purify an OMP of 45.5kDa from strain BE1, a sample of total OMPs was
solubilised in the non-ionic detergents C^Eg (2% w/v) or Triton-XlOO (1% v/v) and
separated on a GradiFrac FPLC system using an ion-exchange Hi-Trap Q Sepharose
(anion exchanger) or Hi-Trap SP (cation exchanger) 1ml column (Pharmacia). A pH
range of4-8 in 1 pH intervals of sodium acetate was used for the SP column and a
pH range of 5-8 in 1 pH intervals of20mM Tris-HCl for the Q column and the
proteins were eluted with a NaCl solution (1M) concentration gradient of 0-100% for
30 ml with a flow-rate of lml/min. The recovered tractions were separated by SDS-
PAGE as previously described. The ion-exchange column diluted the protein to a
level where it would not be visualised With a coomassie stain therefore the more
sensitive silver stain was used. As this did not purify the OMP of interest, the
proteins were separated by SDS-PAGE and electroblotted onto a polyvinylidene
difluoride membrane (PVDF) (Matsudaira, 1987). A pre-wetted PVDF membrane
was applied to an SDS gel containing the separated proteins and a constant voltage of
50V applied for 30 minutes at room temperature to transfer the proteins. The transfer
buffer was 90mM CAPS 3-[cyclohexylamino]-l-propanesulfonic acid, 10%
methanol pHl 1. The membrane was stained with 0.1% Coomassie Blue R-250 in
40% methanol, 1% acetic acid for 1 minute and destained with 50% methanol before
air-drying. The 45.5kDa band of interest was excised from the membrane and N-
terminally sequenced at GlaxoSmithKline laboratories, Collegeville, PA, USA.
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2.10 Pulsed-field gel electrophoresis (PFGE)
Typing ofA. baumannii was performed by PFGE using a modification ofpreviously
described methods (Seifert et al, 1994). Cells were grown overnight in LB broth
(Gibco BRL) at 35°C and harvested by centrifugation at 10,000g for 20 minutes.
After washing twice in SE buffer (75mM NaCl, 25mM EDTA, pH 7.4), the cells
were adjusted to 109 cfu/ml in SE buffer. 500pl of cells were added to 700pl of 2%
low-melting agarose (Sea-plaque) in SE buffer and kept at 55°C until put into plugs.
The plugs were incubated in lysis buffer (50mM Tris, 50mM EDTA, 1% sarkosyl,
lmg/ml proteinase K, pH 8.0) for 24 hours at 55°C in a water bath. Cell lysis was
complete when the plugs change from opaque to clear. After washing in TE buffer 5
times, the DNA plugs were restricted with 20 units ofApal overnight at 37°C. The
plugs were placed into a 1.2% PFGE-grade agarose gel and run in 0.5xTBE buffer
(45mM Tris, 45mM boric acid, ImM EDTA, pH 8.0) for 24 hours at 4.5 volts/cm
with a pulse time of 5-20 seconds at 14°C. Finished gels were stained in ethidium
bromide and visualised on a u/v transilluminator.
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Chapter 3: Speciation of Acinetobacter Isolates
using tRNA fingerprinting
3.1 Introduction
The molecular method of tRNA fingerprinting was used to speciate a collection of
Acinetobacter bloodstream isolates from the University of Iowa College ofMedicine.
They were originally speciated by Vitek as: 48 A. baumannii, 18 A. anitratus,
18 A. hvoffii, 13 A. calcoaceticus and 4 Acinetobacter spp. The method of tRNA
fingerprinting relies on species-conserved spacer regions of tRNA (Lu et al, 2000).
PCR of isolates using universal primers yields unique species-specific banding
patterns that are compared to the profiles of known DNA groups. However, this
method cannot differentiate between genospecies 1 (A. calcoaceticus) and
genospecies 3, therefore they will be grouped together as species 1/3 (Ehrenstein et
al, 1996). Differentiation between species 2 (A. baumannii) and 13TU is also not
possible, and though there was no standard 13TU used in this study, any isolate with
the species banding pattern ofA. baumannii will be grouped as species 2.
3.2 Results
One of the strains was immediately discarded as it fermented glucose and
acinetobacter is a non-fermenter. The colony morphology of this strain was very
different from acinetobacter; turning MacConkey agar purple and having a very
distinct smell, akin to brewing. Of the remaining 100 strains, tRNA fingerprinting
was carried out at least twice per strain. The first round was done numerically
according to strain number; i.e. SB1, SB2... etc. The second round of speciation
grouped like-species together to ensure that the correct primary identification had
been made. Each round ofPCR was conducted in tandem with the standard strains.
Figure 3.1 shows the fingerprinting pattern of the standard strains. The gels did not
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always photograph clearly therefore species identification was determined directly on
a u/v transilluminator and by using BioRad Quantity One software to compare
banding patterns.
Figure 3.1. Fingerprint of the standard strains. Lane A: 100bp Marker,
B-l: genospecies 1-8, J: genospecies 12, rf: relative front
Lanes B and D (species 1 & 3) have identical patterns and therefore cannot be
distinguished using this method. The other strains have different patterns, with at
least 3 bands per strain that are distinguishable with ethidium bromide staining. The
faint bands were not always clear on a gel and the molecular weights of the bright
bands were used for visual matching. For example, species 1 & 3 have two bright
bands corresponding to approximately 380bp and 250bp, while species 2 has two
bands at 300bp and 250bp.
Figure 3.2 shows the banding profiles of lanes B, C & D using Quantity One
software. This reiterates that species 1 and 3 have the same pattern and that using the
software one can discriminate between the other species. The lane profiles of the
other species are shown in Appendix III. In determining species identity using the
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software, the intensity of the band is unimportant as this is related to the
concentration of PCR product on the gel. It is the pattern of peaks, corresponding to
the bands, that was used to determine species identity.
Using this method, the Acinetobacters were reclassified as 9 genospecies 1/3,
71 genospecies 2 (A. baumannii), 7 genospecies 4 (A. haemolyticus), 2 genospecies 5
(A. junii), 2 genospecies 7 (A. johnsonnii), 1 genospecies 8 (A. Iwoffii) and 2
genospecies 12 (A. radioresistens). The remaining 6 isolates either did not amplify
by PCR or their banding pattern did not match against the 9 standard DNA groups
used in this study, therefore they remain unspeciated. Appendix IV lists all strains
with their original species identification alongside the results of this study.
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Figure 3.2. Banding pattern of Figure 3.1
Lane B





Figure 3.3 shows a typical gel with species 1, 2 & 3 and unspeciated isolates. A
visual match to speciate the isolates show that SB91 & SB101 are species 2 and that
SB94 is species 1/3. This is confirmed in Figure 3.4 with the intensity profiles of
two standard strains and two of the unknowns. The peaks to right of the graph
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correspond to primer dimers and are disregarded. The presence ofprimer dimers
was not found in all gels (Figure 3.8).
Figure 3.3. Lane A: 100bp marker, B: sp1, C: sp3, D: sp2, E: SB91, F: SB94,
G: SB101, rf: relative front
Quantity One software allows for the direct comparison of lanes within a gel as
shown in Figure 3.4. This figure shows that the blue line, corresponding to species 3
(Lane C), has a different profile to that of lanes D and E (species 2).
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This PCR fingerprinting technique does not guarantee success as an isolate does not
always amplify by PCR, illustrated with SB95 (Figure 3.5 lane M). Indeed, some of
the isolates proved very difficult to speciate because of this failure, needing multiple
PCR before any product was seen. The banding pattern of lane C in Figure 3.5 is not
clear and speciation is difficult. By comparing the lane banding patterns using
Quantity One software as shown in Figure 3.6, its pattern closely matches that of
lane L (species 7) but is different from lane I (species 8). The background smearing
and faint bands of some isolates make species identification difficult which is why
the procedure was performed more than once. In Figure 3.5, lanes D, E and F match
genospecies 4 (lane B) and their intensity profiles confirm this (Figure 3.7).
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Figure 3.5. Lane A: 100bp ladder, B: sp4, C: SB31, D: SB56, E: SB58, F: SB92,
G: sp5, H: SB85, I: sp8, J: SB100, K: sp6, L: sp7, M: SB95, N: sp1, 0:sp2,
rf: relative front
Figure 3.6. Banding pattern of lanes C, I & L from Figure 3.5




Figure 3.7. Banding patterns of lanes B, D, E & F
Band Intensity of Figure 3.5
Relative front
Figure 3.8 shows a second round of speciation. In this gel, all the isolates were
identified as belonging to species 2 with the exception of lane K which has the
fingerprint characteristic of species 1/3. This gel is easier to interpret when
compared to Figure 3.5 as there are fewer patterns.
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Figure 3.8. Lane A: PCR Ladder, B: sp2, C: SB41, D: SB43, E: SB46, F: SB45,
G: SB47, H: SB49, I: SB52, J: SB53, K: SB57, L: SB62, M: negative control, N:
SB64, O: SB67
3.3 Discussion
The use ofuniversal primers to speciate organisms was described by Lu et al (2000).
Their method included the digestion of the PCR products with a variety of restriction
enzymes. Ehrenstein et al (1996) omitted this step and instead used fluorescene-
labelled primers. In the present study, restriction ofPCR products and the use of
labelled primers were deemed unnecessary as the PCR yielded at least three species
specific bands that were visible upon ethidium bromide staining. The use of
Quantity One software gave similar profiles as those published by Ehrenstein et al
(1996). These were sufficient to speciate with a high degree ofcertainty. The
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technique did not always yield clear banding patterns and strains had to be analysed
more than once to be certain of species identification.
The speciation ofAcinetobacter spp. has been the subject ofmany studies and it was
not until the advent ofmolecular techniques that the taxonomy began to be resolved.
In particular, DNA-DNA hybridisation has been used extensively to speciate the
Acinetobacters into 19 DNA-groups (I. Tjernberg, PhD thesis). Prior to this,
taxonomy was based on phenotypical parameters. However these do not adequately
differentiate between DNA groups 13, 14 & 15TU and 16 & 17BJ. Even in the
present study, differentiation between genospecies 1, 2, 3 & 13TU was not possible
owing to the limitations of the technique.
The BioLog system was tested by Bernards et al (1995) on 129 Acinetobacter strains
belonging to 13 DNA groups. This system clustered species 1, 2, 3 & 13TU together
as well as 4 & 6 and 10& 11. Only species 7 and 14 were unclustered. However, six
strains of four different groups did not cluster with their respective DNA groups,
showing the systems limitations. The commonly used API20NE also cannot
distinguish between species 1, 2, 3 & 13TU, the Acb complex (Bernards et al, 1996).
This may in part be caused by limitations of the database that holds species
information. As Acinetobacter is not considered to be a major pathogen, there may
be little commercial interest in developing the database and chemical tests to cover
all the DNA groups. Perhaps clinicians are happy with the loose term
Acinetobacter? In any event, as most commercial tests are used by routine clinical
laboratories it is probably more important to determine a source of infection than to
get bogged down in taxonomy (I. Tjernberg, personal correspondence). Thus typing
of isolates may be given higher priority.
Automated machines not only speciate organisms, they also generate antibiotic
sensitivity data. This must prove useful to clinicians; being able to name an
organism and what drugs may be used for treatment. However the acinetobacters not
only suffer from mis-speciation with automated machines, but also false sensitivity
testing. This is described in a study by Tsakris et al (2000). A Vitek GNS-506 had
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recorded a high-prevalence of imipenem resistant A. baumannii. However, upon disc
diffusion, agar dilution and broth microdilution, it was found that all 35 imipenem
resistant strains were sensitive.
In the present study, the finding that out of an original 18 A. Iwoffii there was only 1
speciated by a molecular technique is not surprising. O'Hara and coworkers (1997)
evaluated Vitek and found that it gave a 1 in 5 positive result for A. Iwoffii. However
the authors were basing the accuracy of the machine against strains that had
previously been biochemically tested. If in their study they had used characterised
DNA groups then the accuracy of their study would be more valid. In a more recent
study, Joyanes et al (2001) found that a Vitek 2 correctly identified only 76% ofA.
baumannii.
Not all biochemical testing to speciate the acinetobacters has such a low rate of
success. The phenotypic identification scheme ofBouvet and Grimont has been
shown to correlate well with DNA-DNA hybridisation (Bouvet and Grimont, 1987;
Seifert et al, 1997). The method ofBouvet and Grimont utilises 14 carbon sources,
only two of which are used in Vitek and three in the Crystal E/NF identification
systems. The growth of an organism over a temperature range is also used by
Bouvet and Grimont, something which neither of the automated systems can do,
which is the crux of the matter; they are useful for speciating "regular" bacteria but
not for atypical nosocomial pathogens like the acinetobacters.
However, one cannot criticise diagnostic laboratories for using biochemical testing
and automated machines, as they need rapid identification of samples and do not
have the resources for more involved study. The Vitek 2 system in the study by
Joyans gave a result in only 3 hours, something which tRNA fingerprinting cannot
achieve. The problem with the machines is more to do with the fact that they have to
differentiate a broad range of organisms. A species can only be given a name when
it is phenotypically distinguishable from other members of its genus. Only seven of
the 19 Acinetobacter DNA groups fit this criteria, the most obvious being the Acb
complex. However the tRNA ofA. baumannii and 13TU are very similar and
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explains why they cannot be speciated by this technique. Even by DNA-DNA
hybridisation they have a similarity of level of 70%, which is the cut-off value for
new DNA groups (A. T. Bernards, PhD thesis).
There exists other PCR-based methods which can be used to identify Acinetobacter
such as ARDRA which relies on amplified ribosomal DNA which is then restricted
with a variety of restriction enzymes (Berlau et al, 1999; Koeleman et al, 1997; Lu et
al, 2000). However this method may need up to 6 different restriction enzymes
making it considerably more laborious and expensive, both in materials and
manpower, than tRNA fingerprinting.
In conclusion, tRNA fingerprinting, even with its limitations, is a more accurate
technique for species identification than a commercial system. Owing to its lack of
discrimination between the Acb complex, it is not as discriminatory as DNA-DNA
hybridisation. However tRNA species identification is rapid, reliable, cheap and
easy to interpret, therefore is a useful tool that could easily be used in a routine
laboratory.
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Chapter 4: Killing Kinetics of Seven
Fluoroquinolones against A. baumannii ATCC
19606
4.1 Introduction
The action of the fluoroquinolones in vivo is bactericidal, but unusually these drugs
exhibit a biphasic dose-response. This is measurable in vitro, where the lethality of
the drug increases proportionally to its concentration until an optimum bactericidal
concentration (OBC) is reached. Above this point, the bactericidal activity steadily
decreases with further increases in concentration. The newer fluoroquinolones have
been predominately tested against Gram positive species and the biphasic response
has seldom been demonstrated. In this chapter, the fixed-time killing activity of
increasing concentrations of fluoroquinolone on A. baumannii ATCC 19606 was
compared against ciprofloxacin and levofloxacin and five new fluoroquinolones, and
the time-dependant killing was examined at the OBC and at 4xMIC.
4.2.1 Results: Dose Response
Table 4.1 shows the MIC and OBC values for the antimicrobials used against A.
baumannii ATCC 19606. A representative graph to determine the OBC of
gemifloxacin is shown in Figure 4.1.
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Table 4.1. MIC and OBC values for the fluoroquinolones tested against
A. baumannii ATCC 19606
Antimicrobial OBC (mg/L) MIC (mg/L) 4 x MIC (mg/L)
Ciprofloxacin 4 0.5 2
Gemifloxacin 4 0.12 0.5
Grepafloxacin 8 0.12 0.5
Levofloxacin 4 0.5 2
Moxifloxacin 4 0.25 1
Sparfloxacin 8 0.12 0.5
Trovafloxacin 4 0.06 0.25
Figure 4.1. Dose response of A. baumannii ATCC 19606 to gemifloxacin.
Concentration (mg/L)
All the drugs tested exhibited a biphasic dose-response, similar to that shown in
Figure 4.1, with the lowest point of the graph corresponding to the OBC. The MIC
of the drug is also seen in the graph where the percentage survival drops below
100%. In the case ofgemifloxacin, the MIC by agar dilution is 0.12mg/L. The
graph cuts below 100% survival at a concentration just above 0.06mg/L, thus the
MIC is 0.12mg/L. The killing rate decreases with concentrations above the OBC.
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4.2.2 Results: Kill-Curves
The killing kinetics for the fluoroquinolones at both the OBC and four-times the MIC
are shown in Figures 4.2-^4.8. The most rapid killing is within the first hour of drug
challenge, with the greatest rate seen at the OBC. However, with both gemifloxacin
and levofloxacin, there is little difference in killing between the concentrations. The
rate ofkill decreases after 1 hour. One of the most striking results is that after 24
hours, none of the drugs had killed 100% of the challenge organism.
There is little difference between killing rates at the OBC and 4xMIC with
gemifloxacin (Figure 4.2). A reduction in viable organisms of >2iogio is seen in the
first hour at both concentrations, and after 24 hours the number of organisms has
been reduced by 5iogio- With trovafloxacin (Figure 4.3), a greater difference is seen
between the two concentrations. At the OBC, there is >2iogio reduction in viable cells
compared with <2iogio at 4xMIC in the first hour. The difference is less pronounced
after 24 hours, with both concentrations reducing cell numbers by 6]0gio from the
starting inoculum.
Moxifloxacin reduces cell numbers by 3iogio in the first hour at the OBC and 2iogio at
4xMIC (Figure 4.4). After 24 hours, both concentrations reduce cell numbers by
>5iogio- Levofloxacin sees the greatest initial kill-rate in the first half-hour, reducing
cell counts by 3iogio at both OBC and 4xMIC (Figure 4.5). Thereafter the drug
remains almost bacteriostatic for a further 2.5 hours. After 24 hours there is a
reduction in viable cells that is 6iogio less than the starting inoculum. Ciprofloxacin
and grepafloxacin (Figures 4.6 and 4.7) exhibit similar killing rates in the first hour,
reducing viable cell counts by 3iogio at the OBC and <2iogio at 4xMIC and 5iogio after
24 hours. Sparfloxacin is the most potent of the drugs tested. In the first hour at the
OBC, it reduced cell numbers by 4iogio (Figure 4.8). At 4xMIC, it is less potent,
reducing cell numbers by 3iogio- After 24 hours the difference between the
concentrations is still visible, with cell numbers reduced by 6iogio at the OBC and
4i0gio at 4xMIC.
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Figure 4.4. Bactericidal activity of moxifloxacin against A. baumanniiATCC 19606.
Figure 4.5. Bactericidal activity of levofloxacin against A. baumannii ATCC
19606.
—I 1 1 1 1 1 !
0.5 1 1.5 2 2.5 3 24 hours
Time (h)
76
Chapter 4: Killing Kinetics





























Chapter 4: Killing Kinetics




0.5 2.5 24 hours
4.3 Discussion
In this study all test fluoroquinolones exhibited the typical biphasic response of this
drug class. The OBCs of these agents were found to be within one dilution of each
other, indicating that the killing mechanism for each drug is similar even though their
respective MICs vary greatly. A similarity in OBC values has been reported by
Lewin et al (1992) who found that the E. coli, S. aureus and S. epidermidis OBCs of
sparfloxacin were identical at 0.9mg/L. In the same study, the OBCs for
ciprofloxacin were 3mg/L for S. aureus and S. epidermidis and 1.5mg/L for E. coli.
In the present study, the OBCs for these drugs were 8mg/L and 4mg/L respectively,
which may reflect the innate resistance ofA. baumannii to these drugs.
The biphasic-dose response is poorly understood. Crumplin and Smith (1975) have
shown that at the most bactericidal concentration, nalidixic acid inhibits DNA
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bactericidal, nalidixic acid appears to inhibit both RNA and DNA synthesis. The
OBC also correlates with the maximum SOS response (Lewin et al., 1989). This is
not surprising as quinolones cause the formation of cleaved complexes ofDNA and
this would be expected to elicit an SOS response. However, this does not mean that
the SOS response is responsible for cell-death. SOS mutants of E. coli are not any
less susceptible to quinolones than their SOS wild-type. However, it has been shown
that SOS-independent recombination-repair aids survival and that recombination-
repair mutants are more susceptible to nalidixic acid (Lewin et al 1989).
Although bacterial killing is optimal at the OBC, this concentration is not necessarily
found in vivo, as the peak-serum levels (Cmax) of the fluoroquinolones do not reach
these concentrations. For example, Morrissey (1997) cites Cmax values for
ciprofloxacin and trovafloxacin as 2.6mg/L and 3.0mg/L respectively. Their OBCs
against A. baumannii ATCC 19606 are greater than these values, therefore outside
therapeutic levels. This has led Morrissey (1997) to propose the bactericidal index
which links bacterial killing over a drug concentration range that is achievable
in vivo. The bactericidal index gives a single value that represents the bactericidal
activity for an antibiotic against a strain. Using this method, Morrissey demonstrated
that trovafloxacin had greater bactericidal activity than ciprofloxacin against E.
faecalis.
In the present study, the bactericidal index was not calculated but results achieved at
four times the MIC are a much better indicator of a drug's in vivo efficacy than the
OBC. These data show that gemifloxacin exhibited superior killing kinetics at four
times the MIC compared with ciprofloxacin. Furthermore, its killing kinetics at four
times the MIC were almost equal to those at the OBC even though the concentration
was much lower (0.5 mg/L versus 4 mg/L, respectively). Only levofloxacin showed
equal killing kinetics at the OBC and four times the MIC, though at a concentration
four-times higher than that of gemifloxacin (2 mg/L versus 0.5 mg/L, respectively).
Trovafloxacin was found to be bactericidal againstA baumannii ATCC 19606,
reducing viable cell counts by 6iogjo over 24 hours. Appleman et al (2000) reports
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that trovafloxacin was bacteriostatic against multiresistant A. baumannii. The strains
Appleman used were moderately susceptible to trovafloxacin (no MIC data given)
suggesting that a GyrA mutation is present (Chapter 6). With a resistant Gyrase
enzyme, the drug will be targeting topoisomerase IV. Given that the role of
topoisomerase IV is to decatenate double-stranded DNA after DNA synthesis but
before cell division, inhibition of this enzyme will lead to bacteriostasis and not cell-
death. This suggests that cell-death may be cell-cycle dependant.
A working hypothesis of fluoroquinolone action is that upon drug challenge, cells
that are undergoing DNA synthesis will be killed by the drug. Death is mediated
through the action ofDNA Gyrase. Cells that have completed DNA synthesis but
have not yet divided will not be killed as the lethal cleavable complexes will not be
formed. The fluoroquinolone will bind to topoisomerase IV and will thus be unable
to decatenate their DNA and will filament. Filamentation has been described in
fluoroquinolone-treated cells (Smith, 1984; Tanaka et al, 1996). This effect is also
seen in cells with perturbed cell cycles (Domian et al, 1997; Holland, 1998).
The kill-curve assay is based on viable cell counts because of the filamentation
phenomena and thus spectroscopic methods cannot be used to monitor cell-death by
a reduction in turbidity. As the effect of fluoroquinolones is reversible, when the
drug is removed from the cells and plated on drug-free media, the bacteria will be
able to divide and thus be viable. Because time-kill assays are performed on log-
phase bacteria, one will assume that most of the cells are actively synthesising DNA
and thus are susceptible to drug challenge. However, a proportion of the cells will be
in their G2 phase and upon drug challenge, bacteriostasis will occur. This hypothesis
explains why there is such a rapid kill-rate in the first hour of fluoroquinolone
challenge and thereafter kill-rates slow down. To put this to the test, cells will have
to be synchronised to be at the same part of the cell-cycle before drug-challenge.
In conclusion, these data show that the newer fluoroquinolones are bactericidal
against A. baumannii ATCC 19606. The initial one hour period shows the greatest
kill-rate, thereafter the kill-rate slows down.. However, none of the drugs tested
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killed 100% of the initial inoculum after 24 hours. The OBC drug concentration is
not achievable in vivo therefore a concentration of four times the MIC was also used.
This showed that the newer fluoroquinolones are more potent than ciprofloxacin but
not more so than levofloxacin.
81
Chapter 5: Clinical MICs
Chapter 5: Clinical MICs
5.1 Introduction
Bacteria of the genus Acinetobacter, particularly Acinetobacter baumannii, are
increasingly being isolated from hospitalised patients. In this setting, these pathogens
are associated with bacteraemia, secondary meningitis, urinary tract infection and
pneumonia, particularly in immunocompromised individuals. Acinetobacter spp.
have become resistant to almost all currently available antimicrobial agents,
including the aminoglycosides, older fluoroquinolones and broad-spectrum (3-
lactams. The majority of strains are resistant to cephalosporins and some demonstrate
resistance to the carbapenems, including imipenem (Lyytikinen et al, 1995; Paton et
al, 1993). The inability to eradicate these bacteria has allowed them to colonise
those niches left vacant when more susceptible microbes are eradicated. Resistance
to ciprofloxacin has been found in Acinetobacter spp. within the hospital setting
(Rodriguez Bano, 1999; Villers et al, 1998), and is more pronounced in areas of
high fluoroquinolone use, particularly where there is a history of prior ciprofloxacin
use (Muder et al, 1991). This study compared the in-vitro activity by MIC of
ciprofloxacin, gemifloxacin, grepafloxacin, gatifloxacin, levofloxacin, ofloxacin,
moxifloxacin, sparfloxacin, trovafloxacin, imipenem, azithromycin and cefuroxime
against the clinical isolates of Acinetobacter outlined in chapter 3.
5.2 Results
The range ofMICs of the 12 antibiotics against the isolates are shown in Table 5.1.
As there was a small number of isolates except for A. baumannii, MIC50/MIC90
values were not calculated. These values have been calculated against species 2 and
are shown in Table 5.1. The MICs of all the strains are shown in Appendix VI.
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All the non-A baumannii isolates tested were sensitive to imipenem, and with two
exceptions, resistant to cefuroxime. Resistance to azithromycin was seen in all but
three isolates. Only one isolate was sensitive to both azithromycin and cefuroxime.
There was no correlation between strains in the higher MIC range against imipenem
being in the high range against cefuroxime. Resistance to the fluoroquinolones was
found primarily in A. baumannii although it was also found in one A.
calcoaceticus!species 3 and one A. haemolyticus isolate.
Table 5.1 MIC range of Acinetobacter spp
Species Antimicrobial Range Species Antimicrobial Range
(mg/L) (mg/L)
1/3 Cip 0.12-128 2 Cip 0.015->128
(n = 9) Gat 0.03-8 (n = 71) Gat 0.008-128
Gem 0.03-16 Gem 0.008->128
Gre 0.06-32 Gre 0.015-64
Lev 0.12-16 Lev 0.008-64
Mox 0.03-8 Mox 0.008-64
Ofl 0.25-32 Ofl 0.03->128
Spa 0.03-8 Spa 0.008-32
Tro 0.03-8 Tro 0.008-32
Imi 0.06-0.25 Imi 0.008-2
Cef 32-128 Cef 2->256
Azi 1-4 Azi 0.12->128
Cip: ciprofloxacin, Gat: gatifloxacin, Gem: gemifloxacin, Gre: grepafloxacin,
Lev, levofloxacin, Mox: moxifloxacin, Ofl: ofloxacin, Spa: sparfloxacin,
Tro: trovafloxacin, Imi: imipenem, Cef: cefuroxime, Azi: azithromycin
Species Antimicrobial Range Species Antimicrobial Range
(mg/L) (mg/L)
4 Cip 0.06-0.25 5 Cip 0.12-0.5
(n = 7) Gat 0.06-0.25 (n = 2) Gat 0.12-0.25
Gem 0.03-0.12 Gem 0.06-0.12
Gre 0.03-0.12 Gre 0.06
Lev 0.12-0.5 Lev 0.12-0.25
Mox 0.06-0.12 Mox 0.06-0.12
Ofl 0.25-1 Ofl 0.25-0.5
Spa 0.015-0.06 Spa 0.03-0.06
Tro 0.015-0.06 Tro 0.03
Imi 0.06-0.25 Imi 0.12
Cef 2-128 Cef 8-32
Azi 0.5-2 Azi 0.5-2
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7 Cip 0.12-16 8 Cip 0.12
(n = 2) Gat 0.06-4 (n = 1) Gat 0.03
Gem 0.06-1 Gem 0.015
Gre 0.03-0.5 Gre 0.015
Lev 0.25-4 Lev 0.12
Mox 0.06-0.5 Mox 0.06
Ofl 0.5-8 Ofl 0.25
Spa 0.015-0.5 Spa 0.008
Tro 0.015-0.5 Tro 0.008
Imi 0.008-0.25 Imi 0.25
Cef 64 Cef 32















Trovafloxacin and sparfloxacin were the most potent of the fluoroquinolones against
all the acinetobacters and ofloxacin was the least potent. Gatifloxacin and
moxifloxacin were equipotent against species 1/3. Levofloxacin, the [-isomer of the
racemic ofloxacin is one dilution more potent than ofloxacin. As the number of
non-A. baumannii isolates is too low to draw conclusions, the remainder of this
chapter will focus on the activity of the fluoroquinolones against A. baumannii.
A. baumannii MIC50, MIC90 and the range ofMICs are shown graphically in Figure
5.1. These data show that the MIC50S for all the fluoroquinolones tested are below
breakpoint levels. Trovafloxacin and sparfloxacin were 16-fold more potent than
ciprofloxacin. Gemifloxacin and grepafloxacin were 8-fold more potent than
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ciprofloxacin and 4-fold more potent than levofloxacin and gatifloxacin. However at
least 10% of the isolates are resistant to all the fluoroquinolones as seen with the
MIC90 values. All the fluoroquinolones with the exception of ciprofloxacin had
MIC90S of 16 or 32 mg/L, well above therapeutic levels. Some isolates recorded
MICs to ciprofloxacin, gemifloxacin and ofloxacin of>128mg/L.
Cefuroxime was the least potent of all the drugs tested, with an MIC50 of 64mg/L.
Azithromycin had slightly higher activity with an MIC50 of 2mg/L but its MIC90
was 64mg/L. The most potent of the drugs tested was imipenem with even the
highest MIC recorded (2mg/L) within therapeutic levels.
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Figure 5.1. Range, MIC50 and MIC90 of A. baumannii against 12 antibiotics. Those
drugs with an MIC range higher than that tested have the values above their data





















Cip Gat Gem One Lev Mox Ofl Spa Tro Inri Cef Az
Antibiotic
An MIC50 or MIC90 value does not indicate resistance levels to the antibiotic and are
used to monitor a population of bacterial isolates over time to determine changes in
sensitivity. What is ofparamount importance is the percentage of isolates that are
resistant to each antibiotic; this relates MIC to breakpoint values. For example, both
gemifloxacin and grepafloxacin record the same MIC50 and MIC90which is just one
dilution either side of trovafloxacin and sparfloxacin. However, Figure 5.2 illustrates
the resistance levels seen within the A. baumannii isolates. These data show that
resistance to gemifloxacin is higher than that seen with grepafloxacin and that
grepafloxacin now equals potency with sparfloxacin. Ciprofloxacin when viewed
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this way becomes the least potent with 34% of isolates resistant. Trovafloxacin
retains its potency in both figures.
Figure 5.2. Resistance levels of 71 A. baumannii isolates to 12 antimicrobials
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Cip Gat Gem Gre Lev Mox Ofl Spa Tro Imi Cef Azi
Drug
What is also of interest is that the newer fluoroquinolones, such as sparfloxacin and
trovafloxacin, which were developed as anti-Gram positive drugs, are markedly
superior to both ciprofloxacin and levofloxacin, both ofwhich are recognised as anti-
Gram negative drugs. Imipenem, the drug of choice to treat A. baumannii infections,
retains its potency with all isolates susceptible. Only one strain showed an MIC
below breakpoint for cefuroxime and four were sensitive to azithromycin.
5.3 Discussion
Fluoroquinolones are not marketed by drug companies to treat acinetobacter
infections although they are sometimes used against them. Risk factors for
acinetobacter infection also includes the use of a fluoroquinolone (Cendrero et al,
1999; Friedrich, White and Bosso, 1999; Villers et al, 1998) and thus it is of interest
to know the activity of the newer drugs of this class in order to determine if the
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organism may be selected for in the nosocomial environment. Resistance to
ciprofloxacin in A. baumannii has been reported frequently (Bajaksouzian et al,
1997; Berlau et al, 1999; Horrevorts et al, 1997; Moreau et al, 1996; Sahm et al,
2001). The question is "Does resistance to ciprofloxacin also have a corresponding
effect on the newer fluoroquinolones?"
In the present study, it has been shown that cross-resistance does occur irrespective
of the fluoroquinolone tested. However, some strains that are ciprofloxacin resistant
are susceptible to the newer drugs. Some of the newer fluoroquinolones such as
gemifloxacin and moxifloxacin have poor serum distribution, evidenced by their low
breakpoint values of 0.5mg/L and lmg/L respectively (Andrews et al, 1999; Wise
and Andrews, 1999). In spite of this, they perform marginally better than
ciprofloxacin with a breakpoint of 2mg/L. If improvements in their
pharmakokinetics can be achieved, then the effects of cross-resistance will be
minimised. Trovafloxacin and sparfloxacin although being the most potent of the
drugs are of limited use in the clinical setting as they have been withdrawn because
of toxic side-effects and are reserved as a drug of last choice.
Cross-resistance to sparfloxacin, grepafloxacin, gemifloxacin, moxifloxacin,
trovafloxacin and gatifloxacin is not found in S. pneumoniae isolates with low-level
resistance to ciprofloxacin (8mg/L) (Jones et al, 2000; Marchese, Debbia and Schito,
2000; Ogasawara, Okamoto and Inoue, 1999; Pan and Fisher, 1998; Pestova et al,
2000), Streptococcus mitis (Gonzalez et al, 1998) or E. coli against sparfloxacin
(Mouneimne et al, 1999; Tavio et al, 1999). However, P. aeruginosa does exhibit
resistance to trovafloxacin and sparfloxacin but not ciprofloxacin (Wise et al, 1997).
Limited data have been published on the newer fluoroquinolones and the
acinetobacters and this study was the first to encompass a large number ofA.
baumannii isolates and fluoroquinolones. Heinemann et al (2000) investigated the
comparative activities of new and old fluoroquinolones against A. baumannii. Their
data support that found in this study, that against fluoroquinolone susceptible
isolates, ciprofloxacin is the least potent drug and trovafloxacin the most potent.
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Most comparative studies on antibiotics that are published only show MIC data in the
form ofMIC50 and MIC90. While this format is useful as it condenses many data into
a single graph or figure, it does not give the whole picture (Jones, 2000). As the
fluoroquinolones are not topical agents and their efficacy is linked to serum
concentration, MIC data should also be linked to breakpoint levels. Even the use of
breakpoints is fraught with difficulty. BSAC and NCCLS have different breakpoints
and it has been argued that susceptibility testing should be standardised worldwide
(Gould, 2000). Indeed, in the case of azithromycin, two breakpoints have been
recommenced, with the NCCLS reporting a value of 4mg/L and the BSAC 0.5mg/L.
Using the breakpoint of 0.5 mg/L set by Wise and Andrews (Wise and Andrews,
1999), gemifloxacin inhibited 68% of the Acinetobacter spp. investigated in this
study. The rank order of inhibitory activity of the quinolones against A. baumannii
using MIC50/MIC90 was: trovafloxacin = sparfloxacin > gemifloxacin =
grepafloxacin > moxifloxacin > levofloxacin = gatifloxacin > ofloxacin >
ciprofloxacin. This is similar to previously published data, (Bergogne-Berezin,
1996). The MIC50 and MIC90 values for gemifloxacin, trovafloxacin, grepafloxacin,
sparfloxacin, ciprofloxacin and ofloxacin reported in this study against A.
calcoaceticus are in agreement with the findings of Paek et al. (Paek, Kim and Choo,
1998), but are slightly different from those recorded by Oh et al, (1996), who
reported MIC90S that were one dilution higher. This order of activity changes
somewhat ifwe apply the published breakpoint values and view the data through
resistance levels. Thus, trovafloxacin > sparfloxacin = grepafloxacin > levofloxacin
> moxifloxacin = gatifloxacin > gemifloxacin = ofloxacin > ciprofloxacin. These
data show that the perceived potency of a drug can change depending upon how the
data is viewed.
A previous study has noted resistance levels to ciprofloxacin, trovafloxacin and
sparfloxacin of 93.3%, 56.7% and 66.7%, respectively, in multidrug-resistant
A. baumannii (breakpoints: ciprofloxacin > 2 mg/L; and sparfloxacin and
trovafloxacin > 4mg/L) (Pascual et al, 1997). In the present study, a breakpoint
value of2mg/L was used for trovafloxacin. Heinemann et al (2000) used a
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breakpoint value of 2mg/L and found trovafloxacin resistance in 14.7% of isolates.
In contrast, using the same breakpoints this study reported resistance rates of 34% for
ciprofloxacin, 27% for trovafloxacin and 28% for sparfloxacin.
A decrease in sensitivity to one quinolone was mirrored by a decrease to all the
others. However, this reduction in sensitivity did not impair sensitivity to the non-
quinolone agents, as all strains were sensitive to imipenem and most were resistant to
cefuroxime and azithromycin. Previous studies of the activity of azithromycin
against Acinetobacter spp. have shown that a concentration of 4 mg/L is sufficient to
inhibit most isolates (Fass, 1993). In the present study, MIC50 values for
azithromycin was below 4 mg/L. However, this value is above the breakpoint of 0.5
mg/L set by the British Society for Antimicrobial Chemotherapy, and thus these
isolates are recorded as being resistant to azithromycin (British Society for
Antimicrobial Chemotherapy, 1991). The high MIC50 value (64 mg/L) recorded for
cefuroxime against these Acinetobacter test strains is in agreement with a survey by
Traub and Spohr (1989). These researchers recorded similarly high MICs against the
cephalosporins, with little species difference being noted. The 100% susceptibility of
test strains to imipenem reported in the present study also reflects the findings of
previous investigators (Pieroni et al, 1997; Traub and Spohr, 1989). This may reflect
the collection of strains used for their study. Data from the worldwide SENTRY
survey show imipenem resistance rates to be at 11% (Gales et al, 2001).
In conclusion, the newer fluoroquinolones exhibit greater potency against
Acinetobacter spp. than ciprofloxacin. However, a reduction in ciprofloxacin
sensitivity is mirrored by a reduction in sensitivity to the newer fluoroquinolones.
This reduction does not necessarily translate into resistance therefore there is
potential for these drugs to be useful in the treatment ofAcinetobacter spp.
infections. The molecular mechanism of resistance to these drugs will be
investigated in chapter 6.
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Chapter 6: Mutations leading to fluoroquinolone
resistance in clinical isolates of A. baumannii
6.1 Introduction
Acinetobacter baumannii is increasingly isolated in the nosocomial environment
where it is recognised as a serious threat to the immunosuppressed (Cisneros et al,
1996; Towner, 1997). With the increasing use of fluoroquinolones within the
hospital environment, selection of resistant phenotypes is not uncommon (Horrevorts
et al, 1997). In this study, the susceptibility of one clinical A. johnsonii isolate, 16
clinical isolates ofA. baumannii and the standard A. baumannii ATCC 19606 was
determined against eight fluoroquinolones. The gyrA and parC genes were
amplified by PCR and restricted with Hinfl. This restriction enzyme cuts the PCR
products within the codon encoding a serine residue at positions 83 and 80 in GyrA
and ParC respectively (Vila et al, 1997). Loss of this site is associated with an
increase in MIC and thus is a useful genotypic marker of reduced sensitivity. Six of
the strains were further analysed by sequencing gyrA andparC. PFGE was used to
investigate the relationship between strains and their outer membrane profiles were
*
examined to determine if there was any significant differences in protein expression
that may contribute to fluoroquinolone resistance.
6.2 Results
6.2.1 Antibiotic susceptibility
The MIC data and results of RFLP are summarised in Table 6.1. Ifwe apply the
criteria ofMIC range to those organisms that have MICs below breakpoint values,
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trovafloxacin is the most potent of the drugs, followed by sparfloxacin and
gemifloxacin. The older fluoroquinolones, ciprofloxacin and ofloxacin, are the least
potent. Levofloxacin, the L-isomer of ofloxacin, is 2-fold more potent than
ofloxacin. Against the resistant strains, trovafloxacin is still the most potent drug,
followed by sparfloxacin and levofloxacin. Gemifloxacin loses its potency against
resistant strains, recording an MIC as high as >128 mg/L.
6.2.2 Restriction of gyrA and parC
The strains in Table 6.1 can be divided into three groups: group A, with Hinfl-
restricted gyrA and parC PCR products, group B with gyrA that is uncut butparC is
cut, and group C with both genes uncut. No strain had lost the parC restriction site
without a loss ofgyrA. The MIC data show that group A strains are susceptible to all
the fluoroquinolones used in the study. Ciprofloxacin is the least potent drug in this
group and trovafloxacin exhibits the greatest potency. There is a wide variation of
MIC amongst group A to each drug; for example 0.03-2 mg/L (66-fold) against
ciprofloxacin and 0.008-1 mg/L (125-fold) with moxifloxacin. The least sensitive of
these strains (SB4) has MICs that are within 1 dilution of ciprofloxacin,
moxifloxacin and gemifloxacin breakpoints.
Group B strains have lost the gyrA restriction site but theirparC gene is still cut by
HinfL. This group are resistant to all the fluoroquinolones with the exception of
trovafloxacin, with a breakpoint value of 1mg/L. Strain SB31 is also resistant to
both moxifloxacin and sparfloxacin. The range ofMICs are less pronounced in this
group compared to group A, the greatest range being 8-fold against sparfloxacin.
The four strains within group B show no MIC range against gemifloxacin and
trovafloxacin.
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Table 6.1. MIC's and RFLP results of the strains tested
MIC mg/L Hinfl restriction
Group Strain Cip Gem Tro Spa Mox Ofl Lev Gre gyrA parC
A SB59 0.03 0.008 0.008 0.008 0.008 0.03 0.008 0.015 + +
SB5 0.25 0.06 0.06 0.03 0.12 1 0.25 0.06 + +
SB32 1 0.06 0.06 0.03 0.12 1 0.5 0.06 + +
SB14 0.5 0.12 0.03 0.03 0.12 0.5 0.25 0.06 + +
19606 1 0.12 0.06 0.12 0.5 1 0.5 0.12 + +
SB10 1 0.12 0.06 0.06 0.25 1 0.5 0.12 + +
SB4 2 0.25 0.12 0.25 1 1 0.5 0.25 + +
SB13 4 1 0.5 4 2 4 1 2 - +
R
SB22 8 1 0.5 1 2 8 4 1 - +
D
SB24 16 1 0.5 1 4 8 4 1 - +
SB31* 16 1 0.5 0.5 0.5 8 4 0.5 - +
SB75 64 32 8 16 16 16 8 64 - -
SB36 64 32 16 16 16 32 16 32 - -
SB67 128 16 8 8 16 16 16 16 - -
c SB47 >128 16 16 16 16 32 16 64 - -
SB1 >128 32 8 16 16 32 16 64 - -
SB87 >128 64 32 32 64 >128 64 32 - -
SB21 >128 >128 32 32 64 64 32 64 - -
Cip: ciprofloxacin, Gem: gemifloxacin, Tro: trovafloxacin, Spa: sparfloxacin, Mox: moxifloxacin, Ofl: ofloxacin, Lev: levofloxacin,
Gre: grepafloxacin, + wild type PCR fragment (cut by Hinfl), - mutant PCR fragment (Hinfl site lost), *species 7 (A. johnsonii)
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Those strains in group C are resistant to all the fluoroquinolones, with some
recording MICs >128mg/L. The highest MICs are recorded against ciprofloxacin.
Trovafloxacin was still the most potent drug closely followed by sparfloxacin. One
strain, SB21, was highly resistant to ciprofloxacin and gemifloxacin, with an MIC
>128mg/L but the MICs to the other drugs were 4-8 fold less. The MIC range in this
group has risen from those seen in group B, with at least a 16-fold increase against
gemifloxacin and levofloxacin.
Figure 6.1 shows a representative agarose gel ofgyrA Hinfl RFLP. Uncut gyrA has
a single band of 343bp. When cut, two fragments are produced of 291bp and 52bp.
The smallest of these bands is unresolved in the gel but restriction can be seen to
have taken place by the reduction in size of the larger band.
Figure 6.1. Hinfl restriction of gyrA PCR products. Lane a: 100bp ladder, b: control
- no restriction enzyme, c: SB5, d: SB22, e:SB24, f: SB10, g: SB4, h: SB67
Figure 6.2 shows a representative parC Hinfl restriction digest. The uncut PCR
product retains its size of 197bp. When cut, two fragments are seen, of 114bp and
53bp.
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Figure 6.2. Hinf\ restriction of parC PCR products. Lane A: 100bp ladder, B:
control - no restriction enzyme, C: SB10, D: SB5, E:SB36, F: SB1, G: SB24, H:
SB75
ABCDEFGH
6.2.3 Sequencing of gyrA
Seven of the strains had the QRDR ofgyrA and parC sequenced, representing 2 each
from groups A & B and 3 from group C. Table 6.2 shows the sequence alignment of
gyrA and Table 6.3 the corresponding amino acid substitutions. At the nucleotide
level, there is a point mutation in the gyrA gene; a C-* T transversion (highlighted in
red) in the Hinfl restriction site (yellow). Three single nucleotide polymorphisms are
found in ATCC19606 (green) one ofwhich is also found in SB1, SB21 and SB36.
The mutation in the restriction site ofgyrA changed the codon from TCA (serine) to
TTA (leucine) at codon 83. No other amino acid substitutions were found in the
strains.
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Table 6.2. gyrA alignment. The Hinf\ restriction site is highlighted in yellow, the
C—»T transversion of the serine residue is in red and single nucleotide polymorphisms
are in green.
Group A 19606 GTTGGTGACG TAATCGGTAA ATATCACCCG CATGGTGACT CAGCTGTTTA
SB10 ATCACCCG CATGGTGACT lAGCTGTTTA
Group B SB13 TCGGTAA ATATCACCCG CATGGTGACT IaGCTGTTTA
SB24 TCGGTAA ATATCACCCG CATGGTGACT lAGCTGTTTA
Group C SB36 CG TAATCGGTAA ATATCACCCG CATGGTGACT lAGCTGTTTA
SB1 TCGGTAA ATATCACCCG CATGGTGACT |AGCTGTTTA
SB21 CG TAATCGGTAA ATATCACCCG CATGGTGACT |AGCTGTTTA
19606 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB10 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB13 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB24 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB36 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB1 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
SB21 TGAAACCATT GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG
19606 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB10 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB13 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB24 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB36 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB1 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
SB21 TTGATGGTCA GGGTAACTTC GGTTCGATCG ATGGTGATAG CGCTGCGGCA
19606 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB10 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB13 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB24 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB36 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB1 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
SB21 ATGCGTTATA CCGAAGTCCG TATGACTAAG CTGGCACATG AGCTTCTTGC
19606 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB10 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB13 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB24 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB36 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB1 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
SB21 AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC GACGGTTCGG
19606 AACGTATCCC TGAAGTACTT CCGACACGSG TTCCAAACTT i§TTAAT|AAC
SB10 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAAC
SB13 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAACTT ATTAA
SB24 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAACTT ATTAA
SB36 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAACTT ITTAATTAAC
SB1 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAACTT ITTAA
SB21 AACGTATCCC TGAAGTACTT CCGACACGTG TTCCAAACTT ITTAATTAAC
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Table 6.3. Amino acid substitutions in GyrA and ParC in sequenced strains
Group Strain GyrA ParC
A ATCC 19606 Wild type Wild type
SB10 None None
B SB13 83 Ser -> Leu None
SB24 83 Ser -> Leu None
C SB36 83 Ser -> Leu 80 Ser -> Leu
SB1 83 Ser ->■ Leu 80 Ser -» Leu
SB21 83 Ser -» Leu 80 Ser -> Leu
6.2.4 Sequencing of parC
Table 6.4 shows the parC sequence alignment. The published gene sequence of
ATCC19606 (GenBank accession number AF108132) was different from that found
in this study (data not shown), a finding confirmed by Scott Cameron (personal
correspondence). Interestingly, the difference was only at the nucleotide level and
did not affect the translated sequence. This difference was not found with gyrA.
There is more heterogeneity within this gene compared to that ofgyrA. A total of
eight point mutations were found, two ofwhich were found in other strains. The
mutation in the restriction site TCG (serine) to TTG (leucine) was in codon 80. No
other amino acid substitutions were found.
97
Chapter 6: Mutations leading to fluoroquinolone resistance
Table 6.4. parC alignment. The Hinfl restriction site is highlighted in yellow, the
C—>T transversion of the serine residue is in red and single nucleotide
polymorphisms are in green.
Group a 19606 ....cttggt aaataccacc cacatggtga ctcggcatgt tatgaagcca
sb10 tgtacttggt aaataccacc cacatggtga ctIggcatgt tatgaagcca
Group b sb13 .gtacttggt aaataccacc cacatggtga ctIggcatgt tatgaagcca
sb24 ggt aaataccacc cacatggtga ctIggcatgt tatgaagcca
Group c sb36 ....cttggt aaataccacc cacatggtga ctIggcatgt tatgaagcca
sb1 ....cttggt aaataccacc cacatggtga ctIggcatgt tatgaagcca
sb21 ....cttggt aaataccacc cacatggtga ct|ggcatgt tatgaagcca
19606 tggtactcat ggctcagcca TTTAGTTAflC gItatccgct aat|gaagg|§
sb10 tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
sb13 tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
sb24 tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
sb36 tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
sbl tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
sb21 tggtactcat ggctcagcca tttagttacc gctatccttt aatcgaaggt
19606 caggggaact ggggttcacc jggatgatcct aaStcttttg ctgcgatgcg
sb10 caggggaact ggggttcacc jggatgatcct aaatcttttg ctg
sb13 caggggaact ggggctcacc tgatgatcct aagtcttttg ctgcg
sb24 caggggaact ggggctcacc tgatgatcct aagtcttttg ctg
sb36 caggggaact ggggttcacc ggatgatcct aaItcttttg ct
SBl caggggaact ggggttcacc tgatgatcct AAjgjTCTTTTG ct
sb21 caggggaact ggggttcacc |gatgatcct aaatcttttg ct
6.3 Outer Membrane Profiles
A coomassie-stained SDS-PAGE outer membrane profile of seven strains are shown
in Figure 6.3. A major band ofapproximately 45kDa is found in all strains. Use of
BioRad Quantity One software shows that this composes about 50% of the total outer
membrane protein. Strains SB 13, SB22 and SB24 (lanes d, e & f, Figure 6.3) have
similar profiles, indicating relatedness. These strains also belong to group B and
have identical gyrA and parC genes (Tables 6.2 & 6.3). There are OMP differences
seen amongst the other strains but it cannot be concluded what role they play in
resistance.
98
Chapter 6: Mutations leading to fluoroquinolone resistance
Figure 6.3. Coomassie-stained SDS-PAGE of clinical isolates. Lane a: MW







d e f g h
21
:
A silver stained SDS-PAGE OMP profile is shown in Figure 6.4. This staining
technique is more sensitive than a coomassie blue stain and therefore more protein
bands are visible. In this gel, the similarity between SB 13 and SB22 is less
pronounced than in Figure 6.3 (lanes d & e, Figure 6.4), with a band just below the
major OMP not visible in SB22 but seen with SB13. This may be due to less protein
loaded in the gel as lane d clearly has more protein. In this gel, SB36, in lane f, has a
similar banding pattern to SB 13 and SB22, however its profile in Figure 6.3 is
different.
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Figure 6.4. Silver stain of OMPs. Lane a: marker, b: SB1, lane c: SB5, d: SB13,
e: SB22, f: SB36, g: SB47
a b c d e f g
6.4 Pulsed-Field Gel Electrophoresis
Figures 6.5, 6.6 & 6.7 show the PFGE profiles of the strains. Three of the strains,
SB22, SB24 (lanes h & I, Figure 6.5) and SB13 (lane d, Figure 6.7), appear to have
the same PFGE pattern. No data were given as to where the isolates came from and
it is possible that they are samples from the same patient, but this is speculative. The
other isolates are heterogeneous in their PFGE patterns.
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Figure 6.5. PFGE of clinical isolates. Lane A, F & J; 50kb marker, B: ATCC 19606,
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Figure 6.7. Lane A, F & J: 50kb marker, B: 19606, C: SB10, D: SB13, E: SB14,









These data show that there is an associated rise in MIC when there is a serine to
leucine substitution at positions 83 and 80 within the QRDR ofA. baumannii GyrA
and ParC respectively, confirming work previously done by Seward and Vila
(Seward and Towner, 1998; Vila, Ruiz, Goni and Deanta, 1997; Vila, Ruiz, Goni,
Marcos and de Anta, 1995). Fluoroquinolones bind to DNA gyrase and
Topoisomerase IV in an area close to the mutated serine residue and this substitution
reduces binding of fluoroquinolones to DNA Gyrase (Willmott and Maxwell, 1993).
With the two successive mutations in gyrA and parC there is an increase in recorded
MIC for all the fluoroquinolones. This rise in MIC has previously been reported in
A. baumannii using ciprofloxacin and nalidixic acid but here it has been extended to
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acid substitutions within GyrA and ParC but none were seen nor were the point
mutations in the areas corresponding to their codons (Vila et al, 1997). However the
mutations identified do not, on their own, account for the range ofMICs within each
group. A second mutation in gyrA was expected as this has been shown to be
necessary for high-level resistance in E. coli (Heisig, 1996). The sequencing of the
gyrA PCR product does not cover those mutations found in E. coli at Ala 67 and Ala
51, which, ifpresent, could account for the MIC range (Friedman, Lu and Drlica,
2001; Yoshida et al, 1990).
Other gene mutations may play a part in the MIC ranges, for example changes in the
QRDR ofgyrB. These contribute to reduced fluoroquinolone sensitivity in E. coli
(Yoshida et al, 1991). However Vila noted that gyrB mutations are not important in
A. baumannii (Vila, 1998) but as a mechanism of resistance they should not be
discounted offhand. It seems unlikely that ParE mutations are involved as they have
not been found to contribute to resistance in Gram negative organisms.
Another explanation for both high fluoroquinolone and MIC ranges without extra
target-site mutations could relate to the innate resistance ofA. baumannii to the
fluoroquinolones. A. baumannii DNA gyrase is less sensitive to fluoroquinolones
than that ofE. coli (Moreau et al, 1996) and it also exhibits low outer membrane
permeability, which has been calculated to be 1-3% that of E. coli (Hancock, 1998;
Sato and Nakae, 1991). A combination of these two properties could contribute to
MIC differential and lack of tertiary mutations.
Evidence for permeability factors comes from SB21. It is hyper-resistant to both
ciprofloxacin and gemifloxacin, both being hydrophilic drugs, but was more
sensitive to the other, more hydrophobic fluoroquinolones. Moreau has shown that
resistant strains ofA. baumannii generally accumulate less drug than sensitive
strains. This affects hydrophilic drugs more than hydrophobic drugs, although they
found no correlation in MIC (Moreau et al, 1996). This relationship has also been
demonstrated in P. aeruginosa and E. coli (Piddock, Jin and Griggs, 2001).
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The outer membrane profiles of the strains were investigated but no conclusions
could be drawn from this. This is unsurprising as outer membrane profiles have
proved to be a useful tool in epidemiology (Horrevorts et al, 1997) and any
differences seen could be due to strain-specific expression. Results ofPFGE showed
that 3 of the strains were related, having similar OMP and PFGE patterns, but their
MICs were not equal. However changes in the outer membrane profile have been
shown to contribute to fluoroquinolone resistance. For example, in P. aeruginosa,
decreased expression ofporin D2 is associated with both fluoroquinolone and
carbapenem resistance (Masuda, Sakagawa and Ohya, 1995; Micheahamzehpour,
Furet and Pechere, 1991) and that there is an association with fluoroquinolone
resistance and overexpression of the outer membrane protein OprM (Li, Barre and
Poole, 2000).
In A. baumannii carbapenem resistance was shown to be associated with a reduction
in a 33kDa OMP (Clark, 1996). Clark used isogenic strains, thus eradicating strain
difference. Other A. baumannii membrane proteins that have been investigated
include a 43kDa and 45.5kDa porin (Nitzan et al, 1999; Sato and Nakae, 1991). A
38Kda OMP has been found to be a virulence factor (Ofori-Darko et al, 2000),
therefore OMP differences between strains may not relate to resistance at all.
In conclusion, fluoroquinolone resistance in A. baumannii is mediated through a
serine 83 mutation in GyrA. The newer fluoroquinolones, although more potent than
ciprofloxacin, are also affected by this mutation although trovafloxacin records MICs
that are below the breakpoint. However, as a treatment option trovafloxacin is of no
use as it has been withdrawn because of severe side-effects.
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Chapter 7: in-vitro Fluoroquinolone Selection
7.1 Introduction
In the previous chapter we have been looking at clinical isolates and their mechanism
of fluoroquinolone resistance through target site mutations. Some questions that may
come to mind is how they occur, at what frequency and in what order? The use of
fluoroquinolones has been associated with the selection of ciprofloxacin resistant
strains in the clinical environment (Horrevorts et al, 1997; Muder et al, 1991; Vila,
1998). We have seen that a serine 83 mutation in GyrA is found in all strains with
ciprofloxacin MICs above breakpoint values and high-level resistance with a
concurrent serine 80 mutation in ParC. These mutations also confer resistance to the
newer fluoroquinolones as seen in chapter 6. In this study the mutation rates and
associated mutations of a laboratory A. baumannii strain were compared between
ciprofloxacin and the newer fluoroquinolones gemifloxacin and moxifloxacin. A
clinical isolate carrying a serine 83 mutation in GyrA was also used to compare
mutation rates once a GyrA mutation was present.
Results
7.2.1 Ciprofloxacin selection of A. baumannii ATCC 19606
The mutation frequencies, fluoroquinolone MICs and Hinfl restriction analysis of the
ciprofloxacin-selected mutants derived from ATCC 19606 are shown in Table 7.1.
First generation mutants were selected at a frequency of 2.4x10"5. These mutants
could be put into two groups: (1) gyrA wild type (2) restriction site lost. One isolate
did not show a change in MIC, suggesting that it was not a true mutant or that it had
mutated and subsequently reverted. The wild type mutants showed a 2-8 fold
increase in MIC to ciprofloxacin, 2-4 fold against gemifloxacin and 2-4 fold against
moxifloxacin. Four of these mutants were resistant to ciprofloxacin but were still
susceptible to gemifloxacin and moxifloxacin, although five and six mutants had
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MICs at breakpoint values respectively. Mutants of this group retained the gyrA and
parC Hinfl restriction site.
Table 7.1. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against









Parent 19606* 0.12 1 0.25 wt wt
-|ST 2.4x10"5 C1 16 128 16 lost wt
generation C2 0.5 2 1 wt wt
C3 0.12 1 0.25 wt wt
C4 0.5 4 1 wt wt
C5 0.25 2 1 wt wt
C6 0.5 2 1 wt wt
C7* 16 128 16 lost wt
C8 0.25 4 0.5 wt wt
C9 0.5 4 1 wt wt
C10 0.5 8 1 wt wt
2nd 1.3x10"6 256C1 32 256 16 lost wt
generation 256C2 32 128 16 lost wt
256C3 >128 >512 32 lost wt
256C4 32 64 8 lost wt
256C5 16 256 16 lost wt
256C6 64 512 32 lost wt
256C7 16 128 16 lost wt
256C8 16 128 4 lost wt
256C9 32 128 16 lost wt
256C10 16 128 16 lost wt
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin, MOX: moxifloxacin,
nt: not tested, wt: wild type cut by Hinfl, lost: not cut by Hinfl
The mutants that lost the gyrA restriction site, CI and C7, showed a 128-fold
increase in ciprofloxacin MIC, 133-fold increase to gemifloxacin and 64-fold
increase to moxifloxacin. These mutants retained the parC site.
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Mutant C7 was further selected on ciprofloxacin. None of the mutants derived from
C7 lost the parC restriction site. As with the first generation, some mutants did not
record an increase in MIC and interestingly, mutant 256C8 was 4-fold more sensitive
to moxifloxacin. Another mutant, 256C4, was 2-fold more sensitive to ciprofloxacin
and moxifloxacin but recorded a gemifloxacin MIC 2-fold greater than C7.
7.2.2 Gemifloxacin selection of ATCC 19606
The mutation frequencies, fluoroquinolone MICs and Hinfl restriction analysis of the
gemifloxacin-selected mutants derived from ATCC 19606 are shown in Table 7.2.
First generation mutants were selected at a frequency lower than ciprofloxacin. This
saw a 4-fold increase in gemifloxacin MIC, a 2-4-fold increase in ciprofloxacin MIC
and a 2-fold increase in MIC ofmoxifloxacin. One of the mutants, API, had a
ciprofloxacin MIC greater than breakpoint level. Hinfl restriction analysis of the
gyrA and parC gene showed no mutation at serine 80 or 83 respectively. Strain API
was plated onto gemifloxacin containing plates at lmg/L to yield 2nd generation
mutants at a frequency of 7x10" . These mutants exhibited a 2-fold increase in MIC
against the three fluoroquinolones. There was no change in the restriction analysis
from the wild type.
Third generation mutants were selected at a lower frequency than the first two steps
at lxlO"9. Three of these strains showed a 16-fold increase in MIC to gemifloxacin
and ciprofloxacin and an 8-fold increase to moxifloxacin. Mutant CP4 had an 8-fold
increase to gemifloxacin and ciprofloxacin but only 2-fold to moxifloxacin, even
though all four of the strains had lost the Hinfi restriction site in gyrA. A 4th
selection step was carried out to see if aparC mutation would be selected. This step
yielded mutants at a frequency that was 3000 times greater than the previous step.
While some of the strains had a gemifloxacin increase in MIC > 8-fold, moxifloxacin
only increased 2-3 fold. None of the mutants had lost the parC restriction site.
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Table 7.2. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against
gemifloxacin-selected mutants of ATCC 19606
Gemifloxacin-selected mutants
Frequency





Parent 19606* 0.12 1 0.25 wt wt
1st 1x10~8 AP1* 0.5 4 0.5 wt wt
generation AQ1 0.5 2 0.5 wt wt
AR1 0.5 2 0.5 wt wt
7x10"8 BP1* 1 8 1 wt wt
generation BP2 1 8 1 wt wt
BP3 1 8 1 wt wt
BP4 1 8 1 wt wt
BP5 1 8 nt wt wt
BP6 1 8 nt wt wt
BP7 1 8 nt wt wt
BP8 1 8 nt wt wt
3rd 1x10"9 CP1* 16 128 8 lost wt
generation CP2 16 128 8 lost wt
CP3 16 128 8 lost wt
CP4 8 64 2 lost wt
4th 3x10"6 DP1 64 >128 16 lost wt
generation DP2 64 >128 16 lost wt
DP3 64 >128 16 lost wt
DP4 128 >128 16 lost wt
DP5 >128 >128 16 lost wt
DP6 >128 >128 32 lost wt
DP7 >128 >128 32 lost wt
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin,
MOX: Moxifloxacin, nt: not tested, wt: wild type - cut by Hinf\, lost: not cut by Hinf\
7.2.3 Analysis of gyrA and parC QRDR
Sequencing of the gyrA QRDR was performed and this is shown in Figure 7.1. The
translated sequence is shown in Figure 7.2. These data confirm the restriction
analysis in Table 7.2. The only change seen in gyrA was a C—->T transversion at
position 56 in mutant CP1 and those derived from it. Mutant M2E is a moxifloxacin-
selected mutant with the same transversion. The mutation substitutes serine 83 into
leucine as described in chapter 6. TheparC QRDR of the mutants were also
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sequenced and were found to be indistinguishable from the wild type parent (Figure
7.3). The translated sequence ofparC is shown in Figure 7.4.
Figure 7.1. Alignment of the gyrA QRDR. The C^-T transversion is in red.
19606 TCGGT AAATATCACC CGCATGGTGA CTCAGCTGTT TATGAAACCA
API TCGGT AAATATCACC CGCATGGTGA CTCAGCTGTT TATGAAACCA
BP1 TCGGT AAATATCACC CGCATGGTGA CTCAGCTGTT TATGAAACCA
CP1 CGTAATCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
DPI TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
DP7 TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
M2E TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
19606 GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
API GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
BP1 GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
CP1 GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
DPI GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
DP7 GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
M2E GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT CAGGGTAACT
19606 CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
API CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
BP1 CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
CP1 CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
DPI CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
DP7 CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
M2E CGATGGCGAT AGCGCCGCGG CAATGCGTTA TACCGAAGTC CGTATGACTA
19606 TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
API TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
BP1 TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
CP1 TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
DPI TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
DP7 TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
M2E TGAGCTTCTT GCAGATTTAG AAAAAGACAC AGTTGACTGG GAAGATAACT
19606 ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
API ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
BP1 ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
CP1 ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
DPI ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
DP7 ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
M2E ACGACGGTTC AGCTGGCACA TCGGTTCGAT TTGTTCGTAT
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Figure 7.2. Translated gyrA amino acid sequence of ATCC 19606 and mutant CP1.







Figure 7.3. Alignment of the parC QRDR. The Serine 80 codon is in red
19606 C TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
API GGTGATGTAC TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
BP1 GGNGATGTAC TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
CP1 GGTGATGTAC TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
DPI TGTAC TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
DP7 TGTAC TTGGTAAATA CCACCCACAT GGTGACTCGG CATGTTATGA
19606 AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
API AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
BP1 AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
CP1 AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
DPI AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
DP7 AGCCATGGTA CTCATGGCTC AGCCATTTAG TTATCGTTAT CCGCTAATTG
19606 AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCTGCG
API AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCTGCG
BP1 AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCTGCG
CP1 AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCTGCG
DPI AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCTGCG
DP7 AAGGACAGGG GAACTGGGGT TCACCAGATG ATCCTAAATC TTTTGCT...
Figure 7.4. Translated parC amino acid sequence of ATCC 19606 and mutant
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7.2.4 Moxifloxacin Selection of ATCC 19606
The mutation frequencies, fluoroquinolone MICs and Hinjl restriction analysis of the
moxifloxacin-selected mutants derived from ATCC 19606 are shown in Table 7.3.
Two first generation mutants were investigated and they showed a 4-fold increase in
moxifloxacin and ciprofloxacin MIC and 2-8-fold to gemifloxacin. The Hinjl
restriction sites were unaffected. Mutant M1B was further selected on moxifloxacin
to produce second generation mutants. One of the five, M2E, had lost the restriction
site in gyrA. This strain had its gyrA QRDR sequenced and it had the same C—>T
transversion in the serine 83 codon as seen in clinical isolates (chapter 6) and
gemifloxacin selected mutants (Figures 7.2 & 7.3). The other four second generation
mutants, although having not lost the restriction site in either gyrA orparC, recorded
higher MICs than M2E. This strain was further selected on moxifloxacin and
yielded mutants that showed an 8-fold increase in moxifloxacin MIC and a 16-fold
increase to ciprofloxacin and gemifloxacin. One mutant, 4M2A, had a 4-fold
increase in gemifloxacin MIC. A further selection step was performed and this
yielded only one mutant at a low frequency. This mutant only showed a 2-fold
increase to the fluoroquinolones tested. It did not lose the parC restriction site.
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Table 7.3. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against
moxifloxacin selected mutants of ATCC19606
Moxifloxacin-selected mutants
Frequency MIC (mg/L) Hinf\ restriction
Of Mutation Strain GEM CIP MOX gyrA parC
Parent 19606* 0.12 1 0.25 wt wt
1st 1x10"7 M1A 0.25 4 1 wt wt
generation M1B* 1 4 1 wt wt
2"d 5x10"8 M2A 2 16 2 wt wt
generation M2B 2 16 4 wt wt
M2C 2 16 2 wt wt
M2D 2 16 4 wt wt
M2E* 1 8 2 lost wt
3rd 8x10"6 4M2A 4 128 16 lost wt
generation 4M2B 16 128 16 lost wt
4M2C 16 128 16 lost wt
4M2D 16 128 16 lost wt
4M2E* 16 128 16 lost wt
4M2F 16 128 16 lost wt
4M2G 16 128 16 lost wt
4M2H 16 128 16 lost wt
4M2I 16 128 16 lost wt
4M2J 16 128 16 lost wt
4th 1x10"9 32MA 32 >128 32 lost wt
generation
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin,
MOX: Moxifloxacin, nt: not tested, wt: wild type - cut by Hinfl, lost: not cut by Hinfl
7.3.1 Ciprofloxacin selection of SB13
The clinical isolate SB 13, previously described in Chapter 6, was selected with
ciprofloxacin to compare mutation rates against strain ATCC 19606. Table 7.4
shows the mutation rates and associated MICs of ciprofloxacin-selected mutants. An
increase in MIC against ciprofloxacin was 1-32-fold, 2-8-fold against moxifloxacin
and 1-32-fold against gemifloxacin. Two of the mutants, 16CSB6 and 16CSB9, lost
theparC restriction site. These mutants recorded the highest gemifloxacin MICs, but
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their ciprofloxacin and moxifloxacin MICs were matched by mutants with the wild
type restriction site.
Table 7.4. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against
ciprofloxacin selected mutants of SB13
Ciprofloxacin-selected mutants
Frequency MIC (mg/L) Hinfl restriction
Of Mutation Strain GEM CIP MOX gyrA parC
Parent SB13* 1 8 2 lost wt
1st 8.5x1 CT7 16CSB1 16 128 8 lost wt
generation 16CSB2 1 8 4 lost wt
16CSB3 8 32 4 lost wt
16CSB4 8 32 4 lost wt
16CSB5 8 64 4 lost wt
16CSB6 32 128 16 lost lost
16CSB7 8 64 16 lost wt
16CSB8 8 64 16 lost wt
16CSB9 32 256 16 lost lost
16CSB10 8 64 8 lost wt
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin,
MOX: Moxifloxacin, nt: not tested, wt: wild type - cut by Hinf\, lost: not cut by HintI
7.3.2 Gemifloxacin Selection of SB13
The mutation frequencies, fluoroquinolone MICs and Hinfl restriction analysis of the
gemifloxacin-selected mutants derived from SB 13 are shown in Table 7.5.
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Table 7.5. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against
gemifloxacin selected mutants of SB13
Gemifloxacin-selected mutants
Frequency MIC (mg/L) Hinfl restriction
Of Mutation Strain GEM CIP MOX gyrA parC
Parent SB13* 1 8 2 lost wt
1st 5x10'7 AA1 8 32 nt lost wt
generation AB1 16 32 nt lost wt
AC1 16 128 16 lost lost
AD1 16 64 nt lost wt
AE1* 16 64 4 lost wt
2nd 5x10"6 BE1 >128 256 16 lost wt
generation BE2 >128 256 8 lost wt
BE3 >128 256 16 lost wt
BE4 >128 256 16 lost wt
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin,
MOX: Moxifloxacin, nt: not tested, wt: wild type - cut by Hinfl, lost: not cut by Hinfl
These data show that SB 13 mutated at a similar frequency as seen against
ciprofloxacin. One mutant, AC1, lost the parC restriction site. Its parC gene was
sequenced and compared to its parent SB13 in Figure 7.5. This shows a C—>T
transversion in the gene as found in clinical isolates. The translated sequence reveals
a serine —♦ leucine substitution corresponding to amino acid residue 80 (Figure 7.6).
This mutant had the highest MIC against moxifloxacin and ciprofloxacin although it
shared a gemifloxacin MIC of 16mg/L with four of the other mutants with wild-type
parC. Mutant AE1 was further selected to produce second generation mutants at a
high frequency. None of these mutants lost the parC restriction site and sequence
analysis showed no difference from that of SB 13 or AE1 (Figure 7.5). The GyrA
gene was also sequenced for these mutants and is shown in Figure 7.7. There was no
difference between the mutants and parents. These mutants were highly resistant to
gemifloxacin and ciprofloxacin but their moxifloxacin MIC was the same as the
ParC mutant AC1.
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Figure 7.5. The parC QRDR of SB13 and mutant AC1. The mutation is shown in
red.
SB13 GTACTTGGTA AATACCACCC ACATGGTGAC TCGGCATGTT ATGAAGCCAT
AE1 GTACTTGGTA AATACCACCC ACATGGTGAC TCGGCATGTT ATGAAGCCAT
BE1 . TACTTGGTA AATACCACCC ACATGGTGAC TCGGCATGTT ATGAAGCCAT
AC1 . . . CTTGGTA AATACCACCC ACATGGTGAC TTGGCATGTT ATGAAGCCAT
SB13 GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
AE1 GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
BE1 GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
AC1 GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
SB13 AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
AE1 AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
BE1 AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
AC1 AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
Figure 7.6. Translated parC QRDR of SB13 and AC1. The serine —> leucine
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Figure 7.7. Alignment of the gyrA QRDR. The mutated H/nfl codon is shown in red.
SB13 TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
AE1 TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
BE1 TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
SB13 TTGTTCGTAT GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT
AEl TTGTTCGTAT GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT
BE1 TTGTTCGTAT GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT
SB13 CAGGGTAACT TCGGTTCGAT CGATGGTGAT AGCGCTGCGG CAATGCGTTA
AE1 CAGGGTAACT TCGGTTCGAT CGATGGTGAT AGCGCTGCGG CAATGCGTTA
BE1 CAGGGTAACT TCGGTTCGAT CGATGGTGAT AGCGCTGCGG CAATGCGTTA
SB13 TACCGAAGTC CGTATGACTA AGCTGGCACA TGAGCTTCTT GCAGATTTAG
AEl TACCGAAGTC CGTATGACTA AGCTGGCACA TGAGCTTCTT GCAGATTTAG
BE1 TACCGAAGTC CGTATGACTA AGCTGGCACA TGAGCTTCTT GCAGATTTAG
SB13 AAAAGACAC AGTTGACTGG GAAGATAACT ACGACGGTTC GGAACGTATC
AEl AAAAAGACAC AGTTGACTGG GAAGATAACT ACGACGGTTC GGAACGTATC
BE1 AAAAAGACAC AGTTGACTGG GAAGATAACT ACGACGGTTC GGAACGTATC
SB13 CCTGAAGTAC TTCCGACACG TGTTCCAAAC TTATTAA...
AEl CCTGAAGTAC TTCCGACACG TGTTCCAAAC TTATTAATTA ACGGTGCTGC
BE1 CCTGAAGTAC TTCCGACACG TGTTCCAAAC TTATTAATTA ACGGTGCTGC
SB13
AEl TGGTATCGCC GTAGGTATGG C
BE1 TGGTATCGCC GTAGGTATNG c
7.3.3 Moxifloxacin Selection of SB13
The mutation rates and associated mutations of SB 13 selected on moxifloxacin are
shown in Table 7.6. First step mutants did not lose the parC Hinfl restriction site as
seen with ciprofloxacin and gemifloxacin selection, however the mutation frequency
was similar. The moxifloxacin and ciprofloxacin MICs rose 4-8 fold and
gemifloxacin 8-16 fold. Mutant M4A was further selected on moxifloxacin and the
second generation mutants retained the parC restriction site. These mutants were
heterogeneous in their MICs. One mutant, M16A, showed no change in
moxifloxacin MIC but was more sensitive to gemifloxacin and ciprofloxacin. The
other mutants had identical ciprofloxacin MICs. Mutant M16D was highly resistant
to gemifloxacin but had a moxifloxacin MIC of 32mg/L while mutant M16G had the
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potency of these drugs switched. Thus the ParC mutation is not necessary for high-
level fluoroquinolone resistance.
Table 7.6. MICs to gemifloxacin, ciprofloxacin and moxifloxacin against
moxifloxacin selected mutants of SB13
Moxifloxacin-selected mutants
Frequency MIC (mg/L) Hinfl restriction
Of Mutation Strain GEM CIP MOX gyrA parC
Parent SB13* 1 8 2 lost wt
1st 6.2x10"7 M4A* 8 64 8 lost wt
generation M4B 4 32 8 lost wt
M4C 4 32 8 lost wt
M4D 4 32 8 lost wt
M4E 4 32 8 lost wt
M4F 16 64 16 lost wt
M4G 16 64 16 lost wt
2nd 4x10"7 M16A 4 32 8 lost wt
generation M16B 32 256 32 lost wt
M16C 32 256 64 lost wt
M16D 256 256 64 lost wt
M16E 32 256 32 lost wt
M16G 32 256 128 lost wt
*: strain used for further selection, GEM: gemifloxacin, CIP: ciprofloxacin,
MOX: Moxifloxacin, nt: not tested, wt: wild type - cut by Hinf\, lost: not cut by Hinfl
7.4 Sensitivity to Non-Fluoroquinolones
The ATCC 19606 mutants were tested for their sensitivity to drugs outwith the
fluoroquinolone class to investigate if non-target mutations have an effect on these
drugs. These data are summarised in Table 7.7. No common pattern was observed.
First step gemifloxacin mutant API recorded non-fluoroquinolone MICs that were 1
dilution higher than the parent ATCC 19606 although the imipenem MIC was
unchanged. No other changes were seen after this selection step. Mutant M1B had
an imipenem MIC 1-dilution higher than the parent but this change was negated at
subsequent selection steps. The biggest differences were seen with the
ciprofloxacin-selected mutants. Mutant C7 recorded an imipenem MIC 1 dilution
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higher than the parent but a tetracycline MIC that was lower. The second step
ciprofloxacin mutants could be grouped into those with an imipenem and tetracycline
MIC that was 0.25mg/L and 4mg/L respectively, and the more sensitive < 0.12mg/L
and lmg/L respectively. Those in the more sensitive group were the least sensitive
to the fluoroquinolones (Table 7.1). Although these data show minor changes in
non-fluoroquinolone sensitivity, they are not indicative of enhanced efflux. What
seems more likely are changes in permeability to the selecting agent that are having
minor affects to the structurally dissimilar non-fluoroquinolones.
Table 7.7. Sensitivity of ATCC19606 mutants to imipenem, sulbactam,
chloramphenicol and tetracycline.
MIC (mg/L) MIC (mg/L)
Strain IMI SUL CHL TET Strain IMI SUL CHL TET
p 19606 0.12 0.5 256 4 1st C7 0.25 1 nt 2
1st AP1 0.12 1 512 8 2nd 256C1 0.25 nt nt 4
2"d BP1 0.12 1 512 8 256C2 0.25 nt nt nt
3rd CP1 0.12 1 512 8 256C3 0.25 nt nt 4
4«h DP1 0.12 1 512 8 256C4 0.12 nt nt 1
DP7 0.12 1 512 8 256C5 0.25 nt nt 4
256C6 0.25 nt nt 4
1st M1B 0.25 0.5 256 8 256C7 0.25 nt nt 4
2nd M2E 0.12 0.5 256 8 256C8 0.06 nt nt 1
3rd 4M2E 0.12 0.5 256 8 256C9 0.12 nt nt 1
4th 32MA 0.12 nt nt nt 256C10 0.25 nt nt 4
P: parent strain, IMI: imipenem, SUL: sulbactam, CHL: chloramphenicol,
TET, tetracycline, nt: not tested
The non-fluoroquinolone MICs of SB 13 selected mutants are shown in Table 7.8.
Gemifloxacin mutants were 1 dilution more sensitive to imipenem than the parent
strain. AE1 was also 1 dilution more sensitive to sulbactam, but there were no
changes in chloramphenicol and tetracycline sensitivity. Mutant M4A was 1 dilution
less sensitive to imipenem, chloramphenicol and tetracycline but 1 dilution more
sensitive to sulbactam. Second generation moxifloxacin mutants were heterogeneous
in their MICs as were ciprofloxacin selected mutants. The acquisition of
fluoroquinolone resistance appears to give no change or only minor changes in non-
fluoroquinolone MICs, as was also found with the ATCC 19606 derived mutants.
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Table 7.8. Sensitivity of SB13 mutants to imipenem, sulbactam, chloramphenicol
and tetracycline.
MIC (mg/L)
Strain IMI SUL CHL TET
Parent SB13 0.5 32 256 128
1st AC1 0.25 32 256 128
AE1 0.5 16 256 128
2"d BE1 0.25 16 512 128
BE2 0.5 16 256 128
BE3 0.25 16 256 128
BE4 0.5 16 256 128
1St M4A 1 16 512 256
2"d M16A 1 16 512 256
M16B 0.5 16 512 256
M16C 1 16 >512 256
M16D 1 16 512 >256
M16E 0.5 16 >512 256
M16G 0.5 32 512 256
1St 16CSB1 0.5 32 512 128
16CSB6 0.5 32 512 128
16CSB7 1 32 >512 256
16CSB9 0.5 16 512 128
16CSB10 0.25 16 <200 128
P: parent strain, IMI: imipenem, SUL: sulbactam, CHL:
chloramphenicol, TET, tetracycline, nt: not tested
The non-fluoroquinolone MICs show that resistance to these drugs is not selected
with the fluoroquinolones tested. No strain that was sensitive to imipenem,
sulbactam, chloramphenicol or tetracycline prior to selection became resistant.
Conversely, if a strain was resistant prior to selection, it retained its resistance.
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7.5 Discussion
It has been shown that the most important mechanism in the acquisition of
fluoroquinolone resistance is the development ofmutations in the target site enzymes
i.e. DNA Gyrase and Topoisomerase IV. Results from clinical isolates have shown
that the primary target ofGram negative organisms is GyrA and for Gram positives
ParC (Gonzalez et al, 1998; Kanematsu et al, 1998; Mouneimne el al, 1999; Nakano
et al, 1997; Yoshida et al, 1990). Since clinical isolates will most probably have
been selected with ciprofloxacin or levofloxacin in vivo, how do the target site
mutations compare against the newer fluoroquinolones moxifloxacin and
gemifloxacin? Because moxifloxacin has only recently been released into the
clinical armoury and gemifloxacin is still undergoing clinical trials, data on isolates
that have encountered these drugs in vivo is lacking. Therefore in vitro mutation
studies provide the best model.
Mutation studies have shown that in E. coli selected on norfloxacin or lomefloxacin,
GyrA mutations are found primarily and ParC mutations are both secondary and rare
(Burucoa , Lhomme and Fauchere, 1999; Tavio et al, 1999). Ciprofloxacin selected
S. pneumoniae acquire a ParC mutation before a GyrA mutation (Pan et al, 1996).
However, S. pneumoniae selected with clinafloxacin selects a GyrA mutation first
(Pan and Fisher, 1998) and C-7 analogues of ciprofloxacin also select for GyrA
mutations primarily (Alovero et al, 2000). With moxifloxacin selected S. aureus,
GyrA is selected first (E. Durham, PhD thesis) but with ciprofloxacin-selected
strains, a GrlA (ParC) mutation is selected primarily (Ferrero, Cameron and Crouzet,
1995). Thus it appears that target site mutations are dependent upon the selecting
agent, at least in the case ofGram positive organisms.
Results obtained in this study show that the newer fluoroquinolones select for a
GyrA mutation primarily, irrespective of the selecting agent and at a frequency
much lower than ciprofloxacin. ParC mutations appear to be limited to selection on
ciprofloxacin and gemifloxacin, although this may be strain dependant as the
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laboratory strain ATCC 19606 did not mutate in its ParC QRDR when selected with
any of the drugs. In spite of this, high-level resistance was recorded against the
fluoroquinolones tested, therefore an alternative mechanism of resistance that is not
dependant upon ParC mutations was selected. These other mutations could come
from mutations in GyrB, ParE or outer membrane changes.
Indeed, both GyrB and ParE mutations have been found in both clinical and
laboratory studies although their contribution is subject to speculation (Dessus-Babus
et al, 1998; Gonzalez et al, 1998; Jones et al, 2000; Kaatz and Seo, 1997;
Mouneimne et al, 1999; Nagai et al, 2000).
Active efflux has been found in laboratory mutational experiments with E. coli,
P. aeruginosa, S. aureus and S. pneumoniae (Jones et al, 2000; Kern et al, 2000; Li,
Livermore and Nikaido, 1994; Mazzariol et al, 2001; Piddock and Jin, 1999).
However, the selection of a multi-drug efflux system (MDR) was not seen in these
data. Kern et al (2000) have shown in Escherichia coli that non-target mutations i.e.
efflux, is associated with an 8-fold increase in non-fluoroquinolone MIC and a 100-
fold increase in fluoroquinolone MIC. In this study, we have found that while the
fluoroquinolone MICs do rise at least 100-fold over several selection steps without
changes in the ParC QRDR, the non-fluoroquinolone MICs are subject to only minor
changes, if any at all, therefore an MDR efflux system was not selected. The rise in
fluoroquinolone MICs without GyrA and ParC mutations, combined with minor
changes in non-fluoroquinolone MICs suggests that permeability mutants are being
selected.
Evidence for this comes from the fact that moxifloxacin potency is the least affected
when there is no ParC mutation. When a GyrA mutation is selected, or if there is a
double GyrA/ParC mutation, gemifloxacin and moxifloxacin are effectively
equipotent (see mutant AC1). However, if there is only the single GyrA mutation
and no ParC mutation in subsequent selection steps, the hydrophilic gemifloxacin is
surpassed in its activity by the hydrophobic moxifloxacin (mutants 256C3, DP4-
DP7, BE1-BE4). Ciprofloxacin, although less potent than gemifloxacin before a
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GyrA mutation, becomes equipotent without a ParC mutation. This strongly
suggests that permeability mutations are being selected. Bazile et al (1992) has
shown that there is a correlation between fluoroquinolone hydrophobicity and
accumulation in Gram negative organisms. The more hydrophobic a drug is, the less
it accumulates. Resistant strains also accumulate less drug, however hydrophobic
drugs are less affected. If the selecting agent is hydrophilic (gemifloxacin and
ciprofloxacin), it is likely that a permeability mutation against hydrophilic agents
will be selected thus explaining the MIC differentials.
Permeability mutations have been found in Gram negative organisms such as
P. aeruginosa and K. pneumoniae (Chevalier et al, 2000; Germ et al, 1999;
Hancock, 1998). Not all permeability mutations lead to decreased fluoroquinolone
sensitivity. K. pneumoniae porin loss in a study by Hernandez et al (2000) was
associated with resistance to the P-lactams but not the fluoroquinolones. The slower
diffusion of the p-lactam allows a P-lactamase to destroy the drug before it reaches
the target. However as no drug-destroying enzyme have been found to have activity
to the fluoroquinolones, they will still reach their target, albeit at a reduced rate,
unless retarded diffusion is coupled to active efflux.
Recently, a new method to investigate the selection of fluoroquinolone resistance in
vitro has been proposed. The mutant prevention concentration (MPC) represents a
threshold above which the selection of resistant mutants is expected to occur only
rarely (Blondeau et al, 2001). It is based on the number ofbacteria in a human
infection reaching 1010 cells. This number of cells are plated onto antibiotic
containing plates in a similar way to determine MIC by agar dilution. The MPC is
the concentration of drug where there are no recoverable cells after 48 hours
incubation. Effectively, it is the MIC when 1010 organisms are plated onto MIC
plates. However, one flaw of this method is the figure of 1010 organisms which does
not stand up to scrutiny. This number comes from cited references that lead a paper
trail to three articles where numbers of infecting organisms are given. One looked at
neonatal septicaemia caused by E. coli (Dietzman, Fischer and Schoenknecht, 1974).
A quantitative count gave a figure of 50-1000 cfu/ml. Taking the higher figure of
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1000 cfu/ml, one would need 104L of blood to achieve 1010 organisms, however the
human body only contains approximately 5L ofblood. In another reference, the
quantitative count of organisms in aspiration pneumonia was given as > 106 cfu/ml
(Lorber and Swenson, 1974). To achieve 1010 organisms, the lung would have to
contain 10L of fluid. Finally, bacteria recovered from endocarditis yielded up to 300
cfu/ml (Werner et al, 1967). Clearly not even a blue whale would have enough
blood for the recovery of 1010 organisms. For the MPC to be of use, the number of
organisms needs to be re-evaluated.
For this study, a value of2xMIC was used to select resistant organisms. A truer
picture of resistance development could come from using breakpoint values instead
ofmultiples ofMIC. However, if resistant organisms are recovered and they have an
MIC above breakpoint, then further selection using breakpoints would be difficult as
all organisms that are plated will grow and the recovery of secondary mutations
would involve the screening of thousands of colonies. One other criticism ofMIC
multiples is that they are a fixed concentration of drug. In vivo drug concentrations
will change over time as the drug is cleared from the body, something that one
cannot mimic on a petri dish. Animal models exist as do in vitro chamber models
where the concentration of drug fluctuates over time. To date there has been no
comparative study that looks at selection on plates, chamber and animal models.
In vivo selection of fluoroquinolone resistance during urinary tract infections has
been shown to correlate with fluoroquinolone use in E. coli and K. pneumoniae
(Cizman et al, 2001; Deguchi et al, 1997; Muder et al; 1991). Cizman in fact
recommends that fluoroquinolones should only be used as a second choice drug to
prevent resistance emerging. However other studies have found no correlation
between increased usage and resistance (Svetlansky et al, 2001; Pieroni et al, 1997).
Thus it may be that prudent use of these drugs is called for and an overeliance will
only cause problems for the future.
The high mutational rates ofA. baumannii against ciprofloxacin presented here
demonstrate the propensity for the organism to become resistant. First step mutants
had lost the gyrA restriction site at a frequency of 2.4x10"5 compared to gemifloxacin
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and moxifloxacin which needed three and two steps respectively in the order of 10" -
10 y at each step. This high rate may explain why there is a correlation between
ciprofloxacin use and resistant A. baumannii previously discussed. Mutation rates of
1.6xl0"7, 5.4x1 (T8 and 1.9xl0"7 have been reported for E. coli, P. aeruginosa and
K. pneumoniae respectively selected on ciprofloxacin (Gilbert et al, 2001; Schulte
and Heisig, 2000). Perhaps it is not the organism but the selecting drug, as mutation
rates of E. coli are considerably lower when other drugs are used for selection:
1.2xlO~10 for gemifloxacin (Schulte and Heisig, 2000), 5xl0~9-lxl0"n with nalidixic
acid and ofloxacin (Kern et al, 2000), 10~9-10~10 with norfloxacin (Hirai et al, 1986b)
and 10"9-10-4 with norfloxacin and lomefloxacin (Tavio et al, 1999). These cited
papers do not yield much information on the individual selection steps therefore it is
unknown at which point a GyrA mutation was selected. The study by Kern et al
(2000) states that they used an inoculum of 10)0-1012 organisms, however in the
experience of these studies, achieving an inoculum of>109 organisms is difficult.
The gemifloxacin and ciprofloxacin-selected strains follow the pattern for the
development of resistance seen in clinical isolates, namely that GyrA is the primary
target. However mutant M2E had the gyrA mutation but did not record the highest
MICs of it's generation. ParC mutations were not found with mutants derived from
ATCC 19606, but they were found with the clinical isolate SB 13, confirming its role
as the secondary target. However, as aparC mutation was not found in all the highly
resistant mutants, these data suggest that an alternative route to fluoroquinolone
resistance exists with in vitro selected mutants.
Conclusions
If we take the acquisition of a GyrA mutation as the benchmark for the development
of fluoroquinolone resistance, the use of ciprofloxacin has been shown to select for
resistant organisms at high frequency. However, the newer fluoroquinolones
gemifloxacin and moxifloxacin, which require 2-3 independent steps to acquire the
GyrA mutation, are less likely to select for fluoroquinolone-resistant A. baumannii.
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Chapter 8: Stability of Gemifloxacin-Selected
Mutants and Identification of a Porin
8.1 Introduction
There is a thought that if antibiotic pressure is removed from a population of bacteria
then resistance will disappear. In this study, the gemifloxacin-selected mutants from
Chapter 7 have the stability of their mutations investigated by passage on antibiotic-
free agar. Narrow-range MICs are used against some of the mutants to gain a better
understanding of their sensitivity profiles. One mutant after passage is re-selected
with gemifloxacin. In chapters 6 & 7, it has been shown that all isolates exhibiting
high-level resistance to the fluoroquinolones have a serine 83 mutation in GyrA.
However, a serine 80 mutation in ParC, although contributing to high-level
resistance, is not necessary and unrelated strains with seemingly identical QRDRs
can have radically diverse MICs to the same fluoroquinolone. This suggests other
factors are involved besides the GyrA and ParC QRDRs. In this study, the SB 13-
BE1 lineage of gemifloxacin selected mutants from Chapter 7 will be examined and
will show that high-level fluoroquinolone resistance is associated with an altered
outer membrane profile in conjunction with the serine 83 GyrA mutation. This
chapter also begins the process to characterise a porin of 45.5kDa.
8.2 Passage of ATCC 19606 Mutants
The results ofATCC 19606 mutants after lOx passage are shown in Table 8.1. The
parent strain showed no difference in fluoroquinolone MIC after passage. The
majority of the mutants as well as the parent strain ATCC 19606 showed no
difference in their gemifloxacin, ciprofloxacin or moxifloxacin MICs.
Of the three first generation mutants, only mutant API exhibits a lowering ofMIC
against moxifloxacin. Two of the second generation mutants show a two-fold
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reduction in their fluoroquinolone MICs and one mutant a reduction in gemifloxacin
and ciprofloxacin MIC. The other five mutants show no change. The third
generation mutants all have a GyrA mutation which was retained after passage,
however, two of the mutants have a lowering ofMIC to the three fluoroquinolones.
This lowering ofMIC does not bring the MICs below breakpoint level. Of the fourth
generation mutants, only one has a lowering ofMIC to the three fluoroquinolones
and mutant DP4 has a four-fold decrease in MIC to gemifloxacin.
Figure 8.1. MICs of ATCC 19606 gemifloxacin-selected mutants after passage.
The pre-passage MICs are in parenthesis.
MIC (mg/L)
Strain GEM CIP MOX
Parent 19606 0.12 (0.12) 1 (1) 0.25 (0.25)
1 st Gen AP1 0.5 (0.5) 4 (4) 0.5(1)
AQ1 0.5 (0.5) 2 (2) 0.5 (0.5)
AR1 0.5 (0.5) 2 (2) 0.5 (0.5)
2nd Gen BP1 1 (1) 8 (8) 1 (1)
BP2 0.5 (1) 4 (8) 0.5(1)
BP3 1 (1) 8 (8) 1 (1)
BP4 1 (1) 8 (8) 1 (1)
3rd Gen CP1 8(16) 64 (128) 4(8)
CP2 16 (16) 128 (128) 8(8)
CP3 16 (16) 128 (128) 8(8)
CP4 4(8) 16 (32) 2(2)
4th Gen DP1 16 (32) 128 (>128) 16 (16)
DP2 64 (64) >128 (>128) 16 (16)
DP3 64 (64) >128 (>128) 16 (16)
DP4 32 (128) >128 (>128) 16 (16)
DP5 >128 (>128) >128 (>128) 16 (16)
DP6 >128 (>128) >128 (>128) 32 (32)
DP7 >128 (>128) >128 (>128) 32 (32)
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8.3.1 Passage of SB13 Mutants
The MICs of SB 13 gemifloxacin-selected mutants after lOx passage are shown in
Table 8.2. Neither the parent or the two first-generation mutants after passage
showed a change in sensitivity to the fluoroquinolones, imipenem or sulbactam.
SB 13, AE1 and AC1 retained their GyrA mutation and AC1 retained its ParC
mutation. Post-passage, the second generation mutant BE1 showed a reduction in
MIC to the four fluoroquinolones and an increase in its imipenem MIC. Effectively
it had reverted to the antibiotic profile ofAE1 with the exception of its gemifloxacin
MIC which was one dilution higher than AE1. Henceforth, this mutant will be
denoted as BE 1 rev.
Table 8.2. MICs of SB13 derived mutants after 10x passage on antibiotic-free
media. Pre-passage MICs are in parenthesis.
_ __ __
MIC (mg/Lj
Strain GEM CIP MOX SPA IMI SUL
SB13 TJV) 8 (8) 2~(2) 4~(4) 0.5 (0.5)_32 (32)
AC1 16 (16) 128 (128) 16 (16) nt nt nt
AE1 16(16) 64(64) 4(4) 8 (8) 0.5(0.5) 16(16)
BE1 32 (>128) 64 (256) 4(8) 8 (16) 0.5 (0.25) 16 (16)
8.3.2 Narrow-range MICs
Given that there were minor differences in sensitivity to moxifloxacin, sulbactam and
imipenem through the selection steps, narrow-range MICs were performed on them
and BElrev to better understand their sensitivity profiles. Table 8.3 summarises the
data.
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Table 8.3. Narrow Range MICs (mg/L)
Strain MOX SUL IMI
SB13 1.5 23 0.3 Range used:
AE1 3.75 14 0.3 MOX: 0.25 mg/L increments
BE1 11.0 14 0.17 SUL: 1 mg/L increments
BElrev 4.25 13 0.28 IMI: 0.1 mg/L increment
The narrow range MICs recorded are within the range one would expect when
compared to doubling dilution MIC (Table 8.2). By using small increments in the
amount of drug in each plate, a more exact measurement of their sensitivity to the
drugs was determined. Narrow-range plates are however difficult to read as the cut¬
offpoint between growth and no growth is not as distinct as using doubling dilution.
The increase in antibiotic concentration between each plate was extensively tested
until a degree of confidence and reproducibility was reached. If the MIC of the
organism is known, it can aid in the decision as to what range should be used.
These data show that after two selection steps, the moxifloxacin MIC has risen from
1.5mg/L to 11mg/L. This rise has been negated after passage ofBE 1. The first
selection step led to a reduction in sulbactam resistance. This reduction was stable in
both AE1 and BE1. The imipenem MIC did not decrease until the second selection
step and this reduction was reversed after the passage ofBE1. These data suggest
that the first mutational event was stable but the second one was not.
8.4 Growth rates of gemifloxacin-selected SB13 mutants
One phenotypical difference within the SB13-BElrev lineage was their growth rates
in liquid culture and colony size on solid media. With each selection step, the
growth rates and colony sizes were reduced but with the revertant strain, it increased.
This can be seen in the growth curves ofBE1 and BElrev (Figure 8.1).
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Figure 8.1. Growth rate of BE1 and BEIrev in nutrient broth
BE1
-m— BEIrev












The stationary phase lasts for about 80 minutes for both organisms. However after
this point, the growth rate ofBEIrev increases beyond that ofBE1.
This is further illustrated in Figure 8.2 where a loopful of each mutant has been
streaked onto separate MacConkey agar plates. The parent SB 13 has larger colonies
than BE1, however the revertent colony size has increased to nearer that ofAE1.
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Figure 8.2. Colony size of SB13-BE1rev lineage
8.5 Analysis of BEIrev gyrA and parC QRDR
The GyrA and ParC QRDR ofBEIrev was determined and is shown in Figures 8.3
and 8.4. As seen with AE1 and BE1 in Chapter 7, no differences in the QRDRs were
found.
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Figure 8.3. Alignment of the SB13 and BE 1 rev gyrA QRDR
SB13 TCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
BEIrev CGTATTCGGT AAATATCACC CGCATGGTGA CTTAGCTGTT TATGAAACCA
SB13 TTGTTCGTAT GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT
BEIrev TTGTTCGTAT GGCTCAAGAC TTTAGCTTAC GTTATTTATT GGTTGATGGT
SB13 CAGGGTAACT TCGGTTCGAT CGATGGTGAT AGCGCTGCGG CAATGCGTTA
BEIrev CAGGGTAACT TCGGTTCGAT CGATGGTGAT AGCGCTGCGG CAATGCGTTA
SB13 TACCGAAGTC CGTATGACTA AGCTGGCACA TGAGCTTCTT GCAGATTTAG
BEIrev TACCGAAGTC CGTATGACTA AGCTGGCACA TGAGCTTCTT GCAGATTTAG
SB13 AAAAGACAC AGTTGACTGG GAAGATAACT ACGACGGTTC GGAACGTATC
BEIrev AAAAAGACAC AGTTGACTGG GAAGATAACT ACGACGGTTC GGAACGTATC
SB13 CCTGAAGTAC TTCCGACACG TGTTCCAAAC TTATTAA,..
BEIrev CCTGAAGTAC TTCCGACACG TGTTCCAAAC TTATTAATTA ACGGTGCTGC
Figure 8.4. Alignment of the SB13 and BEIrev parC QRDR
SB13 GTACTTGGTA AATACCACCC ACATGGTGAC TCGGCATGTT ATGAAGCCAT
BEIrev ...CTTGGTA AATACCACCC ACATGGTGAC TCGGCATGTT ATGAAGCCAT
SB13 GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
BEIrev GGTACTCATG GCTCAGCCAT TTAGTTACCG CTATCCTTTA ATCGAAGGTC
SB13 AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
BEIrev AGGGGAACTG GGGCTCACCT GATGATCCTA AGTCTTTTGC TGCG
8.6.1 SDS-PAGE of outer membrane proteins
The outer membrane profile of SB13, AE1, BE1 and BEIrev are shown in Figure
8.3. A major band of 40kDa seen in the 4 isolates has been shown to be a trimeric
porin by Jyothisri et al (1999). Lane 4 shows increased expression of a 45.5 kDa
protein (arrow) in BE1. This protein has been identified by Sato and Nakae as a
porin (1991). The increased expression is not seen in AE1 (Lane 3) the parent strain
ofBE1 and is lost after lOx passage with the reverent BEIrev (Lane 5).
Densitometric analysis of the gel shows that this 45.5kDa protein makes up 2% of
the total OMPs for SB13, AE1 and BEIrev, but has increased to 4.7% of the total
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increased to 4.7% of the total OMPs for BE1. The other proteins are subject to
minor differences in expression levels but none of them have a >2-fold increase in
expression.
Figure 8.3. SDS-PAGE outer membrane profile from isogenic mutants and parent
strain. Lane 1, molecular weight marker: Lane 2, SB13: Lane 3, AE1: Lane 4, BE1:




These data suggest that there is an association between high-level fluoroquinolone
resistance and increased expression of the 45.5kDa porin. The remainder of this
chapter deals with determining the amino acid and nucleotide sequence of the porin.
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8.6.2 Purification of the 45.5kDa Porin
The purification of the 45.5kDa porin was attempted using ion exchange
chromatography. Two different columns were used; cation exchange and anion
exchange using a salt gradient to elute the proteins. This did not purify the porin
therefore it was isolated by electroblotting an SDS-PAGE gel onto a PVDF
membrane, coomassie staining the membrane and excising the band of interest with a
scalpel.
8.7.1 N-Terminal Sequencing of the Porin
The excised PVDF membrane-bound porin was N-terminally sequenced at
GlaxoSmithKline laboratories. A 40 amino acid sequence was determined and is
shown in Figure 8.5.
Figure 8.5. 40 amino acid fragment of the 45.5kDa OMP from BE1
SEQSEAKGFVEDANGSILFRTGYLTRDKKQGAKDTSSVAQ
The sequence was analysed in BLAST and was found to have 45% identity to porin
OprE3 and 42.5% identity to OprD2, both from P. aeruginosa (Appendix VII).
8.7.2 Determination of the nucleotide sequence of 28 amino
acids of the Porin
The 40 amino acid sequence was used to design degenerate primers to amplify and
sequence the gene. Appendix I shows the amino acid sequence and the possible
codons. Because serine has six possible codons, the primers were derived from an
area of less degeneracy corresponding to 28 of the amino acids. PCR of the gene
gave a product of 87bp. This was sequenced using the degenerate primers (Figure
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8.6). However, the plus and minus strands did not overlap therefore a consensus
sequence was not possible. The nucleotide sequence of three amino acids in the
middle portion of the fragment were not identified (Figure 8.6). The reason for this
is that when sequencing a PCR product, the first 30-40bp, including the primer
region, does not yield a readable sequence. This means that primer 1 gave the
sequence of the 3' end of the fragment and primer 2 the 5' end of the fragment. As
there was no overlap, this resulted in the missing segment. The primer 2 sequence
was reverse complemented before translation. The translated sequence did not fully
match the original amino acid sequence with one amino acid difference (Figure 8.6).
Nevertheless, inverse PCR primers were designed in order to sequence upstream and
downstream of the known area.
Figure 8.6. Amino acid and nucleotide sequence of the OMP using degenerate
primers. In bold is the amino acid that differs from that using N-terminal sequencing
(in parenthesis).
Amino E AKGFVE D AN
Nucleotide GAG GCG AAA GGG TTT GTG GAG GAT ACG AAC
Amino GSILFRTGYL
Nucleotide GGC TCC ATT No sequence ACA GGT TAT CTA
Amino TG(R)D K K Q G A
Nucleotide ACC GGC GAC AAA AAA CAA GGC GCA
8.7.3 Inverse PCR
Inverse PCR was attempted using primers derived from the sequence in Figure 8.6.
Double digests ofwhole genomic DNA from BE1 was used as template. After
restriction of genomic DNA, re-ligation and PCR, there was no PCR product visible
on the gel. Using software that identifies restriction sites within DNA, a novel
restriction site (JVMV) was found in the 87bp sequence. Attempts to cut the 87bp
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PCR product failed, therefore suspicion on the integrity of the sequence meant that
the inverse PCR was shelved. Another method was then used to determine the
sequence.
8.7.4 Cloning of the PCR fragment
The PCR product was cloned into a pCR 4-TOPO plasmid by Richard Gibbs. The
vector contains Ml 3 priming sites 88bp upstream and 75bp downstream of the insert.
After the plasmid was extracted, it was subjected to PCR using Ml 3 primers to give
a PCR product of252bp. This PCR product was sequenced using the Ml3 primers.
The sequence, when translated, matched the original amino acid sequence (Figure
8.7a). The nucleotide sequence from the clone is compared against the sequence
from using the degenerate primers (Figure 8.7b).
Figure 8.7. (a) Nucleotide and translated amino acid sequences from the cloned
PCR fragment, (b) comparison of the nucleotide sequence from 1: using






(b) 1. GAGGCGAAAGGGTTTGTGGAGGATGCGAACGGCTCCATT ACAG
I II II I I I I I I I I I I I I I I I I I I I I I I I I I II III I I I I
2. GAGGCGAAGGGGTTTGTGGAAGATGCGAACGGTTCTATTCTCTTCCGTACAG
1. GTTATCTAACCGGCGACAAAAAACAAGGCGC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2. GTTATCTAACCCGCGACAAAAAACAGGGCGC
The difference in the nucleotide sequence between using the degenerate primers to
sequence the PCR product and that from the clone are clearly seen in Figure 8.7b.
There are 5 nucleotide differences between them. The missing 9bp fragment has also
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been sequenced using the clone. The nucleotide sequence was put into BLAST but
there was no sequence similarity in the database.
8.8 Re-Selection of BEIrev on Gemifloxacin
The revertant BEIrev was re-selected on gemifloxacin containing agar plates to see
if a ParC mutation would be selected. The MICs of the mutants from this selection
are shown in Table 8.8. The loss of the gyrA restriction site was carried over but
none of the mutants had lost the parC restriction site.
Table 8.8. Selection of mutants from BEIrev (nt: not tested)
MIC (mg/L) Hinf\ Restriction
Strain GEM CIP MOX SPA IMI SUL CHL TET gyrA parC
BEIrev 32 64 4 8 0.25 16 256 128 not cut cut
G32A >128 >256 16 16 nt 16 512 128 not cut cut
G32B 64 128 8 16 nt 8 256 128 not cut cut
G32C >128 256 8 16 nt 16 128 128 not cut cut
G32D 64 128 8 8 nt 16 256 128 not cut cut
G32E >128 >256 32 32 1 8 512 256 not cut cut
G32F >128 >256 16 16 nt 16 256 128 not cut cut
G32G >128 >256 32 32 nt 8 512 256 not cut cut
G32H 64 256 8 8 0.25 8 256 64 not cut cut
A mutational frequency of lxl0 5 was recorded for this selection which was higher
than that to produce the mutants BE1-BE4 from AE1. A rise in MIC against the
fluoroquinolones was seen in all mutants except for two which showed no rise in
their sparfloxacin MIC. However, these mutants recorded a 2-fold increase to
gemifloxacin, ciprofloxacin and moxifloxacin. Two mutants, G32E and G32G,
recorded sparfloxacin and moxifloxacin MICs of 32mg/L and were the only ones to
show a rise in resistance to tetracycline, from 128mg/L to 256mg/L. These two
strains saw a lowering of their resistance to sulbactam and G32E also saw its
imipenem MIC rise 4-fold.
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8.9 Discussion
In many respects, the stability of a mutation is equally as important, if not more, than
the mutation frequency. If an organism has the ability to mutate to an antibiotic it is
of great and obvious concern to the clinician. However if this mutation compromises
the organism to such a degree that it cannot compete with other organisms, then it
will not persist in the environment.
Jones et al (2000) have investigated the stability ofmutations by growing S. aureus
for 500 generations in an antibiotic-free environment. The strains used carried
multiple mutations conferring resistance to the fluoroquinolones. These included
target-site mutations and those in the efflux pump NorA and its promoter. All the
mutations were stably inherited after passage. Strains that were grown for 500
generations with a subinhibitory concentration of ciprofloxacin were found to
accumulate more mutations and their ciprofloxacin MICs rose accordingly. This has
also been demonstrated with clonal lineages of S. aureus in the clinical environment
over a period of years (Jones et al, 1999).
In the present study, the stability of gemifloxacin-selected A. baumannii mutants was
investigated. The mutants from laboratory strain ATCC 19606 did not lose their
GyrA mutation although a few strains did become slightly more sensitive to the
fluoroquinolones. However these mutants, when resistant, did not record MICs
below published breakpoint values (Andrews, Ashby, Jevons and Wise, 1999;
British Society for Antimicrobial Chemotherapy, 1991; Wise and Andrews, 1999),
except for BP2 which became sensitive to moxifloxacin.
A similar picture emerged with mutants derived from the clinical isolate SB 13. The
parent strain and the first generation mutants did not show any difference in their
sensitivity to fluoroquinolones and non-fluoroquinolones after passage. The GyrA
and ParC mutations were carried through passage. Only the second generation
mutant BE1 reverted but it did not become clinically sensitive to the
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fluoroquinolones. The gyrA and parC gene showed no difference between the
revertent and strain SB 13.
The reselection ofmutants from the revertant was at a high frequency and high-level
resistance to the fluoroquinolones resulted. One mutant recorded a four-fold increase
in its imipenem MIC. This suggests that even if a mutation is unstable, the organism
can re-mutate and at a higher frequency.
The selection of SB 13 mutants had an effect on their growth rates. Strain BE1 grew
slower than its parents. This was visible in their colony sizes after an overnight
incubation on solid media and in their growth curves. The effects of fluoroquinolone
mutations on growth rate has been reported in E. coli (Bagel et al, 1999). It was
found that a GyrA serine 83 or aspartic acid 87 mutation had no effect on doubling
time. However, a combination ofGyrA and a ParC mutation in high-level resistance
mutants did have an effect on doubling time. The mutant BE1 only had a serine 83
mutation in GyrA, therefore the slower rate of growth is not caused by target-site
mutations. As a reduction in permeability is hypothesised to be the resistance
mechanism combined with innate efflux, these must be having a knock-on effect on
growth.
The narrow-range MICs show that one-dilution differences seen with doubling
dilution MIC can be significant. However they are sometimes difficult to interpret as
there is no clear cut-offpoint when growth is inhibited, rather the growth on the
antibiotic plates fades gradually. They should not be used for routine MIC
investigations but are useful if permeability mutations are suspected. The data in this
study show that there is a small but significant lowering of sulbactam MIC in the first
mutational step of SB13. The second mutational step gave a small but reproducible
increase in imipenem sensitivity. This lowering ofMIC was negated after passage of
BE1, as was the MIC to the fluoroquinolones. Given that the mutation in BE1
compromised the growth of the organism, any back-mutation would outgrow the
parent genotype which is what was found.
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Resistance to antibacterials mediated through low outer membrane permeability and
porin loss has been well documented in E. coli and P. aeruginosa (Gotoh and
Nishino, 1990; Heisig and Tschorny, 1994; Tavio et al, 1999; Trias and Nikaido,
1990). In A. baumannii, intrinsic antibiotic resistance has been attributed to a small
number ofporins that results in the outer membrane being 1-3% as permeable as
E. coli (Sato and Nakae, 1991). Resistance to imipenem in A. baumannii is
associated with the loss of a 33-36kDa porin (Clark, 1996) and a 23kDa porin (Bou
et al, 2000). However, Moreau et al (1996) and Vila et al{1995) found
fluoroquinolone resistance involved gyrase mutations but not OMP differences.
In Chapters 7 and 8, high-level fluoroquinolone resistance was recorded in mutant
BE1 with a serine 83 mutation in GyrA, no change in ParC and increased expression
of a 45.5kDa porin. The porin was sequenced and was found to have 45% identity to
OprE3 and 42.5% identity to porin D2 ofP. aeruginosa. OprE3 does not appear to
play a role in antibiotic resistance. Okamoto et al (1999) found that there was no
difference in antibiotic sensitivity between P. aeruginosa strains with or without
OprE3. Porin D2 has been shown to form an imipenem permeable pore (Yoneyama
et al, 1992) and to catalyse the diffusion of carbapenems and sparfloxacin
(Micheahamzehpour, Furet and Pechere, 1991). When introduced into lipid bilayers,
D2 allows the passage of imipenem and fluoroquinolones but not tetracycline (Ishii
and Nakae, 1996). In P. aeruginosa, when D2 expression is lowered, the imipenem
MIC is raised (Gotoh and Nishino, 1990; Micheahamzehpour et al, 1991).
Conversely, the more D2, the lower the imipenem MIC. The mutant BE1
overexpressed the porin (4.7 % vs 2 % of total OMPs) and was more sensitive to
imipenem than SB 13, AE1 and BE1 rev. Micheahamzehpour et al (1991) speculate
that because both imipenem and sparfloxacin have a carboxyl and protonated
nitrogen approximately lnm apart, they act as substrates for the porin. However,
moxifloxacin does not have the nitrogen moiety and in the present study was
equipotent with sparfloxacin against BE1. Given that there was more of the porin,
one would expect the sparfloxacin MIC to be lower in BE1 than AE1. The opposite
effect was seen. This of course is speculative, as only the N-terminal 40 amino acids
are known, which is approximately 10% of the whole protein. The functional part of
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the porin that makes up the pore is unknown and it is possible that this portion may
not share homology to D2.
One other factor that contributes to fluoroquinolone accumulation is the molecular
weight of the drug, with heavier drugs accumulating less (Piddock, Jin and Griggs,
2001). Moxifloxacin, with a molecular weight of 437.9g is the heaviest of the drugs
tested and recorded the lowest MICs. Ciprofloxacin has a molecular weight of
331.4g and records the highest MICs, while gemifloxacin has a molecular weight of
374.3g. Sato and Nakae (1991) found that the 45.5kDa porin preferentially allows
the diffusion of low molecular weight drugs over high molecular weight. This does
not explain the greater potency ofmoxifloxacin over gemifloxacin unless the lighter
drugs are preferentially pumped out of the cell. Given that the greatest difference in
drug potency between the "heavy" and "light" drugs was with the mutant
overexpressing the porin is suggestive of a permeability mutation. This will need to
be tested using accumulation assays.
Given that reduced permeability alone will not contribute significantly to
fluoroquinolone resistance is suggestive that the porin may be working in tandem
with an efflux system that preferentially pumps out hydrophilic fluoroquinolones (Li,
Livermore and Nikaido, 1994). Indeed, the hydrophilic ciprofloxacin and
gemifloxacin recorded higher MICs than the hydrophobic moxifloxacin and
sparfloxacin. The 40 amino acid fragment does not show any sequence similarity to
known efflux components, but from these data the involvement of efflux cannot be
discounted.
The fluoroquinolone MICs were elevated in BE1, especially gemifloxacin and
ciprofloxacin, and reverted to parent sensitivity with the reduction in expression of
the porin. There were no differences in the GyrA or ParC QRDRs between the
mutants. These data show that there is an association between fluoroquinolone
resistance and the porin, and that it was selected in preference to a ParC mutation.
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Why would a permeability mutation be selected before or instead of a target site
mutation? Gram negative bacteria have only one gyrA and one parC gene but have
several different porins. For example, P. aeruginosa has to name a few, D2, OprE3,
OprM, OprJ, OprN, ofwhich the latter three are overexpressed in resistant organisms
(Masuda, Sakagawa and Ohya, 1995). The only mutation in GyrA and ParC found in
this thesis is a C—>T transversion in the codons serine 83 (GyrA) and serine 80
(ParC). Two point mutations out of a whole genome! However, a mutation in a
porin could come from at least four different avenues: (1) downregulation mediated
through a mutation in a repressor gene leading to slower diffusion; (2) it can also be
downregulated by a mutation in the promoter that results in inhibition of expression;
(3) structural modifications to the porin that change its affinity to the drug; (4) if the
porin is linked to an efflux system then a mutation in the efflux pump may make it
work more efficiently or be overexpressed and hence keep intracellular levels of drug
below inhibitory concentrations. As there is more than one type of porin per cell,
more mutations are theoretically possible, and the randomness ofmutations makes it
more likely that they will be selected. However, the mutation may compromise a
cells fitness and once the drug is removed, a back mutation may occur as is seen with
BE 1. These ideas have backing from the literature.
Overexpression of the efflux system AcrAB, its regulatory gene marR and deletion
ofOmpF have been shown to contribute to fluoroquinolone resistance in laboratory
mutants and clinical isolates of E. coli (Mazzariol et al, 2001; Oethinger et al, 2000;
Tavio et al, 1999). Deletion of acrAB also lowers the MIC of tetracycline 4-8 fold
and 16-64 fold for chloramphenicol as well as that of the fluoroquinolones
(Oethinger et al, 2000). In the present study, the chloramphenicol MIC was two-fold
less in the revertant but the tetracycline MIC was unchanged, suggesting that
multidrug efflux, if present, was not to the same degree as described above.
Hirai et al (1986a, 1986b) has shown that fluoroquinolones of low hydrophobicity
enter through OmpF and those with high hydrophobicity enter through both OmpF
and LPS. This has led Heisig and Tschorny (1994) to suggest that the hydrophilic
ciprofloxacin will select for a permeability mutation and the hydrophobic nalidixic
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acid a gyrase mutation. However the results from chapter 7 dispute this as
ciprofloxacin selected a gyrase mutation in the first selection step and the more
hydrophobic moxifloxacin a gyrase mutation at the second step. However there may
be a degree of truth in their hypothesis, but not in gyrase as the target, rather ParC, as
the hydrophobic moxifloxacin did not select a mutation in this enzyme but the
hydrophilic gemifloxacin and ciprofloxacin did.
In conclusion, A. baumannii selected on gemifloxacin retain both GyrA and ParC
mutations. Non-target mutations have an effect on the growth rate of the mutants.
This is reversible. However those strains that lost their mutations exhibited a higher
mutation frequency upon subsequent challenge but did not show a ParC mutation.
The isogenic mutant BE1 overexpressed a 45.5kDa porin more than two-fold over its
parent AE1. This overexpression was lost after serial passage on antibiotic-free




These data presented in this thesis show that the newer fluoroquinolones, compared
to ciprofloxacin and levofloxacin, exhibit increased potency against A. baumannii.
The mechanism of resistance to these drugs is the same irrespective of the drug:
GyrA is the primary target and possession of the serine 83 mutation confers
fluoroquinolone resistance, however, GyrA mutants are still susceptible to
trovafloxacin, recording MICs just below breakpoint levels.
The A. baumannii clinical isolates showed a large variation in their susceptibilities to
the fluoroquinolones even when their target enzymes were seemingly identical; this
suggests other factors contribute to decreased sensitivity. These factors can include
GyrB and ParE mutations, drug efflux and reduced permeability. However, what has
to be remembered is that any of these factors, if present, do not on their own cause
resistance. No isolate was found to be resistant that did not have the GyrA mutation.
The presence of a ParC mutation raises the MIC even higher. This mutation is found
only in isolates in possession of a GyrA mutation. Selection of fluoroquinolone
resistant mutants in vitro demonstrate that a GyrA mutation is selected before a ParC
mutation, however not all mutants mutated in their ParC gene, confirming that other
factors are involved in reduced sensitivity.
The selection ofmutants is far higher with ciprofloxacin compared to gemifloxacin
ormoxifloxacin. This suggests that the development of resistant A. baumannii
in vivo will be less frequent when the new-generation of fluoroquinolones are
introduced for clinical use. However this will need to be tested using animal models
as there are fundamental differences between in vitro and in vivo selection. In vitro,
the concentration of drug is fixed at multiples of the MIC. In vivo, drug
concentrations will rise to peak serum levels after drug dosing and then fall over time
as the drug is cleared from the system until the cycle is repeated with further dosing.
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The mutation study raises some interesting questions:
• why was a ParC mutation not selected with ATCC 19606?
• why did moxifloxacin not select for a ParC mutation when both gemifloxacin and
ciprofloxacin did against SB 13?
Only two strains were used, a laboratory strain and a clinical isolate. One can
speculate that the differences seen with the selection ofmutants may be strain-related
and not species-specific, therefore further work using a larger number of clinical
isolates need to be conducted.
Further studies need to be done before firm conclusions can be drawn about the
45.5 kDa porin and its role in fluoroquinolone resistance. Its overexpression in BE1,
combined with the raising of hydrophilic fluoroquinolone MIC but lesser effect on
hydrophobic fluoroquinolones, suggests a permeability mechanism of resistance.
However, reduced permeability on its own will not be enough to confer resistance
unless it is coupled with efflux. For this reason its overexpression is an association
and not the cause of resistance. The whole gene sequence needs to be identified as
only 40 amino acids of the N-terminal was determined. It should also be compared
to that found in its parent strains (SB 13 & AE1) to determine if there is a mutation
within the porin that alters its fluoroquinolone affinity. Northern blotting can be
used to further quantify its level of expression. Finally, the role of fluoroquinolone







































































































































































































































































































































































































































































































































































































































Appendix II: Inverse PCR
Appendix II. Schematic Diagram of Inverse PCR
Piece of known DNA sequence (bold) and primers A and B with
restriction site (L) and unknown DNA containing random restriction
sites (S)




L A B L
PCR using primers A and B
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Appendix III: tRNA Fingerprinting Profiles
Appendix Hi: tRNA Fingerprinting profiles from Figure 3.1
Lane B: Species 1
Relative front
Lane C: Species 2
Relative front '
Lane D: Species 3
relative front
147
Appendix III: tRNA Fingerprinting Profiles
Lane E: Species 4
Relative front
Lane F: Species 5
Relative front
Lane G: Species 6
Relative front
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Appendix III: tRNA Fingerprinting Profiles
Lane H: Species 7
Relative front
Lane I: Species 8
Relative front
Lane J: Species 12
Relative front
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Appendix IV: Acinetobacter spp. identification by tRNA




















































SB27 2 A. anitratus
SB28 2 A. anitratus
SB29 2 2
SB30 2 2
SB32 2 A. anitratus












SB53 2 A. anitratus
SB59 2 spp
SB60 2 2





SB67 2 A. anitratus










SB75 2 A. anitratus
SB76 2 A. anitratus






SB83 2 A. anitratus













Appendix V: Dose Response Curves
Appendix V: Dose response curves to A. baumanniiATCC 19606









Appendix V: Dose Response Curves
Dose response of A. baumannii A7CC19609 to Sparfloxacin
1000 T
Antibiotic concentration (mg/l)
Dose response of A. baumannii ATCC 19606 to Grepafloxacin
Antibiotic concentration (mg/l)
153
Appendix V: Dose Response Curves
Dose reponse of A. baumannii ATCC 19606 to Moxifloxacin
Antibiotic concentration (mg/l)
Dose response of A. baumannii ATCC 19606 to Gemifloxacin
Antibiotic concentration (mg/l)
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MICs of Species 5, 7, 8 & 12
Species Strain Gem Cip Mox Tro Imi Cef Gat Azi Lev Ofl Spa Gre
5 SB18 0.06 0.12 0.06 0.03 0.12 8 0.12 0.5 0.12 0.25 0.03 0.06
5 SB54 0.12 0.5 0.12 0.03 0.12 32 0.25 2 0.25 0.5 0.06 0.06
7 SB31 1 16 0.5 0.5 0.25 64 4 4 8 0.5 0.5
7 SB48 0.06 0.12 0.06 0.015 0.008 64 0.06 0.25 0.25 0.5 0.015 0.03
8 SB39 0.015 0.12 0.06 0.008 0.25 32 0.03 0.5 0.12 0.25 0.008 0.015
12 SB2 0.06 0.06 0.25 0.12 0.5 >128 0.06 16 0.12 0.25 0.12 0.12
12 SB70 0.06 0.25 0.06 0,03 0.12 32 0,12 0.5 0,25 0.5 0.03 0.06
MICs of Species 2
Strain Gem Cip Mox Tro Imi
SB1 32 >128 16 8 0.25
SB4 0.25 2 1 0.12 0.06
SB5 0.06 0.25 0.12 0.06 0.12
SB6 32 >128 64 16 0.25
SB7 32 >128 16 8 2
SB8 0.03 0.03 0.03 0.015 0.03
SB9 32 128 32 16 0.25
SB10 0.12 1 0.25 0.06 0.12
SB11 32 128 16 16 1
SB12 0.12 0.5 0.06 0.03 0.12
SB13 1 8 2 0.5 0. 5
SB14 0.12 0.5 0.12 0.03 0.008
SB15 0.03 0.25 0.03 0.015 0.12
SB17 1 4 1 0.25 0.12
SB20 0.06 0.5 0.06 0.03 0.008
SB21 >128 >128 64 32 0.25
SB22 1 8 2 0.5 0.25
SB23 0.06 0.5 0.12 0.03 0.12
SB24 1 16 4 0.5 0.25
SB25 0.03 0.25 0.06 0.015 0.12
SB27 0.12 0.5 0.12 0.03 0.12
SB28 0.06 0.5 0.12 0.03 0.12
SB29 0.06 0.25 0.06 0.03 0.12
SB30 0.06 0.25 0.06 0.03 0.12
SB32 0.06 1 0.12 0.06 0.06
SB34 0.06 0.5 0.12 0.03 0.06
SB35 0.06 0.5 0.06 0.015 0.12
>128 4 32 16 32 16 64
32 0.5 32 0.5 1 0.25 0.25
128 0.06 4 0.25 1 0.03 0.06
128 64 32 64 128 32 32
>128 8 32 16 32 8 32
8 0.03 0.25 0.12 0.12 0.008 0.015
>128 8 32 16 32 16 32
128 0.25 4 0.5 1 0.06 0.12
>128 8 32 16 32 8 16
64 0.03 1 0.25 0.5 0.008 0.03
64 2 32 1 4 4 2
32 0.12 4 0.25 0.5 0.03 0.06
64 0.06 1 0.12 0.25 0.015 0.03
32 1 >128 1 4 0.5 0.5
64 0.06 4 0.25 0.5 0.015 0.03
16 64 128 32 64 32 64
128 4 32 4 8 1 1
64 0.06 1 0.25 0.5 0.03 0.06
64 2 32 4 8 1 1
128 0.25 1 0.12 0.25 0.03 0.03
128 0.03 1 0.12 0.25 0.06 0.12
128 0.06 2 0.25 0.5 0.03 0.06
128 0.12 4 0.25 0.5 0.03 0.12
64 0.12 16 0.25 0.5 0.06 0.06
64 0.06 2 0.5 1 0.03 0.06
64 0.06 4 0.25 1 0.03 0.06
64 0.06 2 0.25 0.5 0.015 0.06
MICs of Species 2 cont.
Strain Gem Cip Mox Tro imi
SB36 32 64 16 16 0.5
SB38 32 >128 16 16 0.25
SB41 8 128 16 8 0.12
SB43 0.06 0.25 0.06 0.03 0.12
SB45 16 128 16 8 0.5
SB46 0.03 0.25 0.06 0.03 0.12
SB47 16 128 16 - 16 1
SB49 0.12 1 0.12 0.03 0.008
SB51 0.03 0.25 0.03 0.015 0.06
SB52 0.03 0.25 0.06 0.03 0.12
SB53 0.06 0.5 0.06 0.06 0.12
SB59 0.008 0.03 0.008 0.008 0.008
SB60 0.06 0.5 0.12 0.03 0.12
SB61 0.03 0.25 0.06 0.015 0.12
SB62 0.06 0.25 0.06 0.03 0.12
SB63 0.06 0.5 0.12 0.06 0.06
SB64 16 >128 16 16 0.25
SB66 0.015 0.03 0.03 0.015 0.03
SB67 16 128 16 8 2
SB68 0.03 0.25 0.06 0.015 0.25
SB69 0.03 0.25 0.06 0.015 0.12
SB71 0.015 0.12 0.015 0.015 0.12
SB74 0.015 0.015 0.015 0.008 0.015
SB75 32 64 16 8 0.5
SB76 32 128 32 16 0.25
SB77 64 128 32 16 0.25
SB78 0.015 0.25 0.06 0.03 0.12
Cef Gat Azi Lev Ofl Spa_ Gre
>128 16 32 16 32 16 32
>128 16 64 32 32 16 32
64 16 16 8 16 8 16
32 0.06 4 0.5 0.5 0.03 0.06
>128 8 32 16 32 8 16
64 0.06 4 0.25 0.5 0.015 0.03
>128 8 16 16 32 16 64
64 0.06 1 0.25 0.5 0.03 0.06
16 0.03 1 0.25 0.5 0.03 0.06
128 0.25 2 0.25 0.25 0.06 0.06
128 0.25 1 0.25 0.5 0.03 0.06
2 0.008 0.12 0.008 0.03 0.008 0.015
64 0.03 2 0.25 0.25 0.03 0.06
64 0.06 2 0.12 0.25 0.015 0.03
32 0.12 2 0.25 0.5 0.03 0.06
64 0.25 2 0.25 0.5 0.03 0.03
256 8 32 8 16 8 32
8 0.03 0.12 0.12 0.25 0.008 0.015
>256 8 32 16 16 8 16
32 0.12 2 0.12 0.25 0.015 0.015
64 0.12 2 0.12 0.25 0.015 0.03
64 0.03 1 0.06 0.12 0.008 0.015
4 0.12 0.12 0.06 0.12 0.008 0.015
256 32 64 8 16 16 64
256 16 64 8 16 16 32
256 16 64 8 16 16 32




















MICs of Species 2 cont.
Strain Gem Cip Mox Tro Imi
SB79 0.06 0.5 0.12 0.03 0.25
SB80 0.06 0.25 0.12 0.03 0.06
SB81 0.06 0.25 0.06 0.03 0.25
SB82 0.06 0.25 0.06 0.03 0.06
SB83 0.03 0.25 0.06 0.03 0.25
SB84 0.06 0.5 0.12 0.03 0.06
SB86 0.12 1 0.25 0.12 0.06
SB87 64 >128 64 32 1
SB88 0.015 0.12 0.03 0.03 0.06
SB89 0.06 0.5 0.06 0.015 0.12
SB90 0.03 0.5 0.06 0.015 0.12
SB91 16 >128 16 16 0.25
SB93 0.06 0.25 0.06 0.015 0.12
SB97 0.06 0.25 0.12 0.06 0.12
SB98 16 >128 16 8 0.25
SB99 0.06 0.25 0.12 0.12 0.12
SB101 0.03 0.25 0.06 0.06 0.06
256 0.12 2 0.25 0.5 0.03 0.06
16 0.25 2 0.25 0.25 0.03 0.06
256 0.25 2 0.12 0.25 0.03 0.06
64 0.25 2 0.12 0.5 0.03 0.06
256 0.25 2 0.12 0.25 0.03 0.06
32 0.25 2 0.12 0.25 0.03 0.06
128 0.5 4 0.25 0.5 0.12 0.12
256 128 32 64 >238 32 32
64 0.03 1 0.12 0.12 0.03 0.06
128 0.12 1 0.06 0.5 0.015 0.03
64 0.06 2 0.25 0.5 0.015 0.03
>256 16 64 16 32 8 16
32 0.12 2 0.12 0.25 0.03 0.06
128 0.12 2 0.12 0.25 0.03 0.06
256 16 64 16 64 8 16
128 0.25 1 0.25 0.25. 0.03 0.06
64 0.25 2 0.12 0.5 0.015 0.06
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Appendix VII. Comparison of OMP sequence in BLAST
Sequences producing significant alignments:
gi|15597956|ref|NP_251450.1| (NC 002516) probable outer mem... 40
giI 2425172|dbjIBAA22267.il (AB006797) OprE3 [Pseudomonas ae... 40
giI 15596155|ref|NP_249649. 11 (NC 002516) outer membrane por... 38
giI 5712720|gb|AAD47624.11 (AF153710) porin-like protein [Ps... 35
giI 15598784|ref|NP_252278.11 (NC 002516) probable porin [Ps... 30
Alignments
giI 15597956|ref|NP 251450.11 (NC 002516) probable outer membrane
protein [Pseudomonas aeruginosa]
gi111351566|pir| |G83299 probable outer membrane protein PA2760 -
Pseudomonas aeruginosa (strain PAOl)
gi|9948840|gb|AAG06148.1]AE004 704 2 (AE004704) probable outer
membrane protein [Pseudomonas aeruginosa]
Length = 425
Score = 40.4 bits (93), Expect = 0.004
Identities = 18/40 (45%), Positives = 27/40 (67%)
Query: 1 SEQSEAKGFVEDANGSILFRTGYLTRDKKQGAKDTSSVAQ 40
++Q AKGFVED++ + FR GY++RD K G +D + Q
Sbjct: 22 NDQEAAKGFVEDSHLDLFFRNGYISRDYKHGRQDKAEWGQ 61
>giI 2425172|dbjIBAA22267.il (AB006797) OprE3 [Pseudomonas
aeruginosa]
Length = 425
Score = 40.4 bits (93), Expect = 0.004
Identities = 18/40 (45%), Positives = 27/40 (67%)
Query: 1 SEQSEAKGFVEDANGSILFRTGYLTRDKKQGAKDTSSVAQ 40
++Q AKGFVED++ + FR GY++RD K G +D + Q
Sbjct: 22 NDQEAAKGFVEDSHLDLFFRNGYISRDYKHGRQDKAEWGQ 61
>gi115596155|ref|NP 249649. 11 (NC 002516) outer membrane porin
protein OprD precursor [Pseudomonas aeruginosa]
gi|417518|sp|P32722|PORD PSEAE PORIN D PRECURSOR (OUTER MEMBRANE
PROTEIN D2) (IMIPENEM/BASIC AMINO ACID-SPECIFIC OUTER MEMBRANE PORE)
giI 948111pir| IS23771 porin oprD precursor - Pseudomonas aeruginosa
gi111350707|pir| |E83527 outer membrane porin protein OprD precursor
PA0958 [imported] - Pseudomonas aeruginosa (strain PAOl)
giI 453711emb|CAA44855.11 (X63152) protein D2 [Pseudomonas
aeruginosa]
giI 45373|emb|CAA78448.11 (Z14065) OprD porin [Pseudomonas
aeruginosa]
giI 9946864|gb|AAG04347.11AE004529 13 (AE004529) outer membrane
porin protein OprD precursor [Pseudomonas aeruginosa]
giI 444429|prf| |1907161D porin [Pseudomonas aeruginosa] Length = 443
161
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Score = 37.7 bits (86), Expect = 0.028
Identities = 17/34 (50%), Positives = 24/34 (70%)
Query: 1 SEQSEAKGFVEDANGSILFRTGYLTRDKKQGAKD 34
S+Q+EAKGF+ED++ +L R Y RD K G+ D
Sbjct: 28 SDQAEAKGFIEDSSLDLLLRNYYFNRDGKSGSGD 61
giI 5712720|gb|AAD47 624 . 11 (AF153710) porin-like protein
[Pseudomonas sp. BG33R] Length = 249
Score = 34.7 bits (78), Expect = 0.20
Identities = 16/40 (40%), Positives = 27/40 (67%)
Query: 1 SEQSEAKGFVEDANGSILFRTGYLTRDKKQGAKDTSSVAQ 40
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